 A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of 
Different Prime-Boost Vaccination Schedules of 2013 and 2017 A/H7N9 
Inactivated Influenza Vaccines Administered Intramuscularly with or without 
AS03 Adjuvant in Healthy Adults 19-50 Years of Age  
 
DMID Protocol Number:  17-0078 
 
DMID Funding Mechanism:  Vaccine and Treatment Evaluation Units 
 
Pharmaceutical Support:  
Sanofi Pasteur  
GlaxoSmithKline Biologicals 
 
IND Sponsor:  Division of Microbiology and Infectious Diseases, National 
Institute of Allergy and Infectious Diseases, National Institutes of Health  
 
Lead Principal Investigator:  Evan J. Anderson, MD  
DMID Clinical Project Manager: Wendy Buchanan, RN, MS  
DMID Medical Monitor: Mohamed Elsafy , MD  
DMID Medical Officer:   Francisco Leyva, MD, PhD, ScM  
DMID Scientific Lead: Chris Roberts, PhD 
 
Version:  4.0 
December 1 8, 2019 
 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
i STATEMENT OF COMPLIANCE 
This trial will be carried out in accordance with Good Clinical Practice  (GCP) as required by the 
following: 
• United States (US) Code of Federal Regulations (CFR) 45 CFR Part 46: Protection of 
Human Subjects  
• Food and Drug Administration (FDA) Regulations, as applicable: 21 CFR Part 50 
(Protection of Human Subjects), 21 CFR Part 54 (Financial Disclosure by Clinical 
Investigators), 21 CFR Part 56 (Institutional Review Boards), 21 CFR Part 11, and 21 CFR Part 312 (Investigational New Drug Application), 21 CFR 812 (Investigational 
Device Exemptions)  
• International Council for Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use E6(R2) Good Clini cal Practice (ICH E6 GCP) : 
Integrated Addendum to ICH E6(R1) Guidance for Industry, published in the Federal 
Register (83 Federal Register 8882 (2018)), including the latest finalized revision 
• Belmont Report: Ethical Principles and Guidelines for the Prote ction of Human Subjects 
of Research, Report of the National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research  
• National Institutes of Health (NIH) Office of Extramural Research, Research Involving Human Subjects, as appli cable  
• National Institute of Allergy and Infectious Diseases (NIAID) Clinical Terms of Award , 
as applicable  
• Applicable Federal, State and Local Regulations and Guidance 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
ii SIGNATURE PAGE  
The signature below provides the necessary assurance that this trial wil l be conducted according 
to all stipulations of the protocol, including all statements regarding confidentiality, and 
according to local legal and regulatory requirements and applicable US federal regulations and ICH E6  GCP  guidelines. 
I agree to conduct the study in compliance with GCP and applicable regulatory requirements. 
I agree to conduct the study in accordance with the current protocol and will not make changes to 
the protocol without obtaining the sponsor’s approval and Institutional Review Board 
(IRB)/Institutional Ethics Committee ( IEC) approval, except when necessar y to protect the 
safety, rights  or welfare of subjects.  
Site Principal Investigator:  
 
Signed:   
 Date:   
 Name  
Title  
   
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
iii TABLE OF CONTENTS 
STATEMENT OF COMPLIANCE  ................................................................................................. i  
SIGNATURE PAGE  ...................................................................................................................... ii 
TABLE OF CONTENTS  ............................................................................................................... iii 
LIST OF TABLES  ........................................................................................................................ vii  
LIST OF FIGURES  ..................................................................................................................... viii 
LIST OF ABBREVIATIONS  ........................................................................................................ ix 
PROTOCOL SUMMARY ........................................................................................................... xiii 
1 Key Roles  ................................................................................................................................1  
2 Background Information and Scientific Rationale .................................................................3  
2.1 Background Information .............................................................................................3  
2.1.1  Public Readiness and Emergency Preparedness Act  ......................................6  
2.2 Scientific Rationale  .....................................................................................................7  
2.3 Potential Risks and Benefits  .......................................................................................9  
2.3.1  Potential Risks  ................................................................................................9  
2.3.2  Known Potential Benefits .............................................................................16  
3 Study Objectives and Outcome Measures  ............................................................................18  
3.1 Study Objectives  .......................................................................................................18  
3.1.1  Primary  ..........................................................................................................18  
3.1.2  Secondary  ......................................................................................................18  
3.1.3  Exploratory ...................................................................................................18  
3.2 Study Outcome Measures .........................................................................................19  
3.2.1  Primary  ..........................................................................................................19  
3.2.2  Secondary  ......................................................................................................20  
3.2.3  Exploratory ...................................................................................................21  
4 Study Design  .........................................................................................................................23  
5 Study Enrollment and Withdrawal........................................................................................25  
5.1 Eligibility Criteria  .....................................................................................................25  
5.1.1  Subject Inclusion Criteria  .............................................................................25  
5.1.2  Subject Exclusion Criteria  ............................................................................26  
5.2 Treatment Assignment Procedures  ...........................................................................29  
5.2.1  Enrollment and Randomization Procedures..................................................29  
5.2.2  Masking Procedures ......................................................................................30  
5.2.3  Reasons for Withdrawals and Discontinuation of Study Product 
Adm inistration  ..............................................................................................30  
5.2.4  Handling of Withdrawals and Discontinuation of Study Product 
Administration  ..............................................................................................33  
5.2.5  Subject Replacement  .....................................................................................33  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
iv 5.2.6  Termination of Study ....................................................................................34  
6 Study Intervention/Investigational Product ..........................................................................35  
6.1 Study Product Description ........................................................................................35  
6.1.1  Acquisition  ....................................................................................................36  
6.1.2  Formulation, Storage, Packaging, and Labeling ...........................................36  
6.1.3  Study Product Storage and Stability Procedures ..........................................38  
6.2 Dosage, Preparation and Administration of Study Intervention/Investigational 
Product ......................................................................................................................39  
6.3 Modification of Study Intervention/Investigational Product for a Subject ...............41  
6.4 Accountability Procedures for the Study Intervention/Investigational Product .......41  
6.5 Assessment of Subject Compliance with Study Intervention/Investigational Product
...................................................................................................................................42  
6.6 Concomitant Medications/Treatments  ......................................................................42  
7 Study Procedures/Evaluations ..............................................................................................43  
7.1 Clinical Evaluations  ..................................................................................................43  
7.2 Laboratory Evaluations .............................................................................................44  
7.2.1  Clinical Laboratory Evaluations ...................................................................44  
7.2.2  Special Assays or Procedures  .......................................................................45  
7.2.3  Specimen Preparation, Handling and Shipping ............................................49  
8 Study Schedule......................................................................................................................50  
8.1 Screening (Optional) and Enrollment Visits  .............................................................50  
8.1.1  Visit 00, Screening (Day -28 to - 1), Clinic Visit, All Treatment Arms, 
Optional.........................................................................................................50  
8.1.2  Visit 01, Day 1, Enrollment (for subjects previously screened at Day -28 to -1) and First Study Vaccination (Dose 1), Clinic Visit, All Treatment Arms 51
 
8.1.3  Visit 01, Day 1, Enrollment/Baseline (for subjects not previously screened 
at Day -28 to -1) and First Study Vaccination ( Dose 1), Clinic Visit, All 
Treatment Arms  ............................................................................................53  
8.2 Follow- up Visits ........................................................................................................55  
8.2.1  Visit 02, Day 2, Clinic Visit, All Treatment Arms  .......................................56  
8.2.2  Visit 03, Day 4, Clinic Visit, All Treatment Arms  .......................................56  
8.2.3  Visit 04, Day 8, Clinic Visit, All Treatment Arms  .......................................57  
8.2.4  Visit 05, Day 15, Clinic Visit, All Treatment Arms  .....................................58  
8.2.5  Clinic Visit, Treatment Arms 2, 3, 5, and 6 ..................................................58  
8.2.6  Safety Follow -up, Phone Call, Treatment Arms 2, 3, 5, and 6 .....................59  
8.2.7  Second Study Vaccination (Dose 2), Clinic Visit, All Treatment Arms  ......59  
8.2.8  Clinic Visit, All Treatment Arms ..................................................................61  
8.2.9  Clinic Visit, All Treatment Arms ..................................................................62  
8.2.10  Clinic Visit, All Treatment Arms ..................................................................63  
8.2.11  Clinic Visit, All Treatment Arms ..................................................................64  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
v 8.2.12  Clinic Visit, All Treatment Arms ..................................................................64  
8.2.13  Safety Follow -up, Phone Call, All Treatment Arms.....................................65  
8.2.14  Clinic Visit, All Treatment Arms ..................................................................65  
8.2.15  Safety Follow -up, Phone Call, All Treatment Arms.....................................66  
8.2.16  Clinic Visit, All Treatment Arms ..................................................................66  
8.3 Final Visit..................................................................................................................67  
8.3.1  Safety Follow -up, Phone Call, All Treatment Arms.....................................67  
8.4 Early Termination Visit (if needed)  ..........................................................................67  
8.5 Unscheduled Visit (if needed) ..................................................................................68  
9 Assessment of Safety  ............................................................................................................70  
9.1 Specification of Safety Parameters  ...........................................................................70  
9.2 Methods and Timing for Assessing, Recording and Analyzing Safety Parameters .70  
9.2.1  Adverse Events  .............................................................................................70  
9.2.2  Reactogenicity ...............................................................................................72  
9.2.3  Additional Adverse Event Severity Grading ................................................74  
9.2.4  Serious Adverse Events ................................................................................76  
9.2.5  Procedures to be Followed in the Event of Abnormal Laboratory Test 
Values or Abnormal Clinical Findings  .........................................................77  
9.3 Reporting Procedures ................................................................................................77  
9.3.1  Serious Adverse Events ................................................................................77  
9.3.2  Regulatory Reporting for Studies Conducted Under DMID- Sponsored IND
.......................................................................................................................78  
9.3.3  Reporting of Pregnancy ................................................................................79  
9.4 Type and Duration of Follow-up of Subjects after Adverse Events .........................79  
9.5 Halting Rules  ............................................................................................................79  
9.6 Safety Oversight ........................................................................................................81  
9.6.1  Independent Safety Monitor (ISM) ...............................................................81  
9.6.2  Data and Safety Monitoring Board (DSMB) ................................................82  
10 Clinical Monitoring  ...............................................................................................................84  
10.1  Site Monitoring Plan  .................................................................................................84  
11 Statistical Considerations  ......................................................................................................85  
11.1  Introduction ...............................................................................................................85  
11.2  Study Hypothe ses......................................................................................................85  
11.3  Study Outcome Measures .........................................................................................85  
11.4  Sample Size Considerations ......................................................................................85  
11.4.1  Study Population ...........................................................................................85  
11.4.2  Subject Enrollment and Follow-up ...............................................................86  
11.4.3  Sample Size  ...................................................................................................86  
11.5  Planned Interim Analyses  .........................................................................................88  
11.5.1  Interim Safety Review  ..................................................................................89  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
vi 11.5.2  Interim Immunogenicity Review  ..................................................................89  
11.6  Final Analysis Plan  ...................................................................................................90  
11.6.1  Analysis Populations .....................................................................................90  
11.6.2  Safety Data  ....................................................................................................91  
11.6.3  Imm unogenicity Data ....................................................................................92  
11.6.4  Missing Values and Outliers  .........................................................................93  
12 Data Collection Forms and Access to Source Data/Documents  ...........................................95  
13 Quality Control and Quality Assurance ................................................................................96  
14 Ethics/Protection of Human Subjects ...................................................................................97  
14.1  Ethical Standard  ........................................................................................................97  
14.2  Institutional Review Board (IRB) .............................................................................97  
14.3  Informed Consent Process ........................................................................................97  
14.4  Exclusion of Women, Minorities and Children (Special Populations) ...................100  
14.5  Subject Confidentiality  ...........................................................................................101  
14.6  Study Discontin uation .............................................................................................102  
14.7  Costs, Subject Compensation and Research Related Injuries .................................102  
14.8  Future Use of Stored Specimens .............................................................................103  
15 Data Handling and Record Keeping  ...................................................................................106  
15.1  Data Management Responsibilities .........................................................................106  
15.2  Data Capture Methods  ............................................................................................106  
15.3  Types of Data  ..........................................................................................................107  
15.4  Timing/Reports  .......................................................................................................107  
15.5  Study Records Retention .........................................................................................108  
15.6  Protocol Deviations .................................................................................................108  
16 Publication Policy  ...............................................................................................................110  
17 Literature References  ..........................................................................................................111  
Appendices ...................................................................................................................................116  
Appendix A.  SCHEDULE OF STUDY PROCEDURES AND EVALUATIONS  .........117  
Appendix B.  SCHEDULE OF SPECIAL ASSAYS  ........................................................127  
Appendix C.  LIST OF POTENTIALLY IMMUNE- MEDIATED MEDICAL 
CONDITIONS  ....................................................................................................................132  
 
   
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
vii LIST OF TABLES  
Table 1: Study Design  .................................................................................................................. xxi  
 
 
Table 4: Venipuncture Volumes for Treatment Arms 1 and 4 ......................................................47  
Table 5: Venipuncture Volumes for Treatment Arms 2, 3, 5, and 6 .............................................48  
Table 6: Injection Site Reactogenicity Grading  .............................................................................73  
Table 7: Injection Site Reactogenicity Measurements  ...................................................................73  
Table 8: Subjective Systemic Reactogenicity Grading  ..................................................................74  
Table 9: Quantitative Systemic (Oral Temperature) Reactogenicity Grading  ...............................74  
Table 10: Pulse and BP Adverse Event Grading ...........................................................................75  
Table 11: Clinical Safety Laboratory Adverse Event Grading  ......................................................75  
Table 12: Power (%) to Detect Safety Events  ...............................................................................87  
Table 13: Precision of Binomial Confidence Intervals ..................................................................87  
Table 14: Minimum Detectable Difference in Proportion Responders .........................................88  
Table 15: Vaccination Period for Treatment Arms 1 and 4 .........................................................117  
Table 16: Follow-Up Period for Treatment Arms 1 and 4 (Including Early Termination 
and Unscheduled Visits) ...........................................................................................120  
Table 17: Vaccination Period for Treatment Arms 2, 3, 5, and 6 ................................................122  
Table 18: Follow-Up Period for Treatment Arms 2, 3, 5, and 6 (Including Early 
Termination and Unscheduled Visits) ......................................................................125  
Table 19: Special Assays for All Treatment Arms  ......................................................................127  
Table 20: Clinical Laboratory Evaluations, Special Assays and Venipuncture Volumes 
for Treatment Arms 1 and 4  ......................................................................................128  
Table 21: Clinical Laboratory Evaluations, Special Assays and Venipuncture Volumes 
for Treatment Arms 2, 3, 5, and 6 .............................................................................130  
 
  

DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
viii LIST OF FIGURES  
Figure 1: Schematic of Study Design  ......................................................................................... xxii  
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
ix LIST OF ABBREVIATIONS  
A/H1N1  Influenza A Virus of the H1N1 Subtype  
A/H1N2v  Influenza A Virus of the H1N 2 Variant Subtype  
A/H2N2  Influenza A Virus of the H2N2  Subtype  
A/H3N2  Influenza A Virus of the H3N2 Subtype  
A/H3N2v  Influenza A Virus of the H3N2 Variant Subtype  
A/H5N1  Influenza A Virus of the H5N1 Subtype  
A/H5N6  Influenza A Virus of the H5N 6 Subtype  
A/H5N8  Influenza A Virus of the H5N8 Subtype  
A/H7N1  Influenza A Virus of the H7N1 Subtype  
A/H7N7  Influenza A Virus of the H7N7 Subtype  
A/H7N9  Influenza A Virus of the H7N9  Subtype  
A/H9N2  Influenza A Virus of the H9N2  Subtype  
AE Adverse Event/Adverse Experience  
AESIs  Adverse Events of Special Interest  
ALT  Alanine Aminotransferase  
ANCA  Anti-Neutrophil Cytoplasmic Antibody  
AS03  Adjuvant System (03)  
BARDA  Biomedical Advanced Research and Development Authority  
BLA  Biologics License Application  
BMI  Body Mass Index  
BP Blood Pressure  
CDC  Centers for Disease Control  and Prevention  
CFR  Code of Federal Regulations  
CHMP  Committee for Medicinal Products for Human Use  
CI Confidence Interval  
CMS  Clinical Material s Services  
COI Conflict of Interest  
Cr Creatinine  
CROMS  Clinical Research Operations and Management Support  
CSL Commonwealth Serum Laboratories  
CSR  Clinical Study Report  
°C Degrees Celsius  
°F Degrees Fahrenheit  
D Day(s)  
DCF  Data Collection Form  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, NIH  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
x DSMB  Data and Safety Monitoring Board  
eCRF  Electronic Case Report Form  
EDCSM Electronic Data Capture System  
ELISA  Enzyme -Linked Immunosorbent Assay  
ELISpot  Enzyme -Linked Immunosorbent Spot  
ELLA  Enzyme -Linked Lectin Assay  
ESR Erythrocyte Sedimentation Rate  
FACS  Fluorescence -Activated Cell Sorting  
FDA  Food and Drug Administration  
FWA  Federalwide Assurance  
g/dL  Grams per Deciliter  
GBS  Guillain -Barré Syndrome  
GCP  Good Clinical Practice  
GMT  Geometric Mean Titer  
GSK  GlaxoSmithKline Biologicals  
HA Hemagglutinin  
HAI Hemagglutination Inhibition  
Hgb Hemoglobin  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
HPAI  Highly Pathogenic Avian Influenza  
HRSA  Health Resources and Services Administration  
IATA  International Air Transport Association  
ICD-10 10th revision of the International Statistical Classification of 
Diseases and Related Health Problems  
ICF Informed Consent Form  
ICH International Council for  Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
ICS Intracellular Staining  
IEC Institutional Ethics Committee  
IgA Immunoglobulin A 
IgG Immunoglobulin G  
IgM Immunoglobulin  M 
IIV Inactivated Influenza Virus Vaccine  
IIV3  Trivalent IIV 
IM Intramuscular (ly) 
IND Investigational New Drug  Application  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
xi IU/L  International Unit(s) per Liter  
LLC  Limited Liability Company  
MAAE  Medically -Attended Adverse Event  
mcg Microgram(s)  
µL Microliter(s)  
MedDRA Medical Dictionary for Regulatory Activities  
MF59  MF59C.1 Adjuvant  
mg/dL  Milligram(s) per Deciliter  
mITT  Modified Intent -to-Treat  
mL Milliliter(s)  
mm Millimeter(s)  
mmHg  Millimeters of Mercury  
MOP  Manual of Procedures  
N Number of Subjects  
NA Neuraminidase  
NAI Neuraminidase  Inhibiting or Inhibition  
Neut  Neutralizing or Neutralization  
NIAID  National Institute of Allergy and Infectious Diseases, NIH  
NIH National Institutes of Health , DHHS  
NK Natural Killer  
NSAIDs  Non-Steroidal Anti-Inflammatory Drugs  
NOCMCs  New -Onset Chronic Medical Conditions  
OER  Office of Extramural Research  
OHRP  Office for Human Research Protections  
OTC  Over the Counter  
PBMC  Peripheral Blood Mononuclear Cell  
PBS Phosphate Buffered Saline  
pH1N1  2009 H1N1 Influenza  
PHI Personal Health Information  
PI Principal Investigator  
PIMMCs  Potentially Immune -Mediated Medical Conditions  
PLT Platelets  
PP Per Protocol  
PREP Act  Public Readiness and Emergency Preparedness Act  
PRN  As Needed  
QA Quality Assurance  
QC Quality Control  
SAE  Serious Adverse Event/Serious Adverse Experience  
SAP Statistical Analysis Plan  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
xii SDCC  Statistical and Data Coordinating Center  
SMA  Secondary Medical Assessor  
SOC  System Organ Class  
SOP Standard Operating Procedure  
SP Sanofi Pasteur  
SRID  Single Radial Immunodiffusion  
TBD  To Be Determined  
T. Bili  Total Bilirubin  
US United States  
V Visit(s)  
VTEU  Vaccine and Treatment Evaluation Unit  
WBC  White Blood Cells  
WHO  World Health Organization  
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
xiii PROTOCOL SUMMARY  
Title:  A Phase II Study to Assess the Safety, Reactogenicity and 
Immunogenicity of Different Prime -Boost Vaccination Schedules 
of 2013 and 2017 A/H7N9 Inactivated Influenza Vaccines 
Administered Intramuscularly with or without AS03 Adjuvant in 
Healthy Adults 19 -50 Years of Age 
Phase:  II 
Population: Up to 180 males and non- pregnant females, 19 to 50 years of age, 
inclusive, who are in good health and meet all eligibility criteria  
Number of Sites:  5 Vaccine and Treatment Evaluation Unit (VTEU) sites (and their subcontractors) 
Study Duration:  Approximately 22 months 
Subject Participation 
Duration: Up to 18 months 
Estimated Time to Complete 
Enrollment:  Approximately 12 weeks  
Description of Agent:  • Monovalent inactivated split influenza 2013 (A/H7N9/Shanghai/2/2013) and 2017 (A/H7N9/Hong Kong/125/2017) A/H7N9 virus vaccines (2013 and 2017 A/H7N9 inactivated influenza virus vaccines  [IIVs]) 
manufactured by Sanofi Pasteur (SP).  
• AS03 adjuvant manufactured by GlaxoSmithKline 
Biologicals (GSK).  
• Phosphate buffered s aline ( PBS) diluent manufactured by 
Patheon Manufacturing Services LLC. 
Study Objectives:  
 Primary:  
Safety:  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
xiv • To assess the safety and reactogenicity of 2013 and 2017 
A/H7N9 IIVs given with or without AS03 adjuvant 
following receipt of each study vaccine. 
Immunogenicity : 
• To assess the serum hemagglutination inhibition (HAI) and 
neutralizing (Neut) antibody responses following receipt of 
the second study vaccine. 
Secondary:  
Safety:  
• To assess unsolicited non- serious adverse events (AEs) 
following receipt of each study vaccin e. 
• To assess medically -attended adverse events (MAAEs), 
including new-onset chronic medical conditions 
(NOCMCs) and potentially immune- mediated medical 
conditions (PIMMCs), following receipt of each study 
vaccine. 
Immunogenicity : 
• To assess the kinetics and durability of serum HAI and 
Neut antibody responses following receipt of each study 
vaccine. 
Exploratory: 
Immunogenicity:  
• To assess the effects of age, sex, body mass index (BMI), 
and prior receipt of seasonal or non- study pandemic 
influenza vaccine(s) on serum HAI and Neut antibody responses following receipt of the second study vaccine. 
• To assess the neuraminidase (NA) cont ent of the 2013 and 
2017 A/H7N9 IIVs and determine, in at least a subset of samples, the serum antibody responses to N9 NA. 
• To assess, in at least a subset of samples, HA stem -specific 
antibody responses. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
xv • To assess, in at least a subset of samples, the cro ss-
reactivity of serum HAI and Neut antibody responses to 
antigenically drifted  variants of influenza A/H7 viruses. 
• To assess, in at least a subset of samples, the frequency of 
influenza- specific (A/H7N9 antigens) IgA , IgG  and Ig M 
memory B cells (MBCs).  
• To assess, in at least a subset of samples, the frequency of influenza- specific (A/H7N9 antigens) IgA , IgG  and Ig M 
plasmablasts ( antibody- secreting cells [ ASCs ]). 
• To assess, in at least a subset of samples, the multifunctional cytok ine/chemokine profile of influenza 
A/H7N9 -specific CD4 and CD8 T cells.  
• To assess, in at least a subset of samples, the characterization  of circulating T follicular helper (cT
FH) 
cells.  
• To assess, in at least a subset of samples, the study vaccine -induced changes in populations and/or activation 
status of innate immune cells (monocytes, dendritic cells [DCs] and  natural killer [NK] cells) . 
• To assess, in at least a subset of samples, the study 
vaccine -induced activation status of B cells.  
• To assess, in at le ast a subset of samples, the B cell 
receptor repertoire and degree of somatic hypermutation  
generated in response to study vaccination. 
Study Outcome Measures:  
 Primary:  
Safety:  
• Occurrence of all serious adverse events (SAEs) from the 
time of the first study vaccination through approximately 
12 months after the last study vaccination. 
• Occurrence of solicited injection site and systemic 
reactogenicity events from the time of each study 
vaccination through 7 days after each study vaccination. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
xvi • Occurre nce of clinical safety laboratory AEs from the time 
of each study vaccination through approximately 7 days 
after each study vaccination.  
Immunogenicity : 
• For HAI and Neut antibodies, percentage of subjects 
achieving seroconversion against the influenza A/H7N9 
study vaccine viruses (defined as either a pre-vaccination 
titer <1:10 and a post- vaccination titer ≥1:40 or a pre -
vaccination titer ≥1:10 and a minimum four -fold rise in 
post- vaccination antibody titer) approximately 21 days 
after the second study vaccination . 
• For HAI and Neut antibodies, percentage of subjects 
achieving titer ≥1:40 against the influenza A/H7N9 study 
vaccine viruses approximately 21 days after the second 
study vaccination. 
• Geometric m ean t iters (GMTs) of serum HAI and Neut 
antibodies against the influenza A/H7N9 study vaccine viruses approximately 21 days after the second study 
vaccination . 
Secondary:  
Safety:  
• Occurrence of all unsolicited non-serious AEs  from the 
time of each study vaccination through approximately 21 
days a fter each study vaccination.  
• Occurrence of all MAAEs, including NOCMCs and 
PIMMCs, from the time of the first study vaccination 
through approximately 12 months after the last study 
vaccination.  
Immunogenicity : 
• For HAI and Neut antibodies, percentage of subjects achieving seroconversion against the influenza A/H7N9 study vaccine viruses approximately 21 days after the first 
study vaccination as well as immediately prior to and 
approximately 180 days after the second study vaccination. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
xvii • For HAI and Neut antibodies, percentage of subjects 
achieving titer ≥1:40 against the influenza A/H7N9 study 
vaccine viruses immediately prior to each study vaccination, approximately 21 days after the first study 
vaccination and approximately 180 days after the second 
study vaccination. 
• GMTs of serum HAI and Neut antibodies against the influenza A/H7N9 study vaccine viruses immediately prior to each study vaccination, approximately 21 days after the first study vaccination and approximately 180 days after the second study vaccination. 
Exploratory: 
Immunogenicity:  
• For HAI and Neut antibodies, GMTs and percentage of 
subjects achieving seroconversion against the influenza A/H7N9 study vaccine viruses approximately 21 days after the second study vaccination, by age, sex, BMI, and prior 
receipt of seasonal or non- study pandemic influenza 
vaccine(s).  
• GMTs and percentage of subjects achieving 
seroconversion (defined as four-fold change from baseline) of serum anti- NA (by enzyme -linked immunosorbent assay 
[ELISA]) or anti -neuraminidase inhibition ( NAI) (by 
enzyme -linked lectin assay [ELLA]) antibodies 
immediately prior to and approximately 21 days after each study vaccination as well as approximately 180 days after the second study vaccination. 
• Correlate the HA and/or NA content of 2013 and 2017 
A/H7N9 IIVs with the elicited HA or N9 NA- specific 
antibody titer  approximately 21 days after each study 
vaccination  as well as  immediately prior to and 
approximately 180 days after the second study vaccination. 
• GMTs of HA stem -specific antibody immediately prior to 
and approximately 21 days after each study vaccination as 
well as approximately  180 days after the second study 
vaccination . 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
xviii • For HAI and Neut an tibodies, GMTs and p ercentage o f 
subjects achieving seroconversion against antigenically 
drifted variants of influenza A/H7 viruses approximately 21 days after the second study vaccination. 
• Percentage of influenza- specific (A/H7N9 antigens) IgA, 
IgG and IgM MBCs at baseline and approximately 90 and 
180 days after the second study vaccination. 
• Frequency of influenza- specific (A/H7N9 antigens) IgA, 
IgG and IgM plasmablasts  (ASCs ) present in circulation 
approximately 7 days after each study vaccination. 
• Percentage of influenza A/H7N9- specif ic CD4 and CD8 T 
cells producing cytokines/chemokines immediately prior to and approximately 7 days after each study vaccination as 
well as approximately 90 days after the second study 
vaccination . 
• Percentage of cT
FH cells producing cytokines/chemokines 
immediately prior to and approximately 3, 7 and 14  days 
after each study vaccination.  
• Percentage and activation status of innate immune cells (monocytes, DCs and NK cells) immediately prior to and approximately 1, 3, 7 and 14 days after each study vaccination.  
• Percentage of activated B cells immediately prior to and 
approximately 1, 3, 7 and 14 days after each study vaccination.  
• Evaluation of B cell receptor repert oire and d egree of 
somatic hypermutation of anti-HA (H7) and anti- NA (N9) 
antibodies at baseline and approximately 180 days after the 
second study vaccination. 
• Correlation of the above exploratory immunologic 
parameters with HAI and Neut antibodies. 
Description of Study Design:  This is a Phase II clinical trial in up to 180 males and non-
pregnant females, 19 to 50 years of age, inclusive, who are in good 
health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
xix of one or two doses of monovalent inactivated split influenza 2013 
and 2017 A/H7N9 virus vaccines (2013 and 2017 A/H7N9 IIVs) 
manufactured by Sanofi Pasteur (SP), administered intramuscularly at different dosages (3.75 or 15 mcg of hemagglutinin (HA) per dose), given with or without AS03 
adjuvant manufactured by GlaxoSmithKline Biologicals (GSK), 
using different heterologous and homologous prime-boost vaccination schedules . Phosphate buffered saline (PBS) diluent 
manufactured  by Patheon Manufacturing Services LLC  may be 
used to achieve targeted dosages.  
Subjects who are influenza A/H7 vaccine/infection naïve by medical history will be  randomly assigned to 1 of 6 treatment arm s 
to receive one or two doses of the 2013 and 2017 A/H7N9 IIVs in different heterologous and homologous prime -boost combinations 
evaluating the interval between the priming (first) and boosting (second) doses (21 days vs. 4 months) and the presence of the 
adjuvant in the priming (first) and boosting (second) doses (see 
Table 1). 
Reactogenicity will be measured by the occurrence of solicited 
injection site and systemic reactions from the time of each study 
vaccination through 7 days after each study vaccination. Unsolicited non- serious adverse events (AEs) will be collected 
from th e time of each study vaccination through approximately 21 
days after each study vaccination. Serious adverse events (SAEs) and medically -attended adverse events (MAAEs), including new-
onset chronic medical conditions (NOCMCs) and potentially 
immune -mediated medical conditions (PIMMCs), will be 
collected from the time of the first study vaccination through 
approximately 12 months after the last study vaccination. Clinical safety laboratory evaluations (hematology and chemistry) will be 
performed on venous bl ood collected immediately prior to each 
study vaccination and approximately 7 days after each study 
vaccination . 
Immunogenicity testing will include performing serological assays 
to assess hemagglutination inhibition (HAI), neutralizing (Neut) , 
neuraminidase inhibition (NAI), neuraminidase (NA) -specific, and 
HA stem -specific antibody titers at multiple time points following 
each study vaccination.  In addition, peripheral blood mononuclear 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
xx cells ( PBMCs ) will be used to determine broad immunologic 
responses a nd to correlate these responses with serological 
antibody responses described above in each of the treatment arms. 
These responses will include longitudinal assessments of the kinetics, magnitude, specificity, and/or quality of influenza-
specific B and T c ells, circulating T follicular helper (cT
FH) cells 
and innate immune cells (monocytes, dendritic cells [DCs]  and 
natural killer [NK] cells)  as well as  the frequency of influenza-
specific IgA, IgG  and Ig M plasmablasts (antibody- secreting cells  
[ASCs ]) and B cell receptor somatic hypermutation and repertoire 
assessment s. Venous blood will also be collected at multiple time 
points following each study vaccination for the future research use of serum , plasma and PBMCs. 
In addition, we plan to determine the N9 NA -specific antibody 
response to study vaccination as well as assess the NA content of 
the 2013 and 2017 A/H7N9 IIVs using assays that are currently 
under development to  determine if  the NA content in a dose-
specific manner correlates with the N9 NA -specific antibody 
response. 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
1 1 KEY ROLES  
Lead Principal Investigator:  
 Evan J. Anderson , MD  
Emory University School of Medicine 
 
DMID Clinical Project Manager:  Wendy Buchanan, RN, MS  
Division of Microbiology and Infectious Diseases 
NIAID, NIH  
 
DMID Medical Monitor:  Mohamed Elsafy , MD  
Division of Microbiology and Infectious Diseases 
NIAID, NIH  
 
DMID Medical Officer:  
 Francisco Leyva, MD, PhD, ScM  
Division of Microbiology and Infectious Diseases NIAID, NIH  
 
DMID Scientific Lead:  
 Chris Roberts, PhD  
Division of Microbiology and Infectious Diseases NIAID, NIH  
 
Site Principal Investigators:  Robert L. Atmar, MD  
Baylor College of Medicine  
 Emmanuel “Chip” Walter, MD, MPH  
Duke Vaccine and Trials Unit  
 Nadine Rouphael, MD 
The Hope Clinic of Emory Vaccine Center  
 
Evan J. Anderson, MD Emory Children’s Center 
 
Sharon Frey, MD St. Louis University 
 
Jeffery Meier , MD  
University of Iowa Hospitals and Clinics  
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
2 Pat Winokur , MD  
University of Iowa Hospitals and Clinics  
 
Safety and Pharmacovigilance: 
 DMID Pharmacovigilance Group 
Clinical Research Operations and Management Support 
(CROMS)  
 
Statistical and Data Coordinating Center:  The E mmes  Company, LLC  
 
Clinical Materials Services : Fisher BioServices  
 
Central (Clinical)  Laboratory: PPD Global Central Laboratories  
 
HAI and Neut Antibody Assays 
Laboratory: Southern Research  
 
Cellular Immun ology and 
Additional  Serological Assays 
Laboratories: To Be Determined ( TBD ) 
 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
3 2 BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE 
2.1 Background Information  
The continued emergence of novel influenza A viruses in humans including subtypes H5N1, 
H5N6,  H3N2v , H1N2v, H7N7, H9N2, 2009 H1N1, and most recently H7N9, underscores the 
need for focused efforts to prepare for the next influenza pandemic [1 -9]. Four pandemics 
occurred during the last century. It was estimated that during the 1918 influenza A/H1N1 pandemic as many as 40 million deaths occurred worldwide [10]. Excess mortality, high 
morbidity and social disruption were all noted during the 1957 influenza A/H2N2 and the 1968 influenza A/H3N2 pandemics [11] . In April 2009, a novel influenza virus (2009 A/H1N1) 
originated in pigs and spread to humans around the world becoming the first pandemic of this 
century. In each of these influenza pandemics, human populations lacked significant levels of 
pre-existing immunity to  a highly transmissible form of the virus enabling it to spread rapidly. 
Thus, each emergence of a new strain  of influenza virus in the human population has the 
potential to  result in a global public health emergency. 
A major cornerstone of pandemic prepar edness is the capacity to rapidly produce and deliver 
sufficient quantities of safe and effective strain -specific pandemic influenza vaccines. The threat 
of pandemic influenza in 1976 (swine influenza) and again in 1977 (Russian influenza) resulted 
in inactivated influenza virus vaccine (IIV) development programs that provided important 
insights into variables influencing the immune responses to immunization  [12, 13] . Vaccine-
associated factors potentially affecting the immunogenicity of IIVs that were noted during the 
1976 experience and have been refined in subsequent years include the amount of viral 
hemagglutinin (HA) protein in the vaccine, the number and intervals of doses administered, the addition of immune stimulating components (i.e. , adjuvants), and the manufacturing methods 
used to produce the vaccine (i.e., whole virus, split virus or purified surface antigen). Host-
specific factors, including the recipient ’s age, their prior influenza infections and/or vaccinations, 
and the presence of underlying diseases and their treatments, all can influence the immune 
responses elicited by an influenza vaccine.  
Serum antibodies targeting the influenza virus HA and neuraminidase (NA), the major surface 
glycoproteins on influenza viruses, play a key role in protective immunity to influenza virus 
infection  [14]. Since protection against infection with seasonal influenza virus strains has been 
shown to correlate with both serum hemagglutination inhibition (HAI) and neutralizing (Neut) 
antibody levels, their measurements  are used routinely to assess the immunogenicity of both 
seasonal and pandemic IIVs. Recent data also supports an important role for neuraminidase 
inhibiting (N AI) antibodie s in protection against disease  [15]. In a recent human influenza 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
4 challenge study, serum N AI antibody levels we re also identified as an independent correlate of 
protection against influenza illness [16] . In the current study, we plan to assess the NA content of 
the monovale nt inactivated split influenza 2013 and 2017 A/H7N9 virus vaccines (2013 and 
2017 A/H7N9 IIVs) and determine the correlation of the NA content at different vaccine dosages 
with the elicited humoral antibody responses to the N9 NA.  
Several approaches have been used to increase the immunogenicity of IIVs . Standard -dose 
seasonal IIVs contain 7.5 to 15 mcg of HA antigen per seasonal influenza vaccine strain for 
children and adults up to 64 years of age. Clinical studies evaluating increased HA -containing 
influenza vaccines performed over the past 35 years have shown dose- related increases in serum 
and mucosal antibody responses [17-25]. Higher HA dosage influenza vaccines can lead to enhanced antibody responses in the elderly [26]. In 2009, a high-dose seasonal IIV containing 4 
times the standard HA antigen per  seasonal  influenza vaccine strain was approved in the United 
States (US) for use in individuals 65 years of age and older. 
In general, clinical studies evaluating vaccines made from novel avian influenza viruses (e.g., 
A/H5N1, A/H7N7 , 2013 A/H7N9) suggest that these vaccines are substantially less 
immunogenic than those from other novel subtypes (e. g., 2009 A/H1N1 pandemic virus), even 
when administered at high HA dosages [27, 28]. Due to the poor immunogenicity of A/H5 and 
A/H7 vaccines , the inclusion of adjuvants was evaluated to assess their ability to boost anti -viral 
serum IgG  levels. In the US, aluminum salts are licensed as adjuvants in combination with 
several vaccines; however, their use in subvirion influenza A/H5N1 vaccines has shown either 
no effect or a very modest enhancement of immune responses compared to non- aluminum salt 
containing formulations [29-31]. In contrast, the use of oil- in-water emulsion adjuvants, most 
notably proprietary adjuvants AS03 and MF59 produced by GlaxoSmithKline Biologicals (GSK) 
and Novartis (now Seqirus), respectively, has resulted in increased antibody responses to IIVs 
containing novel HAs in numerous clinical trials [32-36]. In an early study, dosage levels 
ranging from 3.75 to 30 mcg of A/H5N1 antigen administered with or without AS03 resulted in 
significant increases in antibody g eometric m ean titers (GMTs) in subjects  who received the 
adjuvanted formulations [34]. These GMTs met the Committee for Medicinal Products for 
Human Use (CHMP) criterion  for seroconversion rate (>40%) after a single dose with adjuvant. 
Following the second vaccine dose, all adjuvanted formulations complied with both CHMP and 
US Food and Drug Administration (FDA) criteria for seroconversion and seroprotection rates, 
whereas from the non-adjuvanted treatment arms  only the 30 mcg formulation met the CHMP 
criterion for seroconversion [34]. GSK received approval for the registration of a pre- pandemic 
AS03 -adjuvanted, monovalent inactivated influenza A/H5N1 virus vaccine by European 
regulatory authorities in 2008 and FDA approva l of their Biologics License Applications (BLA) 
for an Influenza A (H5N1) Virus Monovalent Vaccine Adjuvanted (with AS03) in 2013. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
5 Following the 2009 emergence of the novel A/H1N1 pandemic virus, the European Commission 
granted marketing authorization of G SK’s egg -derived AS03-adjuvanted monovalent inactivated 
influenza 2009 A/H1N1 virus vaccine (Pandemrix™) and Novartis’ egg-derived MF59-
adjuvanted, monovalent inactivated influenza 2009 A/H1N1 virus vaccine (FOCETRIATM). 
These adjuvanted monovalent inactivated influenza 2009 A/H1N1 virus vaccines were widely 
used throughout Europe and in many other countries, albeit not in the US. 
The inclusion of adjuvants in clinical trials evaluating IIVs has also frequently been associated 
with increased injection site reactogenicity [29]. Additionally, in late 2010, a possible association between an increased risk of narcolepsy in children and adolescents who had received the AS03-
containing Pandemrix™ was  reported in Finland and Sweden. Some, but not all, countries in 
which retrospective studies were conducted showed a similar association [37-45]. See Section 
2.3.1 for further discussion. 
Because of the substantial increases in antibody responses when these o il-in-water emulsion  
adjuvants were added to otherwise poorly immunogenic, novel HA influenza vaccines, they may 
be a critical component of the public health response to the next influenza pandemic. As part of its pandemic preparedness efforts, the US Government maintains stockpiles of unique HA-
containing influenza vaccines, including those against influenza A/H7N9  and A/ H5N1  viruses as 
well as AS03 and MF59 adjuvants. The National Institute of Allergy and Infectious Diseases  
(NIAID) has conducted s everal clinical trials to  evaluate A/H7N9 and A/ H5N1 vaccines  
administered with and without these adjuvants in healthy adult and elderly populations and found 
that the vaccines co -administered with adjuvants were w ell-tolerated , exhibited dose-sparing and 
substantially increased the immunogenicity of strain -specific novel HA vaccines  compared to 
non-adjuvanted formulations [46-51]. In response to emerging influenza A/ H5N8 viruses that 
have caused extensive outbreaks in domestic poultry and wild birds in South East Asia [52, 53], NIAID is also conducting two  ongoing clinical trials with an  A/H5N8 vaccine produced by 
bioCSL ( now Seqirus) administered with either AS03 (GSK) or MF59 (Seqirus) adjuvants in 
healthy subjects, 19 to 64 years of age (DMID Protocol 15-0064; [STUDY_ID_REMOVED] and DMID 
Protocol 15-0066; [STUDY_ID_REMOVED]). 
Since March of 2013 [54], avian influenza A/H7N9 virus es have continued to circulate in China 
causing discrete outbreaks (or waves) in humans  with high mortality  over the past 5 years . China 
is currently experiencing it’s “sixth  wave” of A/ H7N9 infections, and as of March 2 , 2018, a 
total of 1,567 laboratory-confirmed human infections with avian influenza A/H7N9 virus es have 
been reported by the World Health Organization [55] . Whereas  most cases have been centered in 
and around mainland China, there have been several traveler -associated cases, including two in 
travelers reported by Canada who were returning from China in early  2015 [56]. Most  of the 
reported human cases have been associated with exposure to infected live poultry or 
contaminated environments, including markets where live poultry are sold. Influenza A/H7N9 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
6 viruses continue to be detected in poultry and their environments in the areas where human cases 
are occurring. Information to date indicates that these viruses do not transmit easily from human 
to human, with most isolates appearing  to have retained their  suscept ibility  to NA inhibitors [56] . 
Laboratory studies have shown that influenza A/H7N9 viruses readily infect cells from human respiratory tract tissue samples and can spread from ferret to ferret by dropl et transmission, 
thereby increasing the concern about the pandemic potential of these viruses [57, 58]. 
During the “fifth wave” of outbreaks which began in October 2016, more human cases of 
A/H7N9 infection were reported in China than during any prior A/ H7N9 epidemic wave [55]. In 
addition, a n antigenically distinct lineage of these fifth wave influenza A/H7N9 viruses known as 
the Yangtze River Delta lineage has recently  emerged and has been associated with  an increasing 
number of human case s [59]. 
The US Department of Health and Human Services (D HHS) recentl y determined  influenza 
A/H7N9 virus as having a significant potential to cause a pandemic, and the greatest risk of 
causing severe disease.  As a result, DHHS has supported the production of fifth wave pre-
pandemic A/H7N9 IIVs for the US stockpile and for a n assessment of safety and 
immunogenicity in clinical trials.  
2.1.1 Public Readiness and Emergency Preparedness Act  
For this protocol, the study products (2013 and 2017 A/H7N9 IIVs manufactured by Sanofi 
Pasteur  and AS03  adjuvant manufactured by  GSK ) are covered under the Public Readiness and 
Emergency Preparedness Act (PREP Act).  Under the PREP Act, covered persons are immune 
from liability actions brought from the administration or use of a covered countermeasure that is the subject of a declaration.  The PREP Act provides immunity for covered persons (such as 
manufacturers, distributers, program planners, and other qualified persons who prescribe, 
administer or dispense the 2013 and 2017 A/H7N9 IIVs with or without AS03 adjuvant ) from 
tort liability, unless the injury was caused by willful misconduct.  
The PREP Act also established the Countermeasures Injury Compensation Program (CICP) to provide compensation for serious injuries that occur as the result of the administration or use of 
certai n countermeasur es. Any requests for compensation must be filed within one year of 
administratio n or use of the countermeasure. Requests would go to the Health Resources and 
Services Administration ( HRSA) Preparedness Countermeasures Injury Compensation Program  
(http://www.hrsa.gov/cicp/ ). Compensation may then be available for medical benefits, lost 
wages and death benefits to eligible individuals for specified injuries in accordance with regulations published by the Secretary of HRSA . Eligibility for compe nsation and the injuries for 
which compensation may be available are further defined by regulation. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
7 An individual who suffers a serious physical injury or death from administration and use of the 
2013 and 2017 A/H7N9 IIVs with or without AS03 adjuvant may  request benefits from the 
CICP . A serious physical injury means an injury that is life -threatening, or results  in or requires 
medical or surgical intervention to prevent permanent impairment of a body function or 
permanent damage to body structure. The  CICP is the payer of last resort. This means that it only 
covers expenses or provides benefits that other third-party payers, such as health insurance, and the Department of Veterans Affairs  or Workers’ Compensation programs do not have an 
obligation to pay.  
If no funds have been appropriated to the compensation program, the Secretary of HRSA  does 
not make a final determination on the individual’s request within 240 days, or if the individual decides not to accept the compensation, the injured individual or his representative may pursue a tort claim in the US  District Court for the District of Columbia, but only if the claim involves 
willful misconduct, is pled with particularity required under the PREP Act, verified, and accompanied by an affidavit by a ph ysician who did not treat the individual and certified medical 
records.  Any award is reduced by any public or private insurance or worker’s compensation 
available to the injured individual. Awards for non-economic damages, such as pain, suffering, 
physical  impairment, mental anguish, and loss of consortium are also limited.  If the individual 
accepts compensation, or if there is no willful misconduct, then the individual does not have a 
tort claim that can be filed in a US  Federal or a State court.  
2.2 Scientific Rationale  
As part of the US Government’s past pandemic preparedness efforts, Sanofi Pasteur under contract to the Biomedical Advanced Research and Development Authority (BARDA)/ DHHS , 
produced several  novel pre- pandemic vaccines that were or are currently being evaluated by 
NIAID’s  VTEU sites to asse ss their safety, reactogenicity  and immunogenicity when mixed prior 
to administration with either AS03 or MF59 oil- in-water adjuvants manufactured by GSK and 
Seqirus , respectively. In general, these “mix and match” clinical trials have demonstrated that 
adjuvant use results in a significant dose- sparing effect .  
The large number of human infections starting with the “fifth wave” of outbreaks  in late 2016 
has increased  the pandemic risk  potential of infl uenza A/H7N9 viruses circulating in China. The 
Yangtze River Delta lineage, a distinct A/ H7N9 viral lineage, has now emerged and has been 
associated with many  of the fifth wave cases. Fifth wave A/H7N9 viruses have led  to a broader 
geographic spread of infected birds and human cases within China than previously reported . 
Further, several  influenza A/ H7N9 viruses in the Yangtze River Delta lineage have recently 
acquired genetic changes characteristic of highly pathogenic av ian influenza (HPAI) viruses and 
have now shown an increased ability to infect and kill poultry [56, 59]. To date, no cases of A/H7N9 from the new viral lineage have been identified in birds or people infected outside of 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
8 China; however, a few cases have been identified in Hong Kong and Taiwan in infected travelers 
returning from China. Importantly, antigenic analysis of the fifth wave influenza A/ H7N9 viruses 
and serolog ical studies indicate that the stockpiled 2013 A/ H7N9 IIV manufactured several years 
ago does not induce protective HAI or Neut antibodies against the Yangtze River Delta lineage . 
Hence, there is broad consensus across DHHS and interagency leadership that a new  vaccine 
should be developed that would be effective against the current ly predominating influenza 
A/H7N9 vir uses. 
Several candidate vaccine viruses are under evaluation by the Centers for Disease Control and 
Prevention ( CDC ) and the World H ealth Organization ( WHO) H5 R eference Laboratories 
Network. Under contract to BARDA/DHHS, Sanofi Pasteur has produced monovalent inactivated split influenza 2013 and 2017 A/H7N9  virus vaccines (2013 and 2017 A/H7N9  IIVs) 
using largely the same manufacturing process as its licensed , seasonal  trivalent IIV (IIV3) . The 
availability of the US Government-stockpiled AS03 (GSK) oil- in-water adjuvant provides an 
opportunity to determine if dose- sparing effects occur when mixing the Sanofi  Pasteur 2013 and 
2017 A/H7N9  IIVs with  the GSK AS03 adjuvant. See Sections 2.3.1 and 6.1 for additional 
details on the 2013 and 2017 A/H7N9 IIVs. 
Heterologous prime-boost vaccination regimens have shown considerable promise in expanding the breadth and durability of cross-clade antibody responses [60, 61]. In addition, the use of adjuvants and extending the interval between the priming (first) and boosting (second) dose s of 
vaccine have also led to more robust cross-clade antibody responses [60-63]. 
The goal of this clinical trial is to assess in healthy adults, 19 to 50 years of age, the safety, 
reactogenicity and immunogenicity of one or two doses 2013 and 2017 A/H7N9 IIVs, administered intramuscularly at different dosages (3.75 or 15 mcg of hemagglutinin (HA) per 
dose), given with or without AS03 adjuvant, using different heterologous and homologous 
prime -boost vaccination schedules to evaluate the study vaccine dosage, dose- sparing potential 
of the adjuvant, optimal prime-boost interval for immunogenicity (two doses administered 21 
days vs. 4 months apart ), and priming effects of different A/H7N9 IIVs. In addition to assessing 
antigen -sparing strategies, another goal of this study is to assess in at least a subset of samples , if 
serum immunoglobulin elicited by the 2013 and 2017 A/H7N9 IIVs recognize antigenically 
drifted variants of influenza A/H7 viruses. Since antibodies targeting the NA may represent an 
independent correlate of protection against influenza infection [15, 16], we plan to as sess the NA 
content of the 2013 and 2017 A/H7N9 IIVs and determine if there is a dose- specific correlation 
of the NA content with the elicited humoral antibody responses to the N9 NA. 
This clinical trial will also investigate novel methods for identifying and assessing alternative 
cellular correlates of protection against influenza infection. These will include longitudinal 
assessments of: 1) the kinetics , magnitude, specificity, and/or quality of influenza- specific B and 
T cells , cT
FH cells and innate immune cells (monocytes, DCs  and NK cells) ; 2) the frequency of 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
9 influenza- specific IgA, IgG  and IgM plasmablasts  (ASCs); and 3) B cell receptor somatic 
hypermutation and repertoire assessments.  
Based on previously conducted studies with a 2013 A/ H7N9 IIV manufactured by Sanofi Pasteur 
administered with or without AS03, we anticipate that two doses of the 2013 and 2017 A/H7N9 
IIVs administered IM at different dosages with or without AS03 adjuvant using different prime-
boost vaccination schedules will be well -tolerated and more immunogenic compared to the non-
adjuvanted study vaccine in healthy adults. 
2.3 Potential Risks and Benefits  
2.3.1 Potential Risks  
The potential risks of participating in this trial are those associated with having blood drawn, the intramuscular ( IM) injection, possible reactions to the 2013 and 2017 H7N9  IIVs, with or 
without PBS diluent, and/or AS03  adjuvant, and breach of confidentiality.  
Drawing blood may cause transient discomfort and fainting. Fainting is usually transient and 
managed  by having the subject lie down and elevate his/her legs . Bruising at the blood draw site 
may occur , but can be prevented or lessened by applying pressure to the blood draw site for a 
few minutes  after the blood is taken. IM injection may also cause transient discomfort and 
fainting.  Drawing blood and IM injection may  cause infection. The use of aseptic (sterile) 
technique will make infection  at the site where blood will be drawn or where the study 
vaccination will be  given extremely unlikely.  
There is a small amount of risk to subjects who report that they are in good health but who have 
an unknown health problem at the time of screening . This trial will screen by  physical exam, 
history, vital signs and erythrocyte sedimentation rate  (ESR). Clinical safety labs for white blood 
cells (WBC), hemoglobin (Hgb), platelets (P LT), alanine aminotransferase (ALT), total bilirubin  
(T. Bili) , and creatinine ( Cr) will be drawn prior to each study vaccination , but results will not be 
reviewed until after each study vaccination . To minimize the risk,  subject s will not receive the 
second study vaccination  unless , the most recently evaluated clinical safety laboratory values 
obtained prior to the second study vaccination are Grade 2 or less and  the subject does not meet 
any of the other criteria listed in Section 5.2.3. 
There is potential for AEs to occur more frequently in the adjuvanted vaccine treatment arms  
[64] than in the non-adjuvanted treatment arms  and there is po tentially a higher risk for AEs to 
occur more frequently in the higher dose influenza antigen treatment arms  than in the lower dose 
influenza antigen treatment arms . 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
10 The 2017 A/H7N9 IIV  to be used  in this clinical trial has  not been  tested for safety in animals ; 
however, it is currently being evaluated in humans. The Division of Microbiology and Infectious 
Diseases (DMID), NIAID is sponsoring two Phase II clinical trials in healthy subjects to assess the safety, reactogenicity and immunogenicity of IM dos es of the 2017 A/H7N9 IIV produced by 
Sanofi Pasteur, Swiftwater, PA, administered with or without the AS03 adjuvant produced by 
GSK and co -administered sequentially or simultaneously with licensed, seasonal influenza 
vaccine ( Fluzone
® Quadrivalent Influenza Vaccine) produced by Sanofi Pasteur, Swiftwater, PA 
(DMID Protocols: 17-0075; NCT 03312231, 17-0077; NCT 03318315). 
The 2013 A/H7N9 IIV to be used in this clinical trial is currently being  tested for safety in 
animals. In addition, DMID, NIAID has sponsored at least five  Phase I I clinical tr ials to assess 
the safety, r eactogen icity and immunogen icity o f IM doses of the 2013 A/H7N9 IIV  produced by  
Sanofi Past eur, Swiftwater, PA, administer ed with or without either AS03 (GSK) or MF59 
(Seqirus) adjuvants  in healthy subjects  (DMI D Protocol s: 13-0032; NC T01938742, 13-0033 ; 
[STUDY_ID_REMOVED] , 13-0034; [STUDY_ID_REMOVED] , 13-0044; [STUDY_ID_REMOVED], and 14- 0015; [STUDY_ID_REMOVED]). 
Overall, the study products administered in these clinical trials were generally safe and well -
tolerated.  
For DMID Protocol 13- 0032, nine SAEs were reported. All were assessed as being not related 
to study product. Two cases of Autoimmune thyroiditis (Hashimoto’s disease/Hashimoto’s 
thyroiditis) , classified as  Adverse Events of Special Interest (AESIs) , were reported in this 
clinical trial: one case was assessed as not related to study product (due to preexisting Thyroid Peroxidase Antibodies) whereas  the other  case was assessed as related to study product (no 
preexisting Thyr oid Peroxidase Antibodies). 
For DMI D Protocol 13-0033, sixt een SAE s were  reported. Fift een of these SAE s were assess ed 
as being not relat ed 
to study product. One SA E was consider ed to be  relat ed: acute inferi or 
myoca rdial infarction. Two AES Is were  repo rted in this c linical tr ial: psori asiform dermatitis and  
celiac di sease; both ass essed as not relat ed to study product , because both disorders pre -existed 
to study vaccination, but both disorders received the diagnosis after study vaccination. 
For DMI D Protocol 13-0034, seventy -five SAEs were reported . All were assessed as being not 
related to study product. Two AESIs were reported in this clinical trial: guttate psoriasis vulgaris 
and lichen planus; both were assessed as related to study product. For DMI D Protocol 13-0044, no SAEs were reported. No AESIs were reported, since this 
clinical trial tested the unadjuvanted 2013 A/H7N9 IIV. For DMI D Protocol 14-0015, one SAE was reported . It was assessed as not related to study 
product. No AESIs were  repo rted in this c linical tr ial. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
11 The monovalent split 2013 A/H7N9 IIV to be used in this clinical trial w as deriv ed from the 
influenza virus A/Shanghai/2/2013 (H7N9). The monovalent split 2017 A/H7N9 IIV to be used 
in this clinical trial w as deriv ed from the infl uenza virus A/Hong Kong/125/2017 (H7N9). The 
manufacturing process for the production of these investigational A/H7N9 vaccines is  similar 
to the process used to produce the licensed , Influenza Virus Vaccine Fluzone® family of 
products , except for a minor modification in the PBS  diluent in the formulation step of the 
2013 A/H7N9 IIV that was made according to previous experiences of manufacturing of 
monovalent pandemic vaccines. As such, the safety profile of the candidate A/H7N9 vaccin es 
should be similar to the current Fluzone® vaccine.  
 
 
 
 
 
 
 
 
 
The pot ential risks to su bjects are an ticipat ed to be sim ilar to those observed  for S anofi P asteur’s 
unadjuv anted licensed , inter-pandemic ( seasonal ) IIVs (Fluzone® and Fluzone® High-Dose), thei r 
unadjuv anted licensed , 2009 A/H1N1 and  A/H5N1 monoval ent IIVs, and their  monovalent split 
2013 A/ H7N9 IIV administered with or without AS03 or MF59 ( see the Sanofi Pasteur 
Investigator’s Brochure  Investigational Pandemic Influenza Virus vaccines, Monovalent 
A/Shanghai/2/2013 (H7N9) product code 504, Monovalent A/Hong Kong/125/2017 (H7N9) 
product code 504, Monovalent A/Indonesia/05/2005 (H5N1) product code 458, Monovalent A/Vietnam/1203/2004 (H5N1) product code 399, Monovalent A/Bar- Headed Goose/Qinghai 
Lake/1A/2005 (H5N1) product code 458, Version Number 1.0, January 2018).  
Occasionally, adult recipients of unadjuvanted licensed, IIVs may devel op influenza- like 
reactions , such as fever, feverishness ( chills/shivering/sweating), fatigue (tired ness), malaise 
(general unwell feeling), myalgia (body aches/muscular pain), arthralgia (joint pain), headache, and/or nausea. Some subjects may develop rea ctions at the injec
 tion site, including pruritus 
(itching), ecchymosis (bruising), erythema (redness), induration (hardness), edema ( swelling ), 
pain, and/or tenderness. Most of these reactions peak in intensity in the first 24 hours after vaccination and  disappear without treatment within 1 or 2 days. Analgesics (e.g., acetaminophen, 

DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
12 ibuprofen or similar non- steroidal anti- inflammatory drugs [NSAIDs] ) and rest may generally 
relieve or lessen these reactions.  Bruising can sometimes occur due to the vaccination procedure. 
In addition, post- marketing surveillance indicates autoimmune disorders as potential risks for 
pandemic vaccines based on those identified for the seasonal IIVs; these may also include , but 
are not limited to, neuritis, convulsions, severe allergic reactions, syncope, encephalitis, 
thrombocytopenia, vasculitis, and Guillain- Barré syndrome (GBS) . Reports of these reactions 
were rare; however, exact incidence rates cannot be precisely calculated.  
Acute and potentially life -threatening allergic reactions (i.e., anaphylaxis) are also possible.  
These reactions occur in about 1 in 4 million people given a vaccination. These reactions can manifest as  skin rash (hives), swelling around the mouth, throat or eyes  (angioedema) , diffi culty 
breathing  (bronchospasm), a fast pulse (tachycardia) , or decrease in  blood pressure 
(hypotension). If these reactions occur, they can usually be stopped by the administration of emergency medications by the study personnel. As with any vaccine or medication, there is a 
very small chance of a death, although researchers do not expect this to occur. 
During the swine influenza ( A/H1N1) vaccine campaign of 1976, some recipients developed a 
paralytic illness called GBS . GBS  is an acute inflammatory neuropathy characterized by 
weakness, hyporeflexia or areflexia, and elevated protein concentrations in cerebrospinal fluid.  
The rate of GBS was significantly increased in individuals receiving the 1976 swine influenza 
(A/H1N1) vaccine at about 1 per 100,000 vaccine recipients. This syndrome has not been seen 
consistently with other influenza vaccines.  Most persons who develop GBS recover completely, 
although the recovery period may be as little as a few weeks or as long as a few years.  About 
30% of those with GBS still have residual weakness after 3 years and about 3% may suffer a relapse of muscle weakness and tingling sensations many years after the initial attack.  Intensive 
surveillance of GBS after administration of IIVs since 1976 has shown a slight increase in risk 
over background cases (more than one additional case of GBS per million persons) following vaccination, typically with onset within 6 weeks after vaccination [65]. Interestingly, although 
vaccination rates have increased in the last 10 years , the numbers of reported cases of vaccine-
associated GBS have declined [66]. A recent study in Canada showed that the 2009 A/H1N1 
vaccine was associated with a small but significant risk of GBS in persons 50 years of age and 
older [67]. An act ive, population-based surveillance study conducted in the US  during the 2009-
2010 influenza season found less than 1 excess GBS case per million doses of 2009 A/H1N1 vaccine administered – a rate similar to that associated with some previously administered 
annual influenza vaccines [68-70]. Another study using the Medicare system showed an elevated risk of GBS  with monovalent 2009 A/H1N1  vaccination (incidence rate ratio = 2.41, 95% 
confidence interval (CI) : 1.14, 5.11; attributable risk = 2.84 per million doses administered, 95% 
CI: 0.21, 5.48) [71]. An international collaboration study also supported a conclusion of an association between 2009 A/ H1N1 vaccination and GBS [72]. It is unknown if the administration 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
13 of the 2013 and 2017 A/H7N9 IIVs to be used in this clinical trial will result in an increased 
incidence of  GBS  as the mechanism leading to this AE  has not been completely elucidated.  
As of November 22, 2015 ( per the GSK AS03 Adjuvant Investigator’s Brochure  dated February 
2016), data are available for 56 GSK-sponsored clinical trials of AS03-adjuvanted monovalent 
pandemic vaccines manufactured by GSK.  More than 18,000 adult (age ≥ 18 years) and 6,900 
pediatric (6 months to 17 years old) clinical trial participants have received at least one dose of a GSK-manufactured, AS03-adjuvanted monovalent pandemic influenza vaccine. Clinical d ata 
collected by GSK as of November 22, 2015, suggest that inactivated monovalent (pre)pandemic 
influenza virus antigens adjuvanted with AS03 have generally acceptable safety and benefit/risk 
profile s, though the incidence rates of solicited injection site  and systemic AEs are higher with 
AS03 -adjuvanted antigens than with antigen alone, a licensed IIV3  or placebo. Some unsolicited 
AEs (e.g., insomnia, dizziness, cystitis) were associated with a  higher relative r isk among AS03 -
adjuvanted H5N1 recipients in contrast to Fluar ix
® or placebo recipients. 
The information and guidance that follow are based on pre- clinical and clinical study results for 
GSK-manufactured AS03- adjuvanted monovalent pandemic vaccines, post -marketing safety 
surveillance data seen with unadjuvanted, IIV3 s and (in the case of the A/H1N1 vaccines) post-
marketing safety surveillance data seen to date for both Pandemrix™ and Arepanrix ™ H1N1  
vaccines . 
The reactogenicity profile in humans of GSK- manufactured  AS03 -adjuvanted vaccines is 
primarily  associated with  the adjuvant. The incidence and severity  of injection site redness, 
swelling and pain at the injection site in recipients of AS03 -adjuvanted vaccines are increased 
relative to monovalent pandemic influenza antigen alone, a licensed  IIV3 or placebo. Th ere is no 
increase in injection site and systemic  reactogenicity  events in  recipients of AS03-adjuvanted 
vaccines  after  a second dose of vaccine relative to the first when given 21 days  apart.  In young 
children (6 months to 6 years old), increased frequency  of fever  has been observed following a 
heterologous booster dose of adjuvanted vaccine administered 6 months after the primary  series.  
As of November 22, 2015, there has been no evidence in clinical trials to support a conclusion that any potential immune -mediated disease or group of diseases was causally related to an AS03 -
adjuvanted vaccine.  There have been no deaths in GSK clinical trials of AS03- adjuvanted 
pandemic influenza vaccines assessed as related  to study vaccine . A total of 1,428 non- fatal SAEs 
have been reported for adult subjects as of November 22, 2015. Fifteen of these events were deemed related to vaccination by the Investigator or GSK.  Of these, six occurred in recipients of 
an adjuvanted H1N1 vaccine: asthma, herpes zoster, hepatic enzyme increased, and pain in extremity, polymyalgia rheumatic, and thrombocytopenia. Three occurred in recipients of 
unadjuvanted H1N1 vaccine:  alanine aminotransferase increased, hypersensitivity, and multiple 
sclerosis.  One SAE classified as related (myalgia) occurred in a subject who received a control 
product. Four SAEs classified as related occurred in recipients of an adjuvanted H5N1 vaccine: 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
14 autoimmune hepatitis, angina pectoris, pulmonary embolism, and non- Hodgkin’s lymphoma.  One 
SAE classified as related (lobar pneumonia) occurred in a recipient of an unadjuvanted H5N1 
vaccine. Overall, the reactogenicity and safety profile of AS03- adjuvanted pandemic vaccines is 
acceptable and no safety concerns have been identified in clinical trial s. 
Narcolepsy is a chronic sleep disorder with a background incidence rate, based on US data, of 
approximately 1.37 per 100,000 per year, with a peak onset between 10 and 19 years of age in 
some datasets.  Narcolepsy, when associated with cataplexy is seen almost exclusively in 
individuals who are HLA DQB1 *0602 allele carriers  [73]. An autoimmune etiology has been 
proposed. In the post- marketing period for adjuvanted H1N1 pandemic vaccines, several 
epidemiological studies conducted in several countries independently of GSK reported an increased risk of narcolepsy with or without cataplexy in subjects who were vaccinated with  
Dresden -manufactured H1N1 ( Pandemrix ™ H1N1 ) vaccine during the 2009- 2010 season. These 
studies have described an absolute risk increase of narcolepsy of approximately 1.4 to 8 additional cases per 100,000 vaccinated children/adolescents, and approximately one additional case per 100,000 vaccinated adults compared to background rates of 0.12 to 0.79 per 100,000 children/adolescents per year and 0.67 to 1.10 per 100,000 adults per year. The observed temporal 
association between narcolepsy  and vaccination with Pandemrix ™ H1N1 is not fully understood, 
and further research  to evaluate the association between narcolepsy and Pandemrix ™ H1N1, and 
other possible contributory factors to the development of narcolepsy during the 2009- 2010  
pandemic,  such as genetic and environmental factors, is being conducted.  A GSK-supported 
study was conducted in Quebec, Canada, to assess the risk of narcolepsy associated with 
Arepanrix H1N1, using various index dates, risk periods, observation periods, and epidemiological designs. Overall, GSK considers that there is no strong evidence of an 
association between Q -Pan-H1N1 and narcolepsy in Quebec. Recently, the CDC conducted a 
study to assess trends in narcolepsy incidence rates before and after 2009 H1N1 influenza 
(pH1N1) vaccination campaigns and to evaluate the risk of narcolepsy following adjuvanted 
pH1N1 vaccines. Results of the incidence rates analysis indi cated no change in narcolepsy rates 
between the period before wild-type pH1N1 virus circulation and the period after the start of 
pH1N1vaccination campaigns in any countries except Sweden, the first signaling country, and Taiwan, where incidence began to increase upon wild-type pH1N1 virus circulation. In the case-
control analysis, no association was observed for AS03-adjuvanted pH1N1 vaccine and 
narcolepsy in children or adults, and in the case- coverage analysis no association was observed 
for narcolepsy in children, the only age groups studied. However, the data for the AS03-adjuvanted pH1N1 vaccine, Pandemrix™, were limited (20th Annual Conference on Vaccine 
Research, April 24 -26th, 2017, Abstract S6- 1). 
No post- marketing data are available for AS03 administered in combination with any GSK -
manufactured H5N1, H7N1, H7N9, or H9N2 antigen. However, millions of doses of GSK-manufactured H1N1 antigens, combined with AS03, were administered in the context of the 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
15 2009/10 pandemic response. In addition to the adverse reactions reported in clinical trials, the 
following have been reported during post- marketing experience with Pandemrix ™ (H1N1) and 
Arepanrix ™ (H1N1):  
• Immune system disorders 
o Rare: anaphylaxis, allergic reactions  
• Nervous system disorders 
o Rare: feb rile convulsions (in subjects below 20 years of age), somnolence **, 
Guillain -Barré syndrome* 
*Spontaneous reports of Guillain-Barré syndrome have been received following 
vaccination with Arepanrix™ (H1N1); however, a causal association between vaccination and Guillain-Barré syndrome has not been established. Data  from a post-
marketing epidemiological study in Canada indicate a small but significant increased relative risk of Guillain -Barré syndrome of 1.80 (95% CI, 1.63-4.62) in the 56-day 
period following vaccination with Arepanrix™ (H1N1, in persons 50 years of age 
and older). The number of GBS cases attributable to vaccination was approximately 
2 per 1 million doses. 
**reported in patients with narcolepsy and as a temporary event following 
vaccination 
o Very rare
1: narcolepsy with or without cataplexy  
1Frequency based on estimated  attributable risk from  epidemiological studies in 
several European countries. 
• Skin and subcutaneous tissue disorders 
o Rare: angioedema, generalized skin reactions, urticaria  
• General disorders and administration site conditions o Rare: injection site reactions (such as inflammation, mass, ecchymosis)  
From post- marketing surveillance with inter -pandemic (seasonal) trivalent vaccines, the 
following additional AE s have been reported: 
• Blood and lymphatic system disorders 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
16 o Transient thrombocytopenia 
• Nervous system disorders 
o Neuralgia, convulsions  
o Neurological disorders, such as encephalomyelitis, neuritis, and Guillain -Barré 
syndrome 
• Vascular disorders  
o Vasculitis with transient renal involvement 
As of November 22, 2015, the available data for women who become pregnant during clinical 
trials of AS03 -adjuvanted (pre) pandemic influenza vaccines do not suggest any causal 
relationship between adverse pregnancy outcomes and receipt of an AS03-adjuvanted vaccine. However, there are no available data related to the risks of exposure to A/H7N9 IIVs 
administered with or without AS03 upon pregnancy and pregnancy outcomes. 
Subjects will be asked to provide personal health information (PHI). All attempts will be made to 
keep this PHI confidential within the limits of the law.  However, there is a chance that 
unauthorized persons will see the subject’ s PHI.  All study records will be kept in a locked file 
cabinet or maintained in a locked room at the participating VTEU sites.  Electronic files will be 
password- protected.  Only people who are involved in the conduct, oversight, monitoring, or 
auditing of this trial will be allowed access to the PHI that is collected.  Any publications from 
this trial will not use information that will identify subjects by name.  Organizations that may 
inspect and/or copy research  records maintained at the participating VTEU sites for quality 
assurance and data analysis include groups such as the IRB, NIAID  and the FDA . 
A description of this clinical trial will be available on  http://www.ClinicalTrials.gov , as required 
by US Law.  This web site will not include information that can identify subjects.
 
There may be other risks, discomforts or side effects  that are unknown at this time. 
2.3.2 Known Potential Benefits  
There are no known be nefits attributable to the receipt of the 2013 and 2017 A/H7N9  IIVs with 
or without AS03 adjuvant. Vaccination using the 2013 and 2017 A/H7N9  IIVs with or without 
AS03 adjuvant may or may not provide protection against a serious disease with the influenza 2013 and 2017 A/H7N9  virus es, should the subject  be exposed . The duration of any such 
protection is currently unknown. The 2013 and 2017 A/H7N9  IIVs with or without AS03 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
17 adjuvant are not expected to offer protection against circulating seasonal influenza viruses. There 
may be pandemic preparedness benefits to society in the future if the vaccine and adjuvants 
being evaluated in this clinical trial prove to be sufficiently safe and immunogenic and can be 
employed if a need for widespread influenza 2013 or 2017 A/H7N9  vaccination occurs.  
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
18 3 STUDY OBJECTIVES  AND OUTCOME MEASURES  
3.1 Study Objectives  
3.1.1 Primary  
Safety : 
• To assess the safety and reactogenicity of 2013 and 2017 A/H7N9 IIVs given with or 
without AS03 adjuvant following receipt of each study vaccine. 
Immunogenicity : 
• To assess the serum hemagglutination inhibition (HAI) and neutralizing (Neut) antibody responses following receipt of the second study vaccine. 
3.1.2 Secondary  
Safety:  
• To assess unsolicited non-serious adverse events (AEs) following receipt of each study 
vaccine.  
• To assess medically -attended adverse events (MAAEs), including new-onset chronic 
medical con ditions (NOCMCs) and potentially immune- mediated medical conditions 
(PIMMCs), following receipt of each study vaccine. 
Immunogenicity : 
• To assess the kinetics and durability of serum HAI and Neut antibody responses following receipt of each study vaccine. 
3.1.3 Exploratory 
Immunogenicity:  
• To assess the effects of age, sex, body mass index (BMI), and prior receipt of seasonal or 
non-study pandemic influenza vaccine(s) on serum HAI and Neut antibody responses 
following receip t of the second study vaccine. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
19 • To assess the neuraminidase (NA) content of the 2013 and 2017 A/H7N9 IIVs and 
determine, in at least a subset of samples, the serum antibody responses to N9 NA. 
• To assess, in at least a subset of samples, HA stem -specific antibody responses.  
• To assess, in at least a subset of samples, the cross -reactivity of serum HAI and Neut 
antibody responses to antigenically drifted variants of influenza A/H7 viruses. 
• To assess, in at least a subset of samples, the frequency of influenza- specific (A/H7N9 
antigens) IgA, IgG  and I gM memory B cells (MBCs).  
• To assess, in at least a subset of samples, the frequency of influenza- specific (A/H7N9 
antigens) IgA, IgG  and Ig M plasmablasts ( antibody- secreting cells [ASCs ]). 
• To assess, in at least a subset of samples, the multifunctional cytokine/chemokine profile 
of influenza A/H7N9-specific CD4 and CD8 T cells. 
• To assess, in at least a subset of samples, the characterization of circulating T follicular 
helper (cT FH) cells.  
• To assess, in at least a subset of samples, the study vaccine-induced changes in populations and/or activation status of innate immune cells (monocytes, dendritic cells [DCs] and natural killer [NK] cells) . 
• To assess, in at least a subset of samples, the study vaccine -induced activation status of 
B 
cells.  
• To assess, in at least a subset of samples, the B cell receptor repertoire and degree of 
somatic hypermutation generated in response to study vaccination. 
3.2 Study Outcome Measures  
3.2.1 Primary  
Safety:  
• Occurrence of all serious adverse events (SAEs) from the time of the first study 
vaccination through approximately 12 months after the last study vaccination. 
• Occurrence of solicited injection site and sy stemic reactogenicity events from the time of 
each study vaccination through 7 days after each study vaccination. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
20 • Occurrence of clinical safety laboratory AEs from the time of each study vaccination 
through approximately 7 days after each study vaccination. 
Immunogenicity:  
• For HAI and Neut antibodies, percentage of subjects achieving seroconversion against the influenza A/H7N9 study vaccine viruses (defined as either a pre- vaccination titer 
<1:10 and a post- vaccination titer ≥1:40 or a pre -vaccination titer  ≥1:10 and a minimum 
four-fold rise in post-vaccination antibody titer) approximately 21 days after the second 
study vaccination. 
• For HAI and Neut antibodies, percentage of subjects achieving titer ≥1:40 against the 
influenza A/H7N9 study vaccine viruses approximately 21 days after the second study 
vaccination.  
• Geometric m ean titers (GMTs) of serum HAI and Neut antibodies against the influenza 
A/H7N9 study vaccine viruses approximately 21 days after the second study vaccination. 
3.2.2 Secondary  
Safety:  
• Occurrence of all unsolicited non- serious AEs from the time of each study vaccination 
through approximately 21 days after each study vaccination. 
• Occurrence of all MAAEs, including NOCMCs and PIMMCs, from the time of the first 
study vaccination through approximately 12 months after the last study vaccination. 
Immunogenicity : 
• For HAI and Neut antibodies, percentage of subjects achieving seroconversion against the influenza A/H7N9 study vaccine viruses approximately 21 days after the first study 
vaccination  as well as  immediately prior to and approximately 180 days after the second 
study vaccination. 
• For HAI and Neut antibodies, percentage of subjects achieving titer ≥1:40 against the 
influenza A/H7N9 study vaccine viruses immediately prior to each study vaccination, approximately 21 days after the first study vaccination and approximately 180 days aft er 
the second study vaccination. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
21 • GMTs of serum HAI and Neut antibodies against the influenza A/H7N9 study vaccine 
viruses immediately prior to each study vaccination, approximately 21 days after the first study vaccination and approximately 180 days after the second study vaccination. 
3.2.3 Exploratory 
Immunogenicity:  
• For HAI and Neut antibodies, GMTs and percentage of subjects achieving 
seroconversion against the influenza A/H7N9 study vaccine viruses approximately 21 
days after the second study vaccination, by age, sex, BMI, and prior receipt of seasonal or 
non-study pandemic influenza vaccine(s).  
• GMTs and percentage of subjects achieving seroconversion (defined as four-fold change from baseline) of serum anti -NA (by enzyme -linked immunosorbent assay [ELISA]) or 
anti-neuraminidase inhibition (NAI) (by enzyme -linked lectin assay [ELLA]) antibodies 
immediately prior to and approximately 21 days after each study vaccination as well as approximately 180 days after the second study vaccination. 
• Correlate the HA and/or  NA content of 2013 and 2017 A/H7N9 IIVs with the elicited HA 
or N9 NA- specific antibody titer approximately 21 days after each study vaccination as 
well as immediately prior to and approximately 180 days after the second study 
vaccination . 
• GMTs of HA stem -specific antibody immediately prior to and approximately 21 days 
after each  study vaccination as well as approximately  180 days after the second study 
vaccination.  
• For HAI and Neut antibodies, GMTs and percentage of subjects achieving 
seroconversion against antigenically drifted variants of influenza A/H7 viruses 
approximately 21 days after the second study vaccination. 
• Percentage of influenza- specific (A/H7N9 antigens) IgA, IgG  and IgM MBCs at baseline 
and approximately 90 and 180 days after the second study vaccination. 
• Frequency of influenza- specific (A/H7N9 antigens) IgA, IgG  and IgM plasmablasts 
(ASCs ) present in circulation approximately 7 days after each study vaccination. 
• Percentage of influenza A/H7N9-specific CD4 and CD8 T cells producing 
cytokines/chemokines immediately prior to and approximately 7 days after each study 
vaccination as well as approximately 90  days after the second study vaccination. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
22 • Percentage of cT FH cells producing cytokines/chemokines immediately prior to and 
approxima tely 3 , 7 and 14  days after each study vaccination.  
• Percentage and activation status of innate immune cells (monocytes, DCs  and NK cells) 
immediately prior to and approximately 1, 3, 7 and 14 days after each study vaccination.  
• Percentage of activated B cel ls immediately prior to and approximately 1, 3, 7 and 14 
days after each study vaccination.  
• Evaluation of B cell receptor repertoire and d egree of somatic hypermutation of anti- HA 
(H7) and anti-NA (N9) antibodies at baseline and approximately 180 days afte r the 
second study vaccination. 
• Correlation of the above exploratory immunologic parameters with HAI and Neut 
antibodies. 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
23 4 STUDY DESIGN  
This is a Phase II clinical trial in up to 180 males and non-pregnant females, 19 to 50 years of 
age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is 
designed to assess the safety, reactogenicity and immunogenicity of one or two doses of monovalent inactivated split influenza 2013 and 2017 A/H7N9 virus vaccines (2013 and 2017 A/H7N9 IIVs) manufactured by Sanofi Pasteur (SP), administered intramuscularly at different 
dosages (3.75 or 15 mcg of hemagglutinin (HA) per dose), given with or without AS03 adjuvant 
manufactured by GlaxoSmithKline Biologicals (GSK), using different heterologous and homologous prime -boost vaccination schedules. Phosphate buffered saline (PBS) diluent 
manufactured by Patheon Manufacturing Services LLC  may be used to achieve targeted dosa ges. 
Subjects who are influenza A/H7 vaccine/infection naïve by medical history will be randomly assigned to 1 of 6  treatment arm s to receive one or two doses of the 2013 and 2017 A/H7N9 IIVs 
in different heterologous and homologous prime -boost combinations evaluating the interval 
between the priming (first) and boosting (second) doses (21 days vs. 4 months) and the presence of the adjuvant in the priming (first) and boosting (second) doses (see Table 1).  
Reactogenicity will be measured by the occurrence of solicited injection site and systemic reactions from the time of each study vaccination through 7 days after each study vaccination. 
Unsolicited non- serious adverse events (AEs) will be collected from the time of each study 
vaccination through approximately 21 days after each study vaccination. Serious adverse events 
(SAEs) and medically -attended adverse events (MAAEs), including new-onset chronic medical 
conditions (NOCMCs) and potentially immune- mediated medical conditions (PIMMCs), will be 
collected from the time of the first study vaccination through approximately 12 months after the last study vaccination. Clinical safety laboratory evaluations  (hematology and chemistry) will be 
performed on venous blood collected immediately prior to each study vaccination and 
approximately 7 days after each study vaccination. 
Immunogenicity testing will include performing serological assays to assess hemagglutination 
inhibition (HAI), neutralizing (Neut), neuraminidase inhibition (NAI), neuraminidase (NA) -
specific, and HA  stem-specific antibody titers at multiple time points following each study 
vaccination. In addition, peripheral blood mononuclear cells (PBMC s) will be used to determine 
broad immunologic responses and to correlate these responses with serological antibody responses described above in each of the treatment arms. These responses will include 
longitudinal assessments of the kinetics, magnitude, specificity, and/or quality of influenza-
specific B and T cells, circulating T follicular helper (cT
FH) cells and innate immune cells 
(monocytes, dendritic cells [DCs] and natural killer  [NK] cells) as well as the frequency of 
influenza- specific IgA, IgG  and IgM plasmablasts (antibody- secreting cells  [ASCs ]) and B cell 
receptor somatic hypermutation  and repertoire assessments. Venous blood will also be collected 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
24 at multiple time points following each study vaccination for the future research use of serum , 
plasma  and PBMCs . 
In addition, we plan to determine the N9 NA -specific antibody response to study vaccination as 
well as assess the NA content of the 2013 and 2017 A/H7N9 IIVs using assays that are currently 
under development to  determine if  the NA content in a dose- specific manner correlates with  the 
N9 NA-specific antibody response. 
For additional details on study procedures and evaluations and study schedule by study 
visits/days , see Sections 7 and 8 as well as  Appendix A:  Schedule of Study Procedures and 
Evaluations  and Appendix B: Schedule of Special Assays . 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
25 5 STUDY ENROLLMENT AND WITHD RAWAL 
Up to 180 males and non-pregnant females, 19 to 50 years of age, inclusive, who are in good 
health and meet all eligibility criteria will be enrolled at up to 5 VTEU sites (and their 
subcontractors) participating in this trial. Th e target population should reflect the community at 
large at each of the participating VTEU sites.  Estimated time to complete enrollment in this trial 
is approximately  12 weeks.  Information regarding this  trial may be provided to potential subjects 
who have previously participated in vaccine trials conducted at each of the participating VTEU sites. Other forms and/or mechanisms of recruitment may also be used. The IRB will approve all 
materials prior to use.  
Subject Inclusion and Exclusion Criteria m ust be assessed by a study clinician licensed to make 
medical diagnoses and listed on the Form FDA 1572 as the site principal investigator (PI) or sub-
investigator.  
No exemptions are granted on Subject Inclusion or Exclusion Criteria in DMID -sponsored 
studies.  Questions about eligibility should be directed toward the DMID Medical Officer. 
5.1 Eligibility Criteria  
5.1.1 Subject Inclusion Criteria  
Subjects eligible to participate  in this trial must meet all of the following inclusion criteria: 
1. Provide written informed consent prior to initiation of any study procedures. 
2. Are able to understand and comply with planned study procedures and be available for all study visits.  
3. Must agree to the collection of venous blood per protocol. 
4. Must agree to have residual specimens and samples/specimens collected during this trial specifically for the purpose of future research  stored for future research use. 
5. Are males or non -pregnant females, 19 to 50 years of age , inclusive. 
6. Are in good health
1. 
1As determined by medical history and  physical examination to evaluate acute or currently ongoing chronic medical 
diagnoses or conditions, defined as those that have been present for at least 90 days, which would affect the assessment 
of the safety of subjects or the immunogenicity of study vaccinations.  Chronic medical diagnoses or conditions should 
be stable for the last 60 days  (no hospitalizations, emergency room  or urgent care for condition and no adverse 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
26 symptoms that need medical intervention such as medication change /supplemental oxygen) . This includes no change in 
chroni c prescription medication, dose  or frequency as a result of deterioration of the chronic medical diagnosis or 
condition in the 60 days prior to enrollment.  Any prescription change that is due to change of health care provider, 
insurance company, etc., or that is done for financial reasons, as long as in the same class of medication, will not be 
considered a deviation of this inclusion criterion.  Any change in prescription medication due to improve ment  of a 
disease outcome, as determined by the site PI or appropriate sub- investigator, will not be considered a deviation of this 
inclusion criterion.  Subjects may be on chronic or as needed (prn) medications if, in the opinion of the site PI or 
appropri ate sub -investigator, they pose no additional risk to subject safety or assessment of reactogenicity and 
immunogenicity and do not indicate a worsening of medical diagnosis or condition.  Similarly, medication changes 
subsequent to enrollment and study vacc ination are acceptable provided there was no deterioration in the subject ’s 
chronic medical condition that necessitated a medication change, and there is no additional risk to the subject or interference with the evaluation of responses to study vaccinatio n. Note: Topical, nasal  and inhaled medications 
(except inhaled corticosteroids as outlined in the Subject Exclusion Criteria (see Section 5.1.2 )) as well as  herbal s, 
vitamins and supplements are permitted.  
7. Oral temperature is less than 100 .0°F.  
8. Pulse is 47 to 100 beats per minute, inclusive. 
9. Systolic blood pressure is 85 to 150 mm Hg, inclusive . 
10. Diastolic blood pressure is 55 to 95 mmHg, inclusive. 
11. ESR is less than 30 mm per hour. 
12. Women of childbearing potential2 must use an acceptable contraception method3 from 30 
days before first  study vaccination until 60 days after last study vaccination. 
2Not sterilized via tubal ligation, bilateral oophorectomy, salpingec tomy , hysterectomy, or successful Essure® 
placement (permanent, non-surgical, non- hormonal sterilization) with documented radiological confirmation test at 
least 90 days after the procedure, and still menstruating or < 1 year has passed since  the last menses if menopausal.  
3Includes  non-male sexual  relationships, abstinence  from sexual intercourse with a male partner,  monogamous 
relationship with vasectomized partner who has been vasectomized for 180 days or more prior to the subject receiving 
the first study vaccination, barrier methods such as con doms or diaphragms /cervical cap  with spermicide, effective 
intrauterine devices, NuvaRing®, and licensed hormonal methods such as implants, injectables or oral contraceptives 
(“the pill”). 
13. Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to study vaccination. 
5.1.2 Subject Exclusion Criteria  
Subjects eligible to participate in this trial must not meet any of the following exclusion criteria:  
1. Have an acute illness
4, as determined  by the site PI  or appropriate sub-investigator, 
within 72 hours prior to study vaccination. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
27 4An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion 
of the site PI or appropriate sub-investigator, the residual symptoms will not interfere with the ability to assess safety 
parameters as required by the protocol.  
2. Have any medical disease or condition that, in the opinion of the site PI or appropriate 
sub-investi gator, is a contraindication to study participation5. 
5Including acute or chronic medical disease or condition, defined as persisting for at least 90 days , that would place 
the subject at an unacceptable risk of injury, render  the subject unable to meet the requirements of the protocol, or may 
interfere with the evaluation of responses or the subject ’s successful completion of this trial . 
3. Have immunosuppression as a result of an underlying illness or treatment, a recent history or current use of immunosuppressive or immunomodulating disease therapy.  
4. Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 3 years prior to study vaccination. 
5. Have known active neoplastic disease or a history of any hematologic malignancy.  Non-
melanoma , treated,  skin cancers are permitted.  
6. Have known human immunodeficiency virus ( HIV), hepatitis B  or hepatitis C infection.  
7. Have known hypersensitivity or allergy to eggs, egg or chicken protein, squalene- based 
adjuvants, or other components of the study vaccine. 
8. Have a history of severe reactions following previous immunization with licensed or unlicensed influenza vaccines.  
9. Have a personal or family history of narcolepsy.  
10. Have a history of GBS . 
11. Have a history of convulsions or encephalomyelitis within 90 days prior to study vaccination.  
12. Have a history of PIMMCs
6 
6Refer to Appendix C: List of Potentially Immune -Mediated Medical Conditions . 
13. Have a history of alcohol or drug abuse within 5 years prior to study vaccination. 
14. Have any diagnosis, current or past, of schizophrenia, bipolar disease or other psychiatric diagnosis that may interfere
7 with subject co mpliance or safety evaluations.  
7As determined by the site PI or appropriate sub-investigator.  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
28 15. Have been hospitalized for psychiatric illness, history of suicide attempt, or confinement 
for danger to self or others within 10 years prior to study vaccination. 
16. Have taken oral or parenteral (including intra -articular) corticosteroids of any dose within 
30 days prior to study vaccination. 
17. Have taken high -dose inhaled corticosteroids8 within 30 days prior to each study 
vaccination.  
8High -dose defined as per age as using inhaled high-dose per reference chart  in the National Heart, Lung and Blood 
Institute Guidelines for the Diagnosis and Management of Asthma (EPR -3) or other lists published in UPTODATE.  
18. Received a licensed , live vaccine within 30 days prior to the first study vaccination, or 
plan to receive a licensed , live vaccine within 30 days before or after each study 
vaccination.  
19. Received or plan to receive a licensed , inactivated vaccine ( excluding all licensed, 
seasonal IIVs) within 14 days before or after each study vaccination. 
20. Received or plan to receive a licensed,  seasonal IIV within  21 days before or after each 
study vacci nation. 
21. Received immunoglobulin or other blood products (except Rho D immunoglobulin) 
within 90 days prior to each  study vaccination. 
22. Received an experimental agent9 within 30 days prior to the first study vaccination or 
expect to receive an experimental agent10 during the trial- reporting period11. 
9Including vaccine, drug, biologic, device, blood product, or medication.  
10Other than from participation in this trial.  
11Approximately 12 months after the last study vaccination . 
23. Are participating or plan to participate in another clinical trial with an interventional 
agent12 that will be received during the trial-reporting period13. 
12Including licensed or unlicensed vaccine, drug, biologic, device, blood product, or medication.  
13Approximately 12 months after the last study vaccination . 
24. Received or plan to receive an influenza A/H7 vaccine14 or have a history of influenza 
A/H7 subtype infection . 
14And assigned to a treatment arm  receiving influenza A/H7 vaccine, i.e., does not apply to documented placebo 
recipients.  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
29 25. Had substantial direct contact15 with live or freshly slaughtered poultry or pigeons while 
in mainland China within the past five years . 
15Substantial  direct  contact is defined as visited a poultry farm and/or a live poultry market.  
26. Occupational exposure to or substantial direct physical contact16 with birds in the past 
year and through 21 days after the last  study vaccination. 
16Exposure to free range chickens in the yard is exclusion ary. Casual contact with birds at petting zoos or county or 
state fairs or having pet birds does not exclude subjects from study participation.  
27. Female subjects who are breastfeeding or plan to breastfeed at any given time from the 
first study vaccination until 30 days after the last study vaccination.  
28. Plan to travel outside the US (continental US , Hawaii  and Alaska) from the time of each 
study vaccination through 21 days after each  study vaccination.  
5.2 Treatment Assignment Procedures  
5.2.1 Enrollment and Randomization Procedures  
Per ICH E6 GCP , screening records will be kept at each participating VTEU sit e to document the 
reason why an individual was screened , but failed trial entry criteria.  The reasons why 
individuals failed screening will be recorded in the Statistical and Data Coordinating Center’s (SDCC)  AdvantageEDC
SM (Electronic Data Capture System) . 
Once consented and upon entry of demographic data and confirmation of eligibility for this trial, 
the subject will be enrolled  and randomly assigned to 1 of 6 treatment arms, stratified by the 
participating VTEU site  and prior receipt of licensed,  seasonal influenza vaccine (defined as 
receipt of at least one of the 2017-2018 and/or 2018-2019 licensed, seasonal influenza vaccines ). 
Subjects will receive two study vaccinations per their randomized treatment assignment (see 
Table 1).  
Enrollment of subjects will be done online using the enrollment module of AdvantageEDCSM. 
The randomization code will be prepared by statisticians at the SDCC and included in the 
enrollment module for th is trial.  AdvantageEDCSM will assign each subject to a treatment arm 
after the demographic and eligibility data have been entered into the system.  A designated 
individual at each participating VTEU site will be provided with a code list for emergency 
unblinding purposes, which will be kept in a secure place. 
Instructions for use of the enrollment module are included in the AdvantageEDCSM User’s 
Guid e. Manual back -up procedures and instructions are provided for use in the event that a 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
30 participating VTEU site temporarily loses access to the Internet or the online enrollment system 
is unavailable.  
5.2.2 Masking Procedures  
This is a partially -blinded  clinical trial. 
Subjects, site investigator s and study personnel performing any study- related assessments 
following study vaccine administration  to the subject are partially -blinded (blinded to treatment 
assignment and unblinded to treatment interval) . Laboratory personnel performing HAI and Neut 
antibody assays will receive serum specimen s blinded to subject ID number and specimen  visit 
number. 
The randomization scheme will be generated by the SDCC and provided to unblinded study 
personnel (i.e., research pharmacist s performing study vaccination preparation s and unblinded 
study vaccine administrator s) at the participating VTEU sites.  
The unblinded study vaccine administrator is a study personnel member credentialed  to 
administer vaccines and may also p articipate in dose preparation, but will not be involved in 
study- related assessments or have subject contact for data collection following study vaccine 
administration  to the subject. 
The Data and Safety Monitoring Board ( DSMB ) may receive data in aggregate and presented by 
treatment arm . The DSMB may also be provided with expected and observed rates of the 
expected AEs in an unblinded fashion, and may request the treatment assignment be unblinded 
for an individual subject if re quired for safety assessment . The DSMB will review grouped and 
unblinded data in the closed session only. 
5.2.3 Reasons for Withdrawals and Discontinuation of Study Product Administration 
Subjects may voluntarily withdraw their consent for trial participation at any time and for any 
reason, without penalty or loss of benefits to which they are otherwise entitled. 
The site PI or appropriate sub- investigator may also withdraw a subject from receiving the study 
vaccine for any reason . 
A subject may withdraw or be withdrawn from this  trial for any of the following reasons: 
• Medical disease or condition, or any new clinical finding for which continued 
participation, in the opinion of the site PI  or appropriate sub-investigator, would 
compromise the safety of the subject, or would interfere with the subject’ s successful 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
31 complet ion of this  trial, or would interfere with the evaluation of responses (for example, 
has baseline significant laboratory abnormalities).  
• Subject no longer meets eligibility criteria  (see Section 5.1). N ote: Medication changes  in 
the 60 days prior to enrollment , as specified in Subject Inclusion Criterion #4, are 
exclusionary for receipt of the first study vaccination only. 
• Subject withdrawal of consent. 
• Subject l ost to follow-up. 
• Termination of this  trial. 
• As deemed necessary by the site PI  or appropriate sub-investigator for noncompliance or 
other reasons. 
• New information becomes available that makes further participation unsafe. 
The second study vaccination will not  be administered to a subject if any of the following 
criteria are met : 
• Medical condition or medication change for which continued participation, in the opinion 
of the site PI  or appropriate sub-investigator, would pose a risk to the subject or would be 
likely to confound interpretation of the results. 
• Presence of signs or symptoms that could confound or confuse assessment of study 
vaccine reactogenicity.  For subjects with injection site or systemic signs or symptoms , or 
with an acute illness, including an oral temperature greater than or equal to 100°F, the 
second  study vaccination should be postponed/deferred until signs, symptoms  or acute 
illness  have /has resolved , or are /is improving as further specified below, and if  within the 
acceptable protocol-specified window for the Dose 2  visit. No exceptions to the protocol-
specified window will be made . Note for afebrile, acute illness only:  If a subject is 
afebrile, his/her acute illness is nearly resolved with only minor residual symptoms remaining, this occurs within the acceptable protocol- specified  window for the Dose 2 
visit, and, in the opinion of the site PI  or appropriate sub-investigator, the residual 
symptoms will not interfere with the ability to assess safety parameters as required by the protocol, the subject may receive the second study vaccination  without further approval 
from the DMID Medical Officer . No exceptions to the protocol-specified window will be 
made. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
32 • Grade 3 solicited or unsolicited AE that occurs without alternative etiology in the 8 days  
after the first study vaccination.  
• Grade 3 solicited or unsolicited AE  that is ongoing, whether or not it is improved or 
resolving. 
• Any unresolved or ongoing Grade 2 solicited or unsolicited AE that does not decreas e to 
Grade 1 or less  prior to the second study vaccination. Note: An unresolved or ongoing 
Grade 1 solicited or unsolicited AE  is permissible following the documented 
determ ination by the site PI  or appropriate sub- investigator, that it would not render study 
vaccination unsafe or interfere with the evaluation of responses. 
• Grade 3 clinical safety laboratory value (according to the toxicity table, Section 9.2.3) 
that does not decrease to Grade 2 or less prior to the second  study vaccination. Note: Any 
clinical safety laboratory parameter may be re- evaluated only once at the central (clinical) 
laboratory in order to assess eligibility prior to the second study vaccination. If the 
clinical safety laboratory value decreases to Grade 2 or less, the subject may receive the second study vaccination. The second study vaccination should be scheduled to occur within the acceptable protocol-specified window for the Dose 2 visit. No exceptions to the protocol-specified window will be made. 
• New onset of illness or condition that meets the Subject E xclusion C riteria  (see Section 
5.1.2). 
• Hospitalization that occurs before administration o f the second study vaccination. 
• Subject no longer meets eligibility criteria  (see Section 5.1). Note: Medication changes 
subsequent to the first study vaccination are not exclusionary for receipt of the second 
study vaccination provided there was no deterioration in the subject’s chronic medical 
condition that necessitated a medication change, and there is no additional risk to the subject or interference with the evaluation of responses to study vaccination. 
• Subject  refusal of further study vaccination. 
• Subject withdrawal of consent. 
• Subject l ost to follow-up. 
• Termination of this  trial. 
• As deemed necessary by the site PI  or appropriate sub-investigator for noncompliance or 
other reasons. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
33 • New information becomes available that makes further participation unsafe. 
5.2.4 Handling of Withdrawals and Discontinuation of Study Product Administration 
The primary reason for withdrawal from this  trial will be recorded on the Study Status data 
collection form (DCF) . Subjects will be encouraged to complete the Early Termination Visit.  
The Early Termination Visit procedures are listed in S ection 8.4. 
Although s ubjects are free to withdraw at any time or may be withdrawn by the site PI  or 
appropriate sub- investigator at any time  (see Section 5.2.3), those subjects who receive only one 
dose of study vaccine will be encouraged to remain in this trial for follow -up safety assessments 
(may be conducted by phone call  rather than in person) continuing through approximately 12 
months after the ir last study vaccination . These subjects will also be encouraged to provide a 
venous blood sample for serological  assays approximately 21 and 180 days after their  last study 
vaccination.  See the protocol -specific Manual of Procedures (MOP) for alternate follow -up 
requirements.  
Every attempt will be made to follow all AEs , including solicited injection site and systemic 
reactions, unsolicited non-serious AEs , SAEs , and MAAEs , including NOCMCs  and PIMMCs, 
ongoing at the time of early withdrawal through resolution as per applicable collection times 
defined for the specific type of AE . 
In the case of subjects who fail to appear for a follow-up safety assessment, extensive effort (i.e., three documented contact attempts via phone calls made on separate occasions and followed by a 
certified letter) will be made to locate or recall them, or at least to determine their health status.  
These efforts wil l be documented in the subject’s study records.  
The site PI  or appropriate sub- investigator will inform the subject that already collected data will 
be retained and analyzed even if the subject withdraws or is withdrawn from this study. 
5.2.5 Subject Replacement  
Subjects who withdraw, or are withdrawn or termi nated from this  trial, or are lost to follow-up 
after signing the informed consent form (ICF) , randomization and receipt of study vaccine will 
not be replaced. However, if a subject withdraws after signing the ICF, but before randomization 
and/or receipt of study vaccine, they may be replaced.  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
34 5.2.6 Termination of Study  
Although the sponsor has every intention of completing this trial, it reserves the right to 
terminate this trial at any time for clinical or administrative reasons. Reasons for termination include , but are not limited to,  study closure due to DSMB review and recommendation, and at 
the discretion of DMID. 
If this trial is prematurely terminated by the spo nsor, any regulatory authority, the site PI , or 
appropriate sub-investigator for any reason, the site PI  or appropriate sub- investigator will 
promptly inform the subjects and assure appropriate therapy or follow-up for the subjects, as 
necessary. The site PI  or appropriate sub-investigator will provi de a detailed written explanation 
of the termination to the IRB.  
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
35 6 STUDY INTERVENTION/I NVESTIGATIONAL 
PRODUCT 
6.1 Study Product Description  
2013 A/H7N9 IIV 
Sanofi Pasteur  has developed a monovalent split 2013 A/H7N9 IIV manufactured using a reverse 
genetics -derived reassortant candidate vaccine virus, IDCDC RG 32A (H7N9), containing the 
HA and NA from avian influenza A/ Shanghai /2/2013 (H7N9) and the PB2, PB1, PA, NP, M and 
NS from A/Puerto Rico/8/1934 (H1N1). The manufacturing process es used  for the 
investigational vaccine are similar to the Fluzone® family of licensed processes , except for a 
minor modification in the PBS  diluent in the formulation step that was made according to 
previous experiences of manufacturing of monovalent pandemic vaccines . 
 
 
 
 
 
 
 
2017 A/ H7N9 IIV  
Sanofi Pasteur  has developed a monovalent split 2017 A/ H7N9 IIV manufactured using a reverse 
genetics -derived reassortant candidate vaccine virus, IDCDC RG56B (H7N9), containing the HA 
and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, 
PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1). The manufacturing process es used  
for the investigational vaccine are  similar to the Fluzone® family of licensed processes . 
 
 
 
 
 

DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
36 PBS Diluent 
The PBS diluent was manufactured by Patheon Manufacturing Services LLC in accordance with  
Good Manufacturing Practice Regulations. 
AS03 Adjuvant [Adjuvant System (03)] 
 
6.1.1 Acquisit
ion 
2013 and 2017 A/H7N9  IIVs will be provided by Sanofi Pasteur  under contract to 
BARDA/DHHS . 
AS03 adjuvant will be provided by GSK under contract to BARDA/DHHS . 
Upon request by DMID, 2013 and 2017 A/H7N9  IIVs and  AS03  adjuvant will be transferred to 
the following address: 
DMID Clinical Materials Services Contract  
Fisher BioServices  
20439 Seneca Meadows Parkway 
Germantown, MD 20876 
Phone: 240-477-1350 
Fax: 240-477-1360 
Email: DMID.CMS@thermofisher.com 
PBS diluent and s terile empty vials (2- mL, 3 -mL or 5-mL) for admixing will be obtained by the 
DMID Clinical Materials Services (CMS)  Contract , Fisher BioServices . 
2013 and 2017 A/H7N9  IIVs, PBS diluent, AS03 adjuvant, and sterile empty vials for study 
vaccine preparation will be provided through the DMID CMS  to the participating VTEU sites 
prior to the start of this  trial upon request and with prior approval from DMID. Should the site PI  
require additional 2103 and 2017 A/ H7N9 IIVs, PBS diluent, AS03 adjuvant, or sterile empty 
vials during this trial, further instructions are provided in the protocol- specific MOP.  
6.1.2 Formulation, Storage, Packaging, and Labeling 
2013 A/H7N9 IIV  

DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
37 Investigational influenza virus A/Shanghai vaccine (H7N9), a monovalent type A inactivat ed 
vaccine for intramuscular (IM) use, is a sterile suspension prepared from pandemic influenza 
virus candidate vaccine propagated in embryonated chicken eggs. Antibiotics are not used in the manufacture of this vaccine.  This vaccine contains no preservative (thimerosal) . There is no 
gelatin added to this vaccine in the manufacturing process. No components of this vaccine 
contain latex . It is essentially clear and slightly opalescent in color  and supplied in single-dose 
glass vials . The vials must be stored at 2°C to 8°C (36°F to 46°F). Do not freeze. Vials will be 
provided with latex- free stoppers . 
 
 
  
  
Detailed mixing instructions to achieve the targeted  dosage is  included in the protocol- specific 
MOP.  
2017 A/ H7N9 IIV  
Investigational influenza virus A/Hong Kong vaccine (H7N9), a monovalent type A inactivated 
vaccine for IM use, is a sterile suspension prepared from pandemic influenza virus candidate vaccine propagated in embryonated chicken eggs. Antibiotics are not used in the manufacture of 
this vaccine.  This vaccine contains no preservative (thimerosal) . There is no gelatin added to this 
vaccine in the manufacturing process. No components of this vaccine contain latex. It  is 
essentially clear and slightly opalescent i n color and supplied in single-dose glass vials . The vials 
must be stored at 2°C to 8°C (36°F to 46°F). Do not freeze. Vials will be provided with latex -
free stoppers . 
 
 
  
  

DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
38 Detailed  mixing instructions to achieve the targeted  dosages are included in the protocol- specific 
MOP.  
PBS Diluent 
 It is
 essentially clear and slightly opalescent in color 
and must be stored at 2°C to 8°C (36°F to 46°F). Vials will be provided with latex free stoppers. 
AS03 Adjuvant [Adjuvant System (03)] 
The AS03 adjuvant is supplied as a preservative -free, oil-in-water , whitish to yellowish 
homogenous milky liquid emulsion presented in 3 mL Type I, single -use glass vials.  The vials 
must be stored at 2°C to 8°C (36°F to 46°F).  Do not freeze. Vials  will be provided with latex -
free stoppers.  
Each of these study products will be labeled according to manufacturer specifications and 
include the statement “Caution: New Drug Limited by Federal Law to Investigational Use.”  
Further details are included in the respective, applicable manufacturers’ Investigator’s Brochures 
for the A/ H7N9 IIV and AS03 adjuvant as well as in the protocol- specific MOP.  
Sterile empty vials (2- mL, 3 -mL or 5 -mL) will be provided with latex -free stoppers . 
6.1.3 Study Product Storage and Stability  Procedures  
The temperature of the storage unit must be manually recorded daily (excluding non-business 
days and holidays, as applicable) and continuously monitored and  recorded during the course of 
this trial per the participating VTEU site stand ard operating procedures (SOPs) , and 
documentation will be maintained.  If the temperature fluctuates outside of the required range, the 
affected study product(s) must be quarantined at the correct storage temperature and labeled as ‘Do Not Use’ (until furt her notice).  The participating VTEU site’s research pharmacist must alert 
the site PI  and study coordinator, if the temperature fluctuates outside of the required range. In 
the event the temperature fluctuates outside of the required range, including accidental deep -
freezing or disruption of the cold chain, the affected study product(s) must not be administered. 
The site  PI or responsible person should immediately contact the DMID Product Support Team 
at DMIDProductSupportTeam@niaid.nih.gov for further instructions before any additional study vaccinations are administered . Based on the information collected, DMID and/or the 
manufacturer will deter mine whether the affected study product(s) can be used. If it cannot be 
used, the site will receive specific instructions on how to return the affected study product(s) to 

DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
39 the DMID CMS  or destroy it on site.  Additional instructions for quarantine and DMID contact 
information are provided in the protocol- specific MOP.  
6.2 Dosage, Preparation and Administration of Study 
Intervention/Investigational Product  
Dosage calculations are based on the actual HA content per 0.5 mL. Each 0.5 mL dose of AS03-
adjuvanted study vaccine contains one dose (0.25 mL) of AS03 adjuvant. 
See the protocol- specific MOP Appendi ces for detailed information on the preparation, labeling, 
storage, and administration of study vaccine for each treatment arm . Study vaccine preparation 
will be performed by the participating VTEU site ’s research pharmacist  on the same day of study 
vaccine administration  to the subject. 
Visually inspect the 2013 and 2017 A/ H7N9 IIV s, PBS diluent and  AS03 adjuvant upon receipt 
and prior to use. If the study product(s) appear (s) to have been damaged, contaminated or 
discolored, contain (s) visible particulate matter , or if there are any concerns regarding the 
integrity,  do NOT use the affected study product(s) . The affected study product(s) must be 
quarantined at 2°C to 8°C (36°F to 46°F) and labeled  as ‘Do Not Use’ (until further notice) . The 
site PI or responsible person should immediately contact the DMID Product Support Team at 
DMIDProductSupportTeam@niaid.nih.gov and DMID Clinical Project Manager for further 
instructions before any additional study vaccinations are administered . Based on the information 
collected, DMID and/or the manufacturer will determi ne whether the affected study product(s) 
can be used.  If the affected study product(s)  cannot be used, the site will receive specific 
instructions on how to return the affected study product(s) to the DMID CMS  or destroy the 
affected study product(s) on si te. If the 2013 or 2017 A/H7N9  IIVs, PBS diluent or AS03 
adjuvant is  unusable, study personnel will use another vial  from the study supply. Replacement 
vials  may be requested by contacting DMID.  Additional instructions for quarantine and DMID 
contact information are  provided in the protocol- specific MOP.  
For those doses that must be admixed with PBS diluent, visually inspect the A/H7N9 IIV plus 
PBS diluent admixture (intermediate or final mixed vial depending on treatment arm) prior to 
use. The A/H7N9 IIV plus PBS diluent admixture will be essentially clear and slightly 
opalescent  in color. For those doses that must be admixed with PBS diluent and AS03 adjuvant, 
visually inspect the A/ H7N9 IIV/PBS diluent plus AS03 adjuvant admixture (final mixed vial) 
prior to use. The A/H7N9 IIV/PBS diluent plus AS03 adjuvant admixture will be milky (whitish 
to yellowish) in color. If the admixture(s)  appear (s) to have been damaged, contaminated or 
discolored, con tain(s) visible pa rticulate matter , or if there are any concerns regarding the 
integrity, do NOT use the affected  admixture (s). The affected admixture (s) must be quarantined 
at 2°C to 8°C (36°F to 46°F) for the A/H7N9 IIV plus PBS diluent admixture or room 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
40 temperature for the A/H7N9 IIV/PBS diluent plus AS03 adjuvant and labeled as ‘Do Not Use’ 
(until further notice). The site PI  or responsible person should immediately contact the DMID 
Product Support Team at DMIDProductSupportTeam@niaid.nih.gov and DMID Cl inical Project 
Manager for further instructions before any additional study vaccinations are administered. 
Based on the information collected, DMID and/or the manufacturer will determine whether the 
affected  admixture (s) can be used.  If the affected admixt ure(s) cannot be used, the site will 
receive specific instructions on how to send the affected  admixture (s) to the DMID CMS  or 
destroy the affected admixture(s)  on site. If the affected  admixture is unusable, the participating 
VTEU site ’s research pharmaci st will prepare another admixture . Additional instructions for 
quarantine and DMID contact information are provided in the protocol- specific MOP.  
For those doses that must be admixed with PBS diluent, the A/H7N9 IIV plus PBS diluent 
admixture  (intermediate or final mixed vial depending on treatment arm) , once mixed, must be 
stored at 2°C to 8°C (36°F to 46°F) in an upright position and must be used within 8 hours. For those doses that must be admixed with PBS diluent and AS03 adjuvant, the A/ H7N9 IIV /PBS 
diluent plus AS03 adjuvant admixture (final mixed vial) , once mixed, must be stored at room 
temperature in an upright position and must be used within 8 hours. 
Only one- 0.5 mL dose of study vaccine should be withdrawn from the intermediate and  final 
mixed vial(s). Gently invert the intermediate and final mixed vial(s) 5 to 7 times immediately 
before the single 0.5 mL dose of study vaccine is withdrawn. Do not shake the intermediate 
and final mixed vial (s). 
Study vaccine administration to the subject will be performed by an unblinded study personnel 
member  who is credentialed  to administer vaccines  and may also participate in dose preparation, 
but will not be involved in study- related assessments or have subject contact for data collecti on 
following study vaccine administration  to the subject. One - 0.5 mL dose of study vaccine will be 
administered to the subject via a single IM injection into  the deltoid muscle of the subject’ s 
preferred arm  on the day of study vaccine administration  to the subject . See the protocol- specific 
MOP for information on how to administer IM injections. The site of injection (right or left arm) and time of study vaccine administration to the subject will be recorded on the appropriate DCF . 
Study vaccinations subsequent to the first study vaccination may be given in the same preferred arm as long as there is no interference with the reactogenicity assessment.  
Aseptic technique will be used for the withdrawal and administration of each dose of study vaccine using a disposable, sterile needle appropriate in length for each subject and a 1- mL 
disposable, sterile syringe.  Each dose of study vaccine must be administered within 30 minutes 
of drawing into the syringe (not to exceed 8 hours total since admixing time), and the prepared 
syringe must be stored at room temperature until administered.  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
41 6.3 Modification of Study Intervention/Investigational Product for a 
Subject  
There will be no dose modifications. If a subject’s second study vaccination is deferred, it should 
be rescheduled to occur within the acceptable protocol-specified window for the Dose 2 visit. No exceptions to the protocol-specified window will be made. 
6.4 Accountability Procedures for the Study Intervention/Investigational 
Product  
After receipt of the 2013 and 2017 A/ H7N9 IIV s, PBS diluent, AS03 adjuvant, and sterile empty 
vials, the site  PI is responsible for study product distribution and disposition, and has ultimate 
responsibility for study product accountability. The site  PI may delegate to the partici pating 
VTEU site ’s research pharmacist responsibility for study product accountability. The 
participating VTEU site’s research pharmacist will be responsible for maintaining complete 
records and documentation of study product receipt, accountability, dispensation, storage 
conditions, and final disposition of the study product (s). Study product accountability records 
and dispensing logs will also capture vial numbers, including intermediate and final mixed vial 
numbers, date of study vac cine preparation/administration, time of study vaccine preparation, 
expiration of study vaccine preparation, time study vaccine is drawn into the syringe, and amount 
of study vaccine withdrawn for administration. Time of study vaccine administration to the  
subject will be recorded  on the appropriate DCF . All study product(s), including the amount of 
2013 and 2017 A/ H7N9 IIVs, PBS diluent, AS03 adjuvant, and admixtures, whether 
administered or not, must be documented on the appropriate study product accounta bility record 
or dispensing log. The sponsor’ s monitoring staff will verify the participating VTEU site ’s study 
product accountability records and dispensing logs per the site monitoring plan. 
Used and unused vials of 2013 and 2017 A/ H7N9 IIV s, PBS diluent, AS03 adjuvant, and 
admixture s will be retained  until monitored and released for disposition, as applicable. This can 
occur on an ongoing basis for used vials of 2013 and 2017 A/ H7N9 IIVs, PBS diluent, AS03 
adjuvant, and admixtures. Used vials of 2013 and 2017 A/H7N9 IIVs, PBS diluent, AS03 
adjuvant, and admixtures may be destroyed in accordance with site- specific SOPs following each 
monitoring visit where study product accountability is monitored, and resolution of any discrepancies. Final disp osition of the unused 2013 and 2017 A/H7N9 IIVs, PBS diluent, AS03 
adjuvant, and sterile empty vials will be determined by DMID and communicated to the participating VTEU sites by the DMID Clinical Project Manager.  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
42 6.5 Assessment of Subject Compliance with Stu dy 
Intervention/ Investigational Product  
Study vaccine will be administered to the subject by an unblinded study vaccine administrator 
via IM injection at all dosing times per the subject’s randomized treatment assignment and as described in Section 6.2. Thus, subject compliance is not anticipated to be an issue. Deviations from the dose schedule may only occur as described in Secti on 6.3. Study vaccine administration 
to the subject will be recorded  on the appropriate DCF .
 
6.6 Concomitant Medications/Treatments  
Administratio n of any medications, therapies  or vaccines will be recorded on the appropriate 
DCF . Concomitant medications will include all current medications and medications taken in the 
60 days  prior to signing the ICF through approximately  21 days after the last  study vaccin ation  
or early termination  (if prior to 21 days after the last study vaccination) , whichever occurs first.  
Medications reported in the electronic case report form (eCRF) are limited to those taken within 
30 days prior to the first study vaccination through approximately 21 days after the last study 
vaccination. Prescription and over- the-counter drugs will be included as well as herbals, vitamins 
and supplements. In addition, receipt of any non-study influenz a vaccines will be solicited 
through approximately 180 days after the last study vaccination , and reported in the eCRF. Use 
of a new medication should prompt evaluation for the occurrence of an y MAAE, including a new 
diagnosis of chronic medical disease or  condition. 
Medications that might interfere with the evaluation of the investigational product(s) should not be used during the trial-reporting period (approximately 12 months after the last study 
vaccination) unless clinically indicated as part of the su bject’s health care. Medications in this 
category include the prohibited medications per  the Subject E xclusion C riteria (see Section 
5.1.2). In addition, the site PI  or appropriate sub- investigator may identify other medic ations that 
should not be used due to a risk to subject safety or assessment of reactogenicity and 
immunogenicity . 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
43 7 STUDY PROCEDURES/EVALUATIONS  
7.1 Clinical Evaluations  
Complete medical history will be obtained by interview of subjects  at the  screening visit 
(optional) or on Day 1 prior to the first study vaccination . Subjects will be queried regarding a 
history of significant medical disorders of the head, eyes, ears, nose, throat, mouth, 
cardiovascular system, lungs, gastrointestinal tract, liver, pancreas, kidney, urologic system, 
nervous system, blood, lymph nodes, endocrine system, musculoskeletal system, skin, and 
genital/reproductive tract.  A history of any allergies, cancer, immunodeficiency, psychiatric 
illness, substance abuse, and autoimmune disease will be solicited. Subjects will also be queried regarding a personal history and family history of narcolepsy. At follow -up clinic visits after the 
first study vaccination, an interim medical history will be obtained by interview of subjects and any changes since the previous clinic visit or phone call  will be note d. The interim medical 
history should include an assessment for new medical conditions and symptoms suggestive of 
PIMMCs. 
Concomitant medications will be collected as described in Section 6.6. At the  screening visit (optional) or on Day 1 prior to the first study vaccination, a physical 
examination  will be performed  on all subjects, by a study clinician licensed to make medical 
diagnoses and listed on the Form FDA 1572 as the site PI  or sub -investigator, to include the 
following organs and organ systems: skin, head and neck, lungs, heart, liver, spleen, extremities, 
lymph nodes, and nervous system, and as an assessment for signs suggestive of PIMMC s. At  
follow-up clinic visits after the first stud y vaccination , a targeted physical examination may be 
performed , if indicated based on the subject’s interim medical history, by a study clinician 
licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI  or sub -
investigator . Targeted physical examination s should also include an assessment for signs 
suggestive of PIMMCs. 
Vital signs (oral temperat ure, pulse and blood pressure [BP] ) will be collected at the screening 
visit (optional) and prior to each study vaccination. Vital signs assessed on Day 1 prior to the 
first study vaccination will be considered as baseline. Subjects must not eat or drink anything hot 
or cold, or smoke within 10 minutes prior to taking oral temperature. 
Height and weight will be collected at the screening visit (optional) or on Day 1 prior to the first 
study vaccination for the calculation of BMI . 
Reactogenicity asses sments will include an assessment of solicited AEs  occurring from the time  
of each study vaccination through 7 days  after each study vaccination, which includes an 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
44 assessment of injection site reactions including pruritus (itching), ecchymosis (bruising), 
erythema (redness), induration (hardness), edema ( swelling ), pain, and tenderness as well as 
systemic reactions including  fever, feverishness ( chills/shivering/sweating), fatigue (tired ness), 
malaise (general unwell feeling), myalgia (body aches/muscular pain exclusive of the injection 
site), arthralgia (joint pain exclusive of the injection site), headache, and nausea. Pre -
administration reactogenicity assessments will be performed immediately prior to each study 
vaccination to establish baseline, then the study vaccination will be given. 
Subjects will be observed in the clinic for at least 20 minutes after each study vaccination . The 
study vaccination site will be examined , post- administration reactogenicity assessments will be 
performed , and any AE/SAEs will be recorded on the appropriate DCF  prior to discharge from 
the clinic.  The study vaccination site will also be examined approximately 1, 3 and 7 days after 
each study vaccination. 
All subjects will complete a Memory Aid from the time  of each study vaccination through 7 days 
after each study vaccination. Memory Aids  will be reviewed with the subjects for any AEs  
(solicited injection site and systemic reactions  as well as  unsolicited  AEs ), SAEs  and 
concomitant medications (including solicitation for receipt of any non-study influenza vaccines) 
approximately 1, 3 and 7 days after each study vaccination via phone call or clinic visit. 
7.2 Laboratory Evaluations  
Clinical laboratory evaluations and special assays are described below. Refer also to Sections 4 
and 8 as well as Appendix A: Schedule of Study Procedures and Evaluations  and Appendix B: 
Schedule of Special Assays . 
7.2.1 Clinical Laboratory Evaluations 
Urine or serum pregnancy tests will be performed locally  by the site at the screening visit 
(optional) and within 24 hours prior to each study va ccination for all women of childbearing 
potential.  Results must be negative and known prior to randomization on Day 1 and 
administration of each study vaccination to be eligible for participation in this trial and receipt of each study vaccination . 
The ESR evaluation will be performed locally by the site at the screening visit (optional) or on Day 1 prior to the first study vaccination. Results must be known prior to randomization on Day 1 and administration of the first  study vaccination , and confirmed as less than 30 mm per hour to 
be eligible for participation in this trial and receipt of the first study vaccination . 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
45 Clinical safety laboratory parameters  (WBC,  Hgb, PLT, ALT, T. Bili, Cr ) will be collected prior 
to each study  vaccination and approximately 7 days after each study  vaccination. These 
evaluations will be performed by the central (clinical) laboratory.  The results from the clinical 
safety laboratory parameters collected on Day 1 prior to the first study vaccination will not be 
available or reviewed prior to the first study vaccination, and will serve as a baseline safety 
assessment only.  The results from the clinical safety laboratory parameters collected prior to the 
second study vaccination will not be available or  reviewed prior to the second study vaccination. 
The volume of venous blood to be collected for ESR and  clinical safety laboratory evaluations  is 
presented in Table 4 and 5. 
7.2.2 Special Assays or Procedures  
Serological Assays  
Once the last subject completes the visits that occur through approximately 21 days after the last 
study vacc ination , serum specimens  collected for these visits will be shipped from the DMID 
CMS  to specified  research labora tories  for serological analysis. O nce the last subject completes 
the visit that occurs approximately 180 days after the last study vaccination , serum specimens  
collected for this visit will be shipped from the DMID CMS to specified research  laboratories to 
conduct the final serological analyses.  
HAI and Neut Antibody Assays 
Assays to determine serum levels of HAI and Neut antibodies will be perf ormed by  Southern  
Research  on specimens  collected at  multiple time points prior to and following each study 
vaccination . Subjects who withdraw early will have these assays run on available sera.  
HA Stem -Specific Assays  
Assays to determine and quantitate HA s tem-specific antibodies are in development, and the 
specified research laboratories  for this assessment are to be determined.  It is anticipate d that 
serum levels of anti -HA stem-specific antibodies will be determined from specimens collected at 
multiple time points prior to and following each study vaccination. Subjects who withdraw early will have these assays run on available sera.  
NA-Specific Assays  
Assays to determine the NA content and NAI antibodies are in develo pment, and the specified 
research laboratories  for this assessment is to be determined . The correlation of the NA content 
in the 2013 and 2017 A/H7N9 IIVs with the elicited N9 NA -specific serum antibody responses 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
46 may be determined from specimens collected at multiple time points prior to and following each 
study vaccination. 
Any research laboratory involved with the determination of NA content or N9 NA- specific 
serum antibody responses will remain blinded to the results from the HAI and Neut antibody 
assay s performed by  Southern Research.  
Cellular Immunology Assays  
This clinical trial will also investigate novel methods for identifying and assessing alternative cellular correlates of protection against influenza infection at multiple time poin ts following each 
study vaccination. These will include longitudinal assessments of: 1) the kinetics, magnitude, 
specificity, and/or quality of influenza- specific B and T cells, cT
FH cells and innate immune cells 
(monocytes, DCs and NK cells) ; 2) the frequency of influenza- specific IgA, IgG  and IgM 
plasmablasts  (ASCs);  and 3) B cell receptor somatic hypermutation and repertoire assessments.  
Given the requirement for freshly isolated PBMCs, the plasmablast assay will be performed only 
on specimens collected from subjects enrolled at the specified site (s), which will perform the 
plasmablast assay . All other frozen PBMCs will be shipped from the DMID CMS to specified 
research laboratories for cellular immunology  analyses.  Residual plasma specimens collected 
during the processing of PBMCs may be frozen and shipped to the DMID CMS. 
Venous blood will also be collected at multiple time points following each study vaccination for 
the future research use of serum , plasma  and PBMCs. 
The volume of venous blood to be collected for serological and cellular  immunology assays as 
well as  future research is presented in Table 4 and 5. Note: There are two  different dosing 
intervals between the priming (first) and boosting (second) doses (21 days vs. 4 months). Treatment Arms  1 and 4 receive study vaccinations on Days 1 and 22; and Treatment Arms  2, 3, 
5, and 6 receive study vaccinations on Days 1 and 121. 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
49 7.2.3 Specimen Preparation, Handling  and Shipping  
7.2.3.1 Instruction s for Specimen Preparation, Handling and Storage 
Instructions for specimen preparation, handling and storage are included in the central (clinical) 
laboratory manual and protocol- specific MOP as appropriate.  
7.2.3.2 Specimen Shipment  
Specimen shipment will occur at intervals during the course of this trial following all applica ble 
International Air Transport Association (IATA) requirements and according to the specifics for 
storage temperature and documentation as detailed in the central (clinical) laboratory manual and protocol- specific MOP as appropriate.  
Specimens for  clinical safety laboratory evaluations will be shipped from the participating VTEU 
sites to the central (clinical) laboratory.  
Specimens for HAI and Neut antibody assays will be shipped from the participating VTEU sites 
to the DMID CMS , and then provided by the D MID CMS  to Southern Research in a blinded 
manner.  
Specimens for additional serological assays will be shipped from the participating VTEU sites to 
the DMID CMS , and then provided by the DMID CMS to the specified research  laboratories in a 
blinded manner. 
Specimens for cellular  immun ology assays using frozen PBMCs will be shipped from the 
participating VTEU sites to the DMID CMS , and then provided by the DMID CMS to the 
specified research  laboratories in a blinded manner. 
Specimens for the plasmablast assay using freshly isolated PBMCs will remain on  site at the 
specified site (s). 
Residual plasma s pecimens collected during the processing of PBMCs may be frozen and 
shipped to the DMID CMS. Specimens for future research  will be shipped from the participating VTEU sites to the DMID 
CMS . 
Further instructions for specimen shipment are included in the central (clinical) lab oratory 
manual and protocol- specific MOP, as appropriate. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
50 8 STUDY SCHEDULE  
Complete study schedule details listed by type of visit are described below.  Refer also to 
Sections 4 and 7 as well as  Appendix A: Schedule of Study Procedures and Evaluations  and 
Appendix B: Schedule of Special Assays . 
Note: There are two  different dosing intervals between the priming (first) and boosting (second) 
doses (21 days vs. 4 month s). Treatment Arms  1 and 4 receive study vaccinations on Days 1 and 
22; and Treatment Arms  2, 3, 5, and 6 receive study vaccinations on Days 1 and 121. 
8.1 Screening (Optional) and Enrollment Visit s 
8.1.1 Visit 00, Screening (Day -28 to -1) , Clinic Visit , All Treatment Arms, Optional 
• Subjects will be provided with a description of this trial (purpose and study procedures) 
and asked to read and sign the ICF. The ICF will be signed prior to performing any study 
procedures, including administration of the first study vaccination. 
• Demographic information will be obtained by interview of subjects. 
• Eligibility criteria will be reviewed with subjects  to ensure eli gibility . 
• Complete medical history will be obtained by interview of subjects to ensure eligibility . 
• All concomitant medications taken within 60 days prior to signing the ICF will be 
reviewed with subjects  to determine stability of chronic diseases and elig ibility . 
Medications reported in the eCRF are limited to those taken within 30 days prior to the 
first study vaccination.  
• Subject receipt of licensed , seasonal influenza vaccine over the current  (2018-2019) and 
previous two influenza seasons  (2016- 2017 and 2017-2018), what type (inactivated or 
live attenuated) and approximate date of vaccination will be recorded on the appropriate DCF , if known. Prior receipt of licensed, seasonal influenza vaccine is not exclusionary, 
as long as it has been administered within the allowable window (see Section 5.1.2).  
• Subject receipt of non- season al influenza vaccine, including those that are experimental , 
what type (inactivated or live attenuated) , what subtype (e.g., A/H3, A/H5, A/H9) and 
approximate date of vaccination will be recorded on the appropriate DCF, if known. Prior 
receipt of non- seasonal influenza vaccine is  not exclusionary, except influenza A/H7 
vaccine (see Section 5.1.2). 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
51 • Vital signs, in cluding oral temperature, pulse and BP, will be obtained to ensure 
eligibility . Subjects must not eat or drink anything hot or cold, or smoke within 10 
minutes prior to taking oral temperature.  
• Height and weight will be collected for the calculation of BMI. 
• A physical examination will be performed on all subjects to include the following organs 
and organ systems: skin, head and neck, lungs, heart, liver, spleen, extremities, lymph 
nodes, and nervous system, and as an assessment for signs suggestive of PIMMC s, by a 
study clinician licensed to make medical  diagnoses and listed on the Form FDA 1572 as 
the site PI  or sub-investigator. 
• A urine or serum pregnancy test may be performed locally by the site for all women of 
childbearing potential. Results must be negative to ensure eligibility.  
• Approximately 4 mL of venous blood will be collected for ESR, and performed locally 
by the site. The ESR value must be confirmed as less than 30 mm per hour to ensure 
eligibility . 
8.1.2 Visit 01 , Day 1, Enrollment (for subjects previously screened at Day -28 to - 1) 
and First Study Vaccination (Dose 1), Clinic Visit , All Treatment Arms  
• Subject’s willingness to participate will be reconfirmed and documented in the subject’s 
study records prior to performing any further study procedures, including administration 
of the first study vaccination.  
• Eligibility criteria, including results of the ESR  evaluation , will be reviewed  with subjects 
prior to the first study vaccination  to ensure continued eligibility . The ESR value must be 
confirmed as less than 30 mm per hour prior to rand omization and first study vaccination . 
• Interim medical history, including an assessment for new medical conditions , stability of 
chronic diseases  and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  prior to the first study vaccination . Any changes in medical history since the 
screening visit will be reviewed with subjects prior to the first study vaccination to ensure continued eligibility . 
• All concomitant medications (including solicitation for receipt of any non-study infl uenza 
vaccines)  will be reviewed with subjects prior to the first study vaccination  for accuracy 
and completeness . Any new concomitant medications taken since the screening visit will 
be reviewed with subjects prior to the first study vaccination  to ensure continued 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
52 eligibility . Medications reported in the eCRF are limited to those taken within 30 days 
prior to the first study vaccination.  
• Vital signs, in cluding oral temperature, pulse and BP, will be obtained prior to the first 
study vaccination to ensure continued eligibility. Vital signs assessed on Day 1 prior to 
the first study vaccination will be considered as baseline. Subjects must not eat or drink 
anything hot or cold, or smoke within 10 minutes prior to taking oral temperature.  
• A targeted physical examination, including an assessment for signs suggestive of PIMMCs, may be performed prior to the first study vaccination, if indicated based on review of complete medical history and any updates obtained by interview of subjects 
since the screening visit , by a study clinician licensed to make medical diagnoses and 
listed on the Form FDA 1572 as the site PI  or sub -investigator . 
• A urine or serum pregnancy test will be performed locally by the site within 24 hours 
prior to t he first study vaccination for all women of childbearing potential. Results must 
be negative and known prior to randomization and the first study vaccination . 
• Subjects will be enrolled in AdvantageEDC
SM and randomly assigned to a treatment arm  
prior to the first study vaccination.  
• Approximately 10 mL of venous blood will be collected immediately prior to the first 
study vaccination for baseline clinical safety labs ( WBC, Hgb, PLT, ALT, T. Bili, Cr) to 
be performed by the central (clinical) laboratory . The results from these evaluations  will 
not be available or reviewed prior to the first study vaccination, and will serve as a 
baseline safety assessment only.  
• Approximately 15 mL of venous blood will be collected immediately prior to the first 
study vaccination for baseline serological  assays.  
• Approximately 64 mL of venous blood will be collected immediately prior to the first study vaccination for baseline cellular immun ology assays . 
• Approximately 16 mL  of venous blood will be collected immediately prior to the first 
study vaccination for future research . 
• Pre-administration reactogenicity assessments will be performed immediately prior to the 
first study vaccination to establish baseline.  
• Subjects will then receive one- 0.5 mL dose of study vaccine via a single IM injection 
into the deltoid muscle of the subjects’ preferred arm. The site of injection (right or left 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
53 arm) and time of study vaccine administration to the subject will be recorded on the 
appropriate DCF . Subjects will be observed in the clinic for at least 20 minutes after the 
first study vaccination. The first study vaccination site will be examined, post-
administration reactogenicit y assessments will be performed , and any AE/SAEs will be 
recorded on the appropriate DCF  prior to discharge from the clinic. 
• Subjects will be provided with a Memory Aid  and other study- related materials to record 
daily oral temperature, solicited injection site and systemic reactions, unsolicited AEs, and concomitant medications . Subjects will be encouraged to take their oral temperature 
around the same time each day. Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature. Subjects will be instructed on how to use their Memory Aid  and how to measure and record AEs prior to discharge 
from the clinic. Subjects will be ins tructed to notify the study center if they develop any 
severe reactions after the first study vaccination. If the site  PI or appropriate sub-
investigator deems the reaction severe enough, further instructions will be given to the subject on the proper course of action, including a return to the clinic for immediate 
evaluation if appropriate. 
8.1.3 Visit 01, Day 1, Enrollment /Baseline  (for subjects not previously screened at Day 
-28 to -1) and First Study Vaccination (Dose 1) , Clinic Visit , All Treatment Arms  
• Subjects will be provided with a description of this trial (purpose and study procedures) 
and asked to read and sign the ICF. The ICF will be signed prior to performing any study 
procedures, including administration of the first study vaccination.  
• Demographic information will be obtained by interview of subjects prior to the first study vaccination . 
• Eligibility criteria will be reviewed  with subjects  prior to the first study vaccination to 
ensure eligibility . 
• Complete medical history will be  obtained by interview of subjects prior to the first study 
vaccination to ensure eligibility . 
• All concomitant medications taken within 60 days prior  to signing the ICF will be 
reviewed with subjects  prior to the first study vaccination to determine stability of 
chronic diseases and eligibility. Medications reported in the eCRF are limited to those 
taken within 30 days prior to the first study vaccination.  
• Subject receipt of licensed , seasonal influenza vaccine over the current (2018-2019) and 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
54 previous two influenza seasons  (2016-2017 and 2017-2018), what type (inactivated or 
live attenuated) and approximate date of vaccination will be recorded on the appropriate 
DCF , if known. Prior receipt of licensed, seasonal influenza vaccine is not exclusionary, 
as long as it has been administered within the allowable window (see Section 5.1.2).  
• Subject receipt of non-seasonal influenza vaccine, including those that are experimental , 
what type (inactivated or live attenuated) , what subtype (e.g., A/H3, A/H5, A/H9) and 
approximate date of vaccination will be recorded on the appropriate DCF, if known. Prior receipt of non- seasonal influenza vaccine is  not exclusionary, except influenza A/H7 
vaccine (see Section 5.1.2). 
• Vital signs, in cluding oral temperature, pulse and BP, will be obtained prior to the first 
study vaccination to ensure eligibility. Vital signs assessed on Day 1 prior to the first 
study vaccination will be considered as baseline. Subjects must not eat or drink anything 
hot or cold, or smoke within 10 minutes prior to taking oral temperature. 
• Height and weight will be collected prior to the first study vac cination for the calculation 
of BMI.  
• A physical examination will be performed on all subjects prior to the first study 
vaccination to include the following organs and organ systems: skin, head and neck, 
lungs, heart, liver, spleen, extremities, lymph nodes, and nervous system, and as an 
assessment for signs suggestive of PIMMC s, by a study clinician licensed to make 
medical diagnoses and listed on the Form FDA 1572 as the site PI or sub -investigator. 
• A urine or serum pregnancy test will be performed locally  by the site within 24 hours 
prior to the first study vaccination for all women of childbearing potential. Results must 
be negative and known prior to randomization and the first study vaccination . 
• Approximately 4 mL of venous blood will be collected for ESR, and performed locally 
by the site  prior to the first study vaccination . The ESR value must be confirmed as less 
than 30 mm per hour prior to randomization and first study vaccination. 
• Subjects will be enrolled in AdvantageEDC
SM and randomly assigned to a treatment arm  
prior to the first study vaccination.  
• Approximately 10 mL of venous blood will be collected immediately prior to the first 
study vaccination for baseline clinical safety labs ( WBC, Hgb, PLT, ALT, T. Bili, Cr) to 
be performed by the central (clinical) laboratory . The results from these evaluations  will 
not be available or reviewed prior to the first study vaccination, and will serve as a 
baseline safety assessment only.  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
55 • Approximately 15 mL of venous blood will be collected immediately prior to the first 
study vaccination for baseline serological  assays.  
• Approximately 64 mL of venous blood will be collected immediately prior to the first 
study vaccination for baseline cellular  immun ology assays.  
• Approximately 16 mL of  venous blood will be collected immediately prior to the first 
study vaccination for future  research . 
• Pre-administration reactogenicity assessments will be performed immediately prior to the 
first study vac cination to es tablish baseline.  
• Subjects will then receive one- 0.5 mL dose of study vaccine via a single IM injection 
into the deltoid muscle of the subjects’ preferred arm.  The s ite of injection (right or left 
arm) and time of study vaccine administration to the subject will be recorded on the 
appropriate DCF . Subjects will be observed in the clinic for at least 20 minutes after the 
first study vaccination. The first study vaccination site will be examined , post-
administration reactogenicity assessments will be performed , and any AE/SAEs will be 
recorded on the appropriate DCF  prior to discharge from the clinic. 
• Subjects will be provided with a Memory Aid  and other study- related materials to record 
daily oral temperature, solicited injection site and systemic reactions , unsolicited AEs, 
and concomitant medications. Subjects  will be encouraged to take their  oral temperature 
around the same time each day.  Subjects must not eat or drink anything hot or cold, or 
smoke within 10 minutes prior to taking oral temperature.  Subjects will be instructed on 
how to use the ir Memory Aid  and how to measure and record AEs prior to discharge 
from the clinic.  Subjects  will be instructed to notify the study center if they develop any 
severe reactions after the first study vaccination. If the site  PI or appropriate sub-
investigator deems the reaction severe enough, further instructions will be given to the 
subject on the proper course of action, including a return to the clinic for immediate evaluation if appropr iate. 
8.2 Follow -up Visits 
Follow-up visits are scheduled in reference to study vaccination dates as indicated for each visit window. 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
56 8.2.1 Visit 02, Day 2, Clinic Visit, All Treatment Arms 
(Window: Day 2+1 day post first study vaccination) 
• Interim medical history, including an assessment for new medical conditions, stability of 
chronic diseases and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes since the previous clinic visit or phone call will be no ted. 
• All concomitant medications (including solicitation for receipt of any non-study influenza vaccines) will be recorded on the appropriate DCF . 
• All AE/SAEs will be recorded on the appropriate DCF.  
• Memory Aid information will be reviewed with subjects.  
• A targeted physical examination, including an assessment for signs suggestive of 
PIMMCs, may be performed, if indicated based on review of interim medical history, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI  or sub-investigator. 
• The first study vaccination site will be examined.  
• Approximately 4 mL of venous blood will be collected for cellular immun ology assa ys. 
• Approximately 16 mL of venous blood will be collected for future research. 
8.2.2 Visit 0 3, Day 4, Clinic Visit, All Treatment Arms  
(Window: Day 4+1 day post first study vaccination) 
• Interim medical history, including an assessment for new medical conditions, stability of 
chronic diseases and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes since the previous clinic visit or phone call will be noted.  
• All concomitant medications (including solicitation for receipt of any non-study influenza vaccines) will be recorded on the appropriate DCF . 
• All AE/SAEs will be recorded on the appropriate DCF.  
• Memory Aid information will be reviewed with subjects.  
• A targeted physical examination, including an assessment for signs suggestive of 
PIMMCs, may be performed, if indicated based on review of interim medical history, by 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
57 a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as 
the site PI  or sub-investigator. 
• The first study vaccination site will be examined.  
• Approximately 8 mL of venous blood will be collected for cellular immun ology assays.  
• Approximately 16 mL  of venous blood will be collected for future  research . 
8.2.3 Visit 0 4, Day 8, Clinic Visit , All Treatment Arms  
(Window: Day 8-1/+2 day s post first study vaccination) 
• Interim medical history , including an assessment for new medical conditions , stability of 
chronic diseases  and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes since the previous clinic visit or phone call will be noted . 
• All concomitant medications (including solicitation for receipt of any non-study influenza 
vaccines) will be recorded on the appropriate DCF . 
• All AE/SAEs will be recorded on the appropriate DCF . 
• Memory Aid information will be reviewed with subjects.  
• A targeted physical examination, including an assessment for signs suggestive of 
PIMMCs, may be performed, if indicated based on review of interim medical history, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI  or sub-investigator. 
• The first study vaccination site  will be examined . 
• Approximately 10 mL of venous blood will be collected for clinical safety labs ( WBC, 
Hgb, PLT, ALT, T. Bili, Cr ) to be performed by the central (clinical) laboratory . 
• Approximately 44 mL of venous blood will be collected for cellular  immun ology assays.  
• Approximately 21 mL  of venous blood will be collected for future research. 
Note: Subjects that complete this visit on Day 7 will be reminded to complete their  Memory Aid  
through the end of Day 8, and study personnel will contact these subjects by phone to review their Memory Aid  information and solicit any AE/SAE s and concomitant medications (including 
solicitation for re ceipt of any non- study influenza vaccines) . Based on the information collected , 
subjects may be asked to return to the clinic for evaluation . 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
58 8.2.4 Visit 0 5, Day 15, Clinic Visit, All Treatment Arms  
(Window: Day 15±1 day post first study vaccination) 
• Interim med ical history, including an assessment for new medical conditions, stability of 
chronic diseases and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes since the previous clinic visit or phone call will be noted. 
• All concomitant medications (including solicitation for receipt of any non-study influenza 
vaccines) will be recorded on the appropriate DCF. 
• All AE/SAEs will be recorded on the appropriate DCF. 
• A targeted physical examination, including an assessment for signs suggestive of PIMMCs, may be performed, if indicated based on review of interim medical history, by 
a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as 
the site PI  or sub-investigator. 
• Approximately 8 mL of venous blood will be collected for cellular immun ology assays.  
• Approximately 16 mL of venous blood will be collected for future research. 
8.2.5 Clinic Visit , Treatment Arms 2, 3, 5, and 6  
Visit 0 6, Day 22 (Window: Day 22+7 days post first study vaccination), 
Treatment Arms 2, 3, 5, and 6  
• Interim medical history, including an assessment for new medical conditions, stability of chronic diseases and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes since the previous clinic visit or phone call will be no ted. 
• All concomitant medications (including solicitation for receipt of any non-study influenza vaccines) will be recorded on the appropriate DCF. 
• All AE/SAEs will be recorded on the appropriate DCF. 
• A targeted physical examination, including an assessment for signs suggestive of PIMMCs, may be performed, if indicated based on review of interim medical history, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI  or sub-investigator. 
• Approximately 15 mL of venous blood will be collected for serological  assays.  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
59 • Approximately 16 mL of venous blood will be collected for future research. 
8.2.6 Safety Follow-up, Phone Call , Treatment Arms 2, 3, 5, and 6  
Visit 07, Day 61 (Window: Day 61±7 days post first study vaccination), 
Treatment Arms 2, 3, 5, and 6  
Subjects will be contacted by phone to query for safety events and concomitant medications (including solicitation for receipt of any non -study influenza vaccines ). AEs li mited to SAEs and 
MAAEs, including NOCMCs and PIMMCs, that have occurred since the previous clinic visit or phone call will be solicited. Based on the information collected , subjects may be asked to return 
to the clinic for evaluation.  
8.2.7 Second Study Vaccina tion (Dose 2), Clinic Visit , All Treatment Arms  
Visit 0 6, Day 22 (Window: Day 22+7 days post first study vaccination), 
Treatment Arms  1 and 4 
Visit 08, Day 121 (Window: Day 121-7/+14 days post first study vaccination), Treatment Arms  2, 3, 5, and 6  
• Eligibility criteria will be reviewed with subjects  prior to the second  study vaccination  to 
ensure continued eligibility . 
• For a subject to receive the second study vaccination, refer to Section 5.2.3 for additional second study vaccination eligibility criteria . 
• Interim medical history, including an assessment for new medical conditions, stability of 
chronic diseases and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  prior to the second study vaccination. A ny changes in medical history since the 
first study vaccination  will be reviewed with subjects prior to the second study 
vaccination  to ensure continued eligibility . 
• All concomitant medications (including solicitation for receipt of any non-study influenza 
vaccines) will be recorded on the appropriate DCF  prior to the second study vaccination. 
Any new concomitant medications taken since the first study vaccination  will be 
reviewed with subjects prior to the second  study vaccination  to ensure continued 
eligibility.  
• All AE/SAEs will be recorded on the appropriate DCF  prior to the second study 
vaccination . Note: AEs will be limited to SAEs  and MAAEs, including NOCMCs and 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
60 PIMMCs, for subjects who are discontinued from receipt of the second study vaccination 
and being followed for safety. 
• Vital signs, in cluding oral temperature, pulse and BP, will be obtained prior to the second 
study vaccination to ensure continued eligibility. Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature. Note: Vital 
signs are not required for subjects who are discontinued from receipt of the second study vaccination and being followed for safety. 
• A targeted physical examination , including an assessment for signs suggestive of 
PIMMCs, may be performed prior to the second study vaccination, if indicated based on review of interim medical history , by a study clinician licensed to make medical 
diagnoses and listed on the Form FDA 1572 as the site PI  or sub -investigator. 
• A urine or serum pregnancy test will be performed locally by the site within 24 hours 
prior to the second s tudy vaccination for all women of childbearing potential. Results 
must be negative and known prior to the second  study vaccination. 
• Approximately 10 mL of venous blood will be collected immediately prior to the second  
study vaccination for clinical safety labs ( WBC, Hgb, PLT, ALT, T. Bili, Cr) to be 
performed by the central (clinical) laboratory . The results from these evaluations  will not 
be available or reviewed prior to  the second  study vaccination.  
• Approximately 15 mL of venous blood will be collected immediately prior to the second  
study vaccination for serological assays.  
• Approximately 32 mL of venous blood will be collected immediately prior to the second  
study vaccination for cellular  immun ology assays.  
• Approxim ately 16 mL of  venous blood will be collected immediately prior to the second  
study vaccination for future  research . 
• Pre-administration reactogenicity assessments will be performed immediately prior to the 
second study vaccination to establish baseline.  
• Subjects will then receive one- 0.5 mL dose of study vaccine via a single IM injection 
into the deltoid muscle of the subjects’ preferred arm.  The second study vaccination may 
be given in the same preferred arm as long as there is no interference with the 
reactogenicity assessment.  The si te of injection (right or left arm) and time of study 
vaccine administration to the subject will be recorded on the appropriate DCF . Subjects 
will be observed in the clinic for at least 20 minutes after the second  study vaccination. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
61 The second study vaccination site will be examined , post- administration reactogenicity 
assessments will be performed , and any AE/SAEs will be recorded on the appropr iate 
DCF  prior to discharge from the clinic. 
• Subjects will be provided with a Memory Aid  and other study- related materials to record 
daily oral temperature, solicited injection site and systemic reactions, unsolicited AEs, 
and concomitant medications. Subjects will be encouraged to take their oral temperature around the same time each day.  Subjects must not eat or drink anything hot or cold, or 
smoke within 10 minutes prior to taking oral temperature. Subjects will be instructed on 
how to use the ir Memory Aid  and how to measure and record AEs prior to discharge 
from the clinic.  Subjects will be instructed to n otify the study center if they develop any 
severe reactions after the second  study vaccination.  If the site  PI or appropriate sub-
investigator deems the reaction severe enough, further instructions will be given to the subject on the proper course of action, including a return to the clinic for immediate 
evaluation if appropriate. 
8.2.8 Clinic Visit, All Treatment Arms  
Visit 07, Day 23 (Window: Day 2+1 day post second study vaccination), Treatment Arms  1 and 4 
Visit 09, Day 122 (Window: Day 2+1 day post second study vaccination), Treatment Arms  2, 3, 5, and 6  
• Interim medical history, including an assessment for new medical conditions , stability of 
chronic diseases  and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes  since the previous clinic visit or phone call will be noted. 
• All concomitant medications (including solicitation for receipt of any non-study influenza 
vaccines) will be recorded on the appropriate DCF . 
• All AE/SAEs will be recorded on the appropriate DCF.  Note: AEs will be limited to 
SAEs  and MAAEs, including NOCMCs and PIMMCs, for subjects who are discontinued 
from receipt of the second study vaccination and being followed for safety. 
• Memory Aid information will be reviewed with subjects.  
• A targeted physical examination, including an assessment for signs suggestive of PIMMCs, may be performed, if indicated based on review of interim medical history, by 
a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as 
the site PI or sub-investigator. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
62 • The second  study vaccination site will be examined.  
• Approximately 4 mL of venous blood will be collected for cellular immun ology assays.  
• Approximately 16 mL  of venous blood will be collected for future  research . 
8.2.9 Clinic Visit , All Treatment Arms  
Visit 0 8, Day 25 (Window: Day 4+1 day post second study vaccination), 
Treatment Arms  1 and 4 
Visit 10, Day 124 (Window: Day 4+1 day post second study vaccination), 
Treatment Arms  2, 3, 5, and 6  
• Interim medical history, including an assessment for new medical conditions , stability of 
chronic diseases  and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes since the previous clinic visit or phone call will be noted. 
• All concomitant medications (including solicitation for receipt of any non-study influenza 
vaccines) will be recorded on the appropriate DCF . 
• All AE/SAEs will be recorded on the appropriate DCF.  Note: AEs will be limited to 
SAEs  and MAAEs, including NOCMCs and PIMMCs, for sub jects who are discontinued 
from receipt of the second study vaccination and being followed for safety. 
• Memory Aid information will be reviewed with subjects.  
• A targeted physical examination, including an assessment for signs suggestive of 
PIMMCs, may be performed, if indicated based on review of interim medical history, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI  or sub-investigator. 
• The second  study vaccination site will be examined.  
• Approximately 8 mL of venous blood will be collected for cellular immunology assays.  
• Approximately 16 mL of  venous blood will be collected for future  research . 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
63 8.2.10 Clinic Visit, All Treatment Arms  
Visit 09, Day 29 (Window: Day 8-1/+2 days post second study vaccination), 
Treatment Arms  1 and 4 
Visit 11, Day 128 (Window: Day 8-1/+2 days post second study vaccination), Treatment Arms  2, 3, 5, and 6  
• Interim medical history, including an assessment for new medical conditions , stability of 
chronic diseases  and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes since the previous clinic visit or phone call will be noted. 
• All concomitant medications (including solicitation for receipt of any non-study influenza 
vaccines) will be recorded on the appropriate DCF . 
• All AE/SAEs will be recorded on the appropriate DCF . Note: AEs will be limited to 
SAEs  and MAAEs, including NOCMCs  and PIMMCs, for subjects who are discontinued 
from receipt of the second study vaccination and being followed for safety. 
• Memory Aid information will be reviewed with subjects.  
• A targeted physical examination, including an assessment for signs suggestive of 
PIMMCs, may be performed, if indicated based on review of interim medical history, by 
a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as 
the site PI  or sub-investigator. 
• The second study vaccination site will b e examined.  
• Approximately 10 mL of venous blood will be collected for clinical safety labs ( WBC, 
Hgb, PLT, ALT, T. Bili, Cr ) to be performed by the central (clinical) laboratory . 
• Approximately 44 mL of venous blood will be collected for cellular  immun ology assays.  
• Approximately 21 mL of venous blood will be collected for future  research . 
Note: Subjects that complete this visit on Day 7 will be reminded to complete the ir Memory Aid  
through the end of Day 8, and study personnel will contact these subjects by phone to review their Memory Aid  information and solicit any AE/SAE s and concomitant medications (including 
solicitation for receipt of any non- study influenza vaccines) . Based on the information collected , 
subjects may be asked to return to the clinic for evaluation . 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
64 8.2.11 Clinic Visit, All Treatment Arms  
Visit 10, Day 36 (Window: 15±1 day post second study vaccination) , Treatment 
Arms  1 and 4 
Visit 1 2, Day 135 (Window: Day 15±1 day post second study vaccination), 
Treatment Arms  2, 3, 5, and 6  
• Interim medical history, including an assessment for new medical conditions, stability of 
chronic diseases and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes since the previous clinic visit or phone call will be noted. 
• All concomitant medications (including solicitation for receipt of any non-study influenza 
vaccines) will be recorded on the appropriate DCF. 
• All AE/SAEs will be recorded on the appropriate DCF.  Note: AEs will be limited to 
SAEs  and MAAEs, including NOCMCs and PIMMCs, for subjects who are discontinued 
from receipt of the second study vaccination and being followed for safety. 
• A targeted physical examination, including an assessmen t for signs suggestive of 
PIMMCs, may be performed, if indicated based on review of interim medical history, by 
a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI  or sub- investigator . 
• Approximately 8 mL of venous blood will be collected for cellular immunology assays.  
• Approximately 16 mL  of venous blood will be collected for future research. 
8.2.12 Clinic Visit , All Treatment Arms  
Visit 11, Day 43 (Window: Day 22+7 days post second study vaccination), Treatment Arms  1 and 4 
Visit 13, Day 142 (Window: Day 22+7 days post second study vaccination), 
Treatment Arms  2, 3, 5, and 6  
• Interim medical history, including an assessment for new medical conditions , stability of 
chronic diseases  and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes since the previous clinic visit or phone call will be noted. 
• All concomitant medications (including solicitation for receipt of any non-study influenza 
vaccines) will be recorded on the appropriate DCF . 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
65 • All AE/SAEs will be recorded on the appropriate DCF . Note: AEs will be limited to 
SAEs  and MAAEs, including NOCMCs and PIMMCs, for subjects who are discontinued 
from receipt of the second study vaccination and being followed for safety . 
• A targeted physical examination, including an assessment for signs suggestive of 
PIMMCs, may be performed, if indicated based on review of interim medical history, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI  or sub-investigator. 
• Approximately 15 mL of venous blood will be collected for serological assays.  
• Approximately 16 mL  of venous blood will be collected for future  research . 
8.2.13 Safety Follow-up, Phone Call , All Treatment Arms  
Visit 12, Day 82 (Window: Day 61±7 days post second study vaccination ), 
Treatment Arms 1 and 4 
Visit 14, Day 181 (Window: Day 61±7 days post second study vaccination ), 
Treatment Arms 2, 3, 5, and 6  
Subjects will be contacted by phone to query for safety events and  receipt of any non -study 
influenza vaccines . AEs limited to SAEs and MAAEs, including NOCMCs and PIMMCs, that 
have occurred since the previous clinic visit or phone call will be solicited. Based on the 
information  collected, subjects may be asked to retur n to the clinic for evaluation. 
8.2.14 Clinic Visit, All Treatment Arms  
Visit 13, Day 112 (Window: Day 91±14 days post second study  vaccination), 
Treatment Arms  1 and 4 
Visit 15, Day 211 (Window: Day 91±14 days post second study vaccination), 
Treatment Arms  2, 3, 5, and 6  
• Interim medical history, including an assessment for new medical conditions , stability of 
chronic diseases  and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes since the previous clinic visit or phone call will be noted. 
• Receipt of any non -study influenza vaccines will be recorded on the appropriate DCF. 
• AEs limited to SAEs and MAAEs, including NOCMCs and PIMMCs, that have occurred 
since the previous clinic visit or phone call will be solicited . 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
66 • A targeted physical examination, inc luding an assessment for signs suggestive of 
PIMMCs, may be performed, if indicated based on review of interim medical history, by 
a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as 
the site PI  or sub-investigator. 
• Approximately 40 mL of venous blood will be collected for cellular immun ology assays.  
• Approximately 16 mL of venous blood will be collected for future research.  
8.2.15 Safety Follow-up, Phone Call , All Treatment Arms  
Visit 14, Day 142 (Window: Day 121±14 days post second study vaccination), 
Treatment Arms 1 and 4 
Visit 16, Day 241 (Window: Day 121±14 days post second study vaccination), 
Treatment Arms 2, 3, 5, and 6  
Subjects  will be contacted by phone to query for safety events  and receipt of any non- study 
influenza vaccines . AEs limited to SAEs and MAAEs, including NOCMCs and PIMMCs, that 
have occu rred since the previous clinic visit or phone call will be solicited. Based on the 
information  collected , subjects may be asked to return to the clinic for evaluation. 
8.2.16 Clinic Visit , All Treatment Arms  
Visit 15, Day 202 (Window: Day 181±14 days post second study vaccination), Treatment Arms 1 and 4 
Visit 17, Day 301 (Window: Day 181±14 days post second study vaccination), Treatment Arms  2, 3, 5, and 6  
• Interim medical history, including an assessment for new medical conditions, stability o f 
chronic diseases  and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes since the previous clinic visit or phone call will be noted. 
• Receipt of any non -study influenza vaccines will be recorded on the appropriate DCF . 
• AEs limited to SAEs  and MAAEs, including NOCMCs and PIMMCs, that have occurred 
since the previous clinic visit or phone call will be solicited . 
• A targeted physical examination, including an assessment for signs suggestive of PIMMCs, may be performed, if indicated based on review of interim medical history, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI  or sub-investigator. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
67 • Approximately 15 mL of venous blood will be collected for serological assays.  
• Approximately 32 mL of venous blood will be collected for cellular  immun ology assays.  
• Approximately 16 mL of  venous blood will be collected for future  research . 
8.3 Final Visit  
8.3.1 Safety Follow-up, Phone Call , All Treatment Arms  
Visit 16, Day 387 (Window: Day 366±14 days post second study vaccination), 
Treatment Arms 1 and 4 
Visit 18, Day 486 (Window: Day 366±14 days post second study vaccination), Treatment Arms  2, 3, 5, and 6  
Subjects will be contacted by phone to query for safety events. AEs limited to SAEs and MAAEs, including NOCMCs and PIMMCs, that have occurred since the previous clinic visit or 
phone call will be solicited . Based on the information collected, subjects may be asked  to return 
to the clinic for evaluation.  
8.4 Early Termination Visit (if needed)  
The following activities will be performed at the Early Termination Visit on subject s who 
withdraw, or are withdrawn or terminated  from this  trial: 
• Interim medical history, includ ing an assessment for new medical conditions, stability of 
chronic diseases and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes since the previous clinic visit or phone call will be noted. 
• All concomitant medications will be recorded on the appropriate DCF  (if prior to 21 days 
after the last study vaccination ). Receipt of any non -study influenza vaccines will also be 
recorded on the appropriate DCF  (if within  180 days after the last  study va ccination ). 
• All AE/SAEs will be recorded on the appropriate DCF . AEs  limited to SAEs  and 
MAAEs, including NOCMCs and PIMMCs, that have occurred since the previous clinic 
visit or phone call will be solicited  (if after 21 days after the last study vaccination).  
• Memory Aid information will be reviewed with subjects (if within 7 days after the last 
study vaccination). 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
68 • Vital signs, in cluding oral temperature, pulse and BP, may be obtained if indicated. 
Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to 
taking oral temperature.  
• A targeted physical examination, including an assessment for signs suggestive of PIMMCs, may be performed, if indicated based on review of interim medical history, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI  or sub-investigator. 
• The study vaccination site will be examined (if within 7 days after the last study 
vaccination).  
• Post- administration reactogenicity assessments will be performed (if within 7 days after 
the last study vaccination).  
• Approximately 10 mL of venous blood will be collected for clinical safety labs ( WBC, 
Hgb, PLT, ALT, T. Bili, Cr) to be performed by the central (clinical) laboratory (if within  
7 days after the last study vaccination) . 
• Approximately 15 mL of venous blood will be collected for serological assays (if within  
21 days after the last  study vaccination).  
• Approximately 24 mL of venous blood will be collected for cellular  immun ology assays 
(if within 21 days after the last study vaccination) . 
• Approximately 16 mL  of venous blood will be collected for future  research  (if within 21 
days after the last study vaccination) . 
8.5 Unscheduled Visit (if needed)  
An Unscheduled Visit may occur at any time during this  trial. Any of th e following activities 
may be performed:  
• Interim medical history, including an assessment for new medical conditions, stability of chronic diseases and symptoms suggestive of PIMMCs , will be obtained by interview of 
subjects  and any changes since the previous clinic visit or phone call will be noted (if 
indicated).  
• All concomitant medications will be recorded on the appropriate DCF  (if prior to 21 days 
after the last study vaccination ). Receipt of any non -study influenza vaccines will also be 
recorded on the appropriate DCF  (if within  180 days after the last  study vaccination ). 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
69 • All AE/SAEs will be recorded on the appropria te DCF . AEs  limited to SAEs  and 
MAAEs, including NOCMCs and PIMMCs, that have occurred since the previous clinic 
visit or phone call will be solicited (if after 21 days after the last study vaccination).  
• Memory Aid information will be reviewed with subjects  (if within 7 days after the last 
study vaccination). 
• Vital signs, in cluding oral temperature, pulse and BP, may be obtained if indicated. 
Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to 
taking oral temperature.  
• A targeted physical examination, including an assessment for signs suggestive of 
PIMMCs, may be performed, if indicated based on review of interim medical history, by 
a study clinician licensed to make medical diagno ses and listed on the Form FDA 1572 as 
the site PI  or sub-investigator. 
• The study vaccination site will be examined (if within 7 days after the last study 
vaccination).  
• Post- administration reactogenicity assessments will be performed (if within 7 days after 
the last study vaccination ). 
• Approximately 10 mL of venous blood will be collected for clinical safety labs ( WBC, 
Hgb, PLT, ALT, T. Bili, Cr) to be performed by the central (clinical) laboratory ( if 
indicated ). 
• Approximately 15 mL of venous blood will be collected for serological assays (if within 
21 days after the last study vaccination). 
• Approximately 24 mL of venous blood will be collected for cellular  immun ology assays 
(if within 21 days after the last study vaccination) . 
• Approximately 16 mL  of venous blood will be collected for future  research  (if within 21 
days after the last study vaccination) . 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
70 9 ASSESSMENT OF SAFETY  
9.1 Specification of Safety Parameters  
Safety will be assessed by the frequency and severity of:  
1. SAEs  occurring from the time of the first study vaccination through approximately 12 
months after the last study vaccination.  
2. Solicited AEs  – reactogenicity events occurring from the time  of each study vaccination 
through 7 days after each study vaccination: 
a) Injection site reactions including pruritus, ecchymosis, erythema, induration 
(hardness)/ edema ( swelling ), pain, and tenderness. 
b) Systemic reactions including  fever, feverishness, fatigue, malaise, myalgia, arthralgia, 
headache, and nausea.  
3. Clinical safety l aboratory AEs  occurring from the time of each study vaccination through 
approximately 7 days after each study vaccination.  Parameters to be evaluated include 
WBC, Hgb, PLT, ALT, T. Bili, Cr. 
4. Unsolicited AEs  –non-serious AEs  occurring from the time of each  study vaccination 
through approximately 21 days  after each  study vaccination . 
5. MAAEs , including NOCMCs  and PIMMCs, occurring from the time of the first study 
vaccination through approximately 12 months after the last study vaccination.  
9.2 Methods and Timing for Assessing, Recording and Analyzing Safety 
Parameters  
9.2.1 Adverse Events  
Adverse Event (AE):  ICH E6  GCP  defines an AE as any untoward medical occurrence in a 
patient or clinical investigation subject administered a pharmaceutical product regardless of its causal relationship to the study treatment.  The FDA defines an AE as any untoward medical 
occurrence as sociated with the use of a drug in humans, whether or not considered drug related. 
An AE can therefore be any unfavorable and unintended sign (including an abnorm al laboratory 
finding), symptom or disease temporally associated with the use of a medicinal ( investigational) 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
71 product. The occurrence of an AE may come to the attention of study personnel during study 
visits and interviews of a study recipient presenting for medical care, or upon review by a study 
monitor. 
AEs, including solicited injection site a nd systemic (subjective and quantitative) reactions, not 
meeting the protocol-defined crite ria for SAEs , will be recorded  on the appropriate DCF  and 
entered into the eCRF.  Information to be collected for unsolicited non- serious AEs includes 
event description, date of onset, licensed study physician’s assessment of severity and 
relationship to study product or alternate etiology (if not related to study product) (assessed only by those with the training and authority to make a diagnosis and listed on the Form FDA 1572 as 
the site PI  or sub-investigator), date of resolution, seriousness, and outcome. AEs occurring 
during the trial -collection and reporting period will be documented appropriately regardless of 
relationship to study product. AEs will be followed through resolution. 
Any medical condition that is present at the time that the subject is screened will be considered 
as baseline and not reported as an AE. However, if the severity of any pre- existing medical 
condition increases, i t will be recorded as an AE.  
AEs must be assessed for severity and relationship to study product (see definitions below). AEs  
characterized as intermittent require documentation of onset and duration of each episode. The start and stop date of each reported AE will be recorded on the appropriate DCF  and entered into 
the eCRF.  
Medically -Attended Adverse Events (MAAEs): For each unsolicited AE experienced, the 
subject will be asked if he/she had received medical attention, defined as hospitalization, an emerg ency room visit or an otherwise unscheduled visit to or from medical personnel for any 
reason. AEs characterized by such unscheduled medical care will be designated as MAAEs.  
New -Onset Chronic Medical Conditions  (NOCMCs) : NOCMCs  are defined as any new ICD -
10 diagnosis ( 10th revision of the International Statistical Classification of Diseases and Related 
Health Problems ) that is applied to the subject during the course of the study, after receipt of the 
study agent, that is expecte d to continue for at least 3 months and requires continued health care 
intervention. 
Potentially Immune- Mediated Medical Conditions (PIMMCs):  PIMMCs  constitute a group 
of AEs that includes diseases which are clearly autoimmune in etiology and other inflamm atory 
and/or neurologic disorders which may or may not have autoimmune etiologies. PIMMCs 
currently in effect are presented in Appendix C : List of Potentially Immune -Mediated Medical 
Conditions . 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
72 Severity of Event:  AEs will be assessed by a licensed study physician listed on the Form FDA 
1572 as the site PI  or sub -investigator using a protocol- defined grading system (see Section s 
9.2.2 and 9.2.3).  For events not included in the protocol-defined grading system, the following 
guidelines will be used to quantify severity: 
• Mild (Grade 1): Events require minimal or no treatment and do not interfere with the 
subject’s  daily activities.  
• Moderate (Grade 2) : Events result in a low level of inconvenience or concern with 
therapeutic measures.  Moderate events may cause some interference with functioning and 
daily activities.  
• Severe (Grade 3) : Events interrupt the subject’s daily activities  and may require systemic 
drug therapy or other treatment. Severe events are usually incapacitating.  
Relationship to Study Product:  The licensed study physician ’s assessment of an AE ’s 
relationship to study product is part of the documentation process, but it is not a factor in 
determining what is or is not reported in this  trial. If there  is any doubt as to whether a clinical 
observation is an AE, the event should be reported. The relationship to study product must be assessed for AEs using the terms: related or not related.  In a clinical trial, the study product must 
always be suspect.  To help assess, the following guidelines are used: 
• Related  – There is a reasonable possibility that the study product caused the AE . 
Reasonable possibility means that there is evidence to suggest a causal relationship 
between the study product and the AE . 
• Not Related  – There is not a reasonable possibility that the administration of the study 
product caused the event. 
9.2.2 Reactogenicity  
Reactogenicity events are AEs that are common and known to occur following administration of  
this type of study vaccine.  The fol lowing Toxicity Grading Scales will be used to grade solicited 
injection site  and systemic ( subjective and quantitative) reactions: 
 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
73 Table 6: Injection Site Reactogenicity Grading  
Injection Site Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Pain – experienced 
without touching the 
injection site 
(spontaneous discomfort)  Subject is aware of pain , 
but it does not interfere 
with daily activity , and if 
pain medication is used, it 
is Over the Counter 
(OTC) and u sed for less 
than 24 hours  Subject is aware of pain; 
there is interference with 
daily activity  or OTC 
pain medication is used 
for more than 24 hours  Subject is aware of pain , 
and it prevents daily 
activity  or pain requires 
prescription medication  
Tenderness – hurts only 
when injection site is 
touched or the arm is 
moved  The area immediately 
surrounding the injection 
site hurts only when 
touched or with arm 
motion, and it does not 
interfere with daily 
activity  The area immediately 
surrounding the injection 
site hurts when touched or 
with arm motion, and it 
interferes with daily 
activity  The area immediately 
surrounding the injection 
site hurts when touched or 
with arm motion, and it 
prevents daily activity  
Pruritus (Itching)  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Ecchymosis (Bruising)*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Erythema (Redness)*  Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
Induration 
(Hardness)/ Edema 
(Swelling )* Does not interfere with 
daily activity  Interferes with daily 
activity  Prevents daily activity  
* Will also be measured in mm but size will not be used as halting criteria.  
Ecchymosis, erythema and induration (hardness)/ edema ( swelling ) as analyzed by measurement 
will be graded as follows: 
Table 7: Injection Site Reactogenicity Measurements  
Injection Site Reaction  Small  Medium  Large  
Ecchymosis (Bruising)*  <20 mm 20 mm – 50 mm >50 mm 
Erythema (Redness)*  <20 mm 20 mm – 50 mm >50 mm 
Induration (Hardness)/ Edema 
(Swelling )* <20 mm 20 mm – 50 mm >50 mm 
* Will not be used as halting criteria.  
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
74 Table 8: Subjective Systemic Reactogenicity Grading  
Systemic (Subjective)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Feverishness 
(Chills/ Shivering/Sweating)  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Fatigue (Tired ness) No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Malaise (General Unwel l 
Feeling)  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Myalgia (Body 
Aches/Muscular Pain)*  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Arthralgia (Joint Pain)*  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Headache No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
Nausea  No interference 
with daily activity  Some interference with 
daily activity  Significant interference, 
prevents daily activity  
* Not at injection site.  
Oral temperature# will be graded as follows: 
Table 9: Quantitative Systemic (Oral Temperature) Reactogenicity Grading  
Systemic (Quantitative)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Fever* – oral† 38.0°C – 38.4°C  
100.4°F – 101.1°F  38.5°C – 38.9°C  
101.2°F – 102.0°F  >38.9°C  
>102.0 °F 
# Oral temperature  assessed on Day 1 prior to the first study vaccination will be considered as baseline.  
* A fever can be considered not related to the study product if an alternative etiology can be documented.  
† Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking oral temperature . 
9.2.3 Additional Adverse Event Severity Grading  
Pulse and BP# will be graded  as follows: 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
75 Table 10: Pulse and BP Adverse Event Grading  
Physiologic Parameter  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Bradycardia – beats per minute 45 – 46 40 – 44 <40 
Tachycardia – beats per minute 101 – 130 131 – 155 >155  
Hypotension (systolic) mm Hg 80 – 84 75 – 79 <75 
Hypotension (diastolic) mm Hg 50 – 54 45 – 49 <45 
Hypertension (systolic) mm Hg 151 – 155 156 – 160 >160  
Hypertension (diastolic) mm Hg 96 – 100 101 – 105 >105  
# Pulse and BP  assessed on Day 1 prior to the first study vaccination will be considered as baseline.  
Clinical safety laboratory values# will be graded as follows: 
Table 11: Clinical Safety Laboratory Adverse Event Grading 
Hematology  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
WBC 103/µL (Decrease)  2.5 – 3.9 1.5 – 2.4 <1.5 
WBC 103/µL (Increase)  10.6 – 15.0 15.1 – 20.0 >20.0  
Hgb g/dL (Decrease) (Female)  10.1 – 11.4 8.5 – 10 <8.5 
Hgb g/dL (Decrease) (Male)  11.0 – 12.4 9.5 – 10.9 <9.5 
Platelets 103/µL (Decrease)  125 – 139 100 – 124 <100  
Platelets 103/µL (Increase)  416 – 550 551– 750 >750  
Chemistry  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
ALT IU/L (Increase) (Female) 44 – 100 101 – 200 >200  
ALT IU/L (Increase) (Male)  61 – 138 139 – 275 >275  
Total Bilirubin mg/dL (Increase) – 
when accompanied by any increase in 
ALT 1.30 – 1.59 1.60 – 1.80 >1.80 
Total Bilirubin mg/dL (Increase) – 
when ALT is normal  1.30 – 1.89 1.90 – 2.40 >2.40 
Creatinine mg/dL (Increase) 
(Female)  1.1 – 1.7 1.8 – 2.0 >2.0 
Creatinine mg/dL (Increase) (Male)  1.4 – 1.7 1.8 – 2.0 >2.0 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
76 # Clinical safety laboratory evaluations assessed on Day 1 prior to the first study vaccination  will be considered 
as baseline.  
9.2.4 Serious Adverse Events  
Serious Adverse Event (SAE): An AE  or suspected adverse reaction is considered “serious” if, 
in the view of either th e site PI  (or appropriate sub- investigator)  or sponsor, it results in any of 
the following outcomes: 
• Death,  
• A life -threatening AE *, 
• Inpatient hospitalization or prolongation of existing hospitalization, 
• A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions, or 
• A congenital anomaly/birth defect.  
• Important medical events that may not result in death, be life -threatening, or require 
hospitalizations may be considered serious when, based upon appropriate medical 
judgment they may jeopardize the patient or subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalization, or the development of drug dependency or drug abuse. 
* Life -threatening AE . An AE  is considered “life- threatening” if, in the view of either the site PI  
(or appropriate sub- investigator)  or sponsor, its occurrence places the patient or subject at 
immediate risk of death.  It does not include an AE  that, had it occurred in a more severe form, 
might have caused death.  
SAEs will be: 
• Assessed for severity and relationship to study product or alternate etiology (if not related to study product) by a licensed study physician listed on the Form FDA 1572 as the site 
PI or sub- investigator.  
• Recorded on the appropriate SAE form and entered into the eCRF.  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
77 • Followed through resolution by a licensed study physician listed on the Form FDA 1572 
as the site PI  or sub -investigator.  
• Reviewed and evaluated by the Independent Safety Monitor (ISM) (as deemed 
necessary ), DSMB  (periodic review unless related), DMID, and IRB.  
9.2.5 Procedures to be Followed in the Event of Abnormal Laboratory Test Values or Abnormal Clinical Findings  
The site PI  or appropr iate sub -investigator is responsible for recording  all AE/SAEs that are 
observed or reported during this  trial, regardless of relationship to study product. AE/SAEs , 
abnormal laboratory test values or abnormal clinical findings will be collected, assessed, documented, reported, and followed appropriately , using a local laboratory as necessary . In 
determining eligibility, refer to Section 5.1 and the protocol- specific MOP.  
9.3 Reporting Procedures  
Solicited injection site and systemic reactogenicity events will be documented and reported from the time of each study vaccination through 7 days after each study vaccination . 
Clinical safety laboratory AEs  will be documented and reported from the time of each study 
vaccination through approximately 7 days after each study vaccination.  
Unsolicited non-serious AEs will be documented and reported from the time of each  study 
vaccination through approximately 21 days  after each  study vaccination. 
SAEs  and MAAEs , including NOCMCs  and PIMMCs , will be documented and reported from 
the time of the first study vaccination through approximately 1 2 months after the last  study 
vaccination . 
9.3.1 Serious Adverse Events  
Any AE that meets a protocol -defined serious criterion must be submitted immediately (within 
24 hours of site awareness) on an SAE form to the DMID Pharmacovigilance Group, at the 
following address: 
 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
78 DMID Pharmacovigilance Group 
Clinical Research Operations and Management Support (CROMS)  
6500 Rock Spring Dr. Suite 650 
Bethesda, MD 20817, USA 
SAE Hot Line: 1 -800-537-9979 (US) or 1-301-897-1709 (outside US) 
SAE FAX: 1 -800-275-7619 (US) or 1 -301-897-1710 (outside US) 
SAE Email Address: PVG@dmidcroms.com 
In addition to the SAE form, selected SAE data fields must also be entered into 
AdvantageEDCSM. Please see the protocol -specific MOP for details regarding this procedure. 
Other supporting documentation of the event may be requested by the DMID Pharmacovigilance Group and should be provided as soon as possible. 
The site will send a copy of the SAE report (s) to the ISM (as deemed necessary) when they are 
provided to the DMID Pharmacovigilance Group. The DMID Medical Monitor and DMID 
Clinical Project Manager will be notified of the SAE by the DMID Pharmacovigilance Group.  
The DMID Medical Monitor will review and assess the SAE for regulatory reporting and potential impact on subject safety and protocol conduct. 
At any time after completion of this  trial, if the site PI  or appropriate sub- investigator becomes 
aware of an SAE that is suspected to be related to study product, the site PI  or appropriate sub-
investigator  will report the event to the DMID Pharmacovigilance Group. 
9.3.2 Regulatory Reporting for Studies Conducted Under DMID -Sponsored IND  
Following notification from the site PI  or appropriate sub-investigator, DMID, the 
Investigational New  Drug (IND) sponsor, will report any suspected adverse reaction that is both 
serious and unexpected. DMID will report an AE as a suspected adverse reaction only if there is 
evidence to suggest a causal relationship between the drug and the AE. DMID will no tify the 
FDA and all investigators (i.e., all participating VTEU site PI s to whom the sponsor is providing 
drug under its IND(s) or under any PI ’s IND(s)) in an IND safety report of potential serious risks 
from clinical trials or any other source, as soon as possible, but in no case later than 15 calendar 
days after the sponsor determines that the information qualifies for reporting as specified in 21 CFR Part 312.32. DMID will also notify the FDA of any unexpected fatal or life- threatening 
suspected advers e reaction as soon as possible, but in no case later than 7 calendar days after the 
sponsor’s initial receipt of the information.  Relevant follow up information to an IND safety 
report will be submitted as soon as the information is available.  Upon request from the FDA, 
DMID will submit to the FDA any additional data or information that the agency deems 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
79 necessary, as soon as possible, but in no case later than 15 calendar days after receiving the 
request.  
All serious events designated as “not related” to st udy product(s) will be reported to the FDA at 
least annually in a summary format.  
9.3.3 Reporting of Pregnancy 
Pregnancies occurring in subjects will be recorded on the Pregnancy Report DCF . No further 
study vaccinations will be administered to pregnant subjects , but with the subject’s permission , a 
venous blood sample for serological  assays approximately 21 and 180 days after the last study 
vaccination will be obtained, and the subject will continue to be followed for safety for the duration of the prescribed safety follow-up period. Efforts will be made to follow all pregnancies 
reported during the course of this trial to pregnancy outcome pending the subject’s permission. 
9.4 Type and Duration of Follow -up of Subjects after Adverse Events  
AEs will be collected , assessed  and followed through resolution from the time of each  study 
vaccination through approximately 21 days  after each  study vaccination. 
SAEs  and MAAEs , including NOCMCs  and PIMMCs , will be collected , assessed  and followed 
from the time of the first study vaccination through  resolution even if this extends beyond the 
trial-reporting period (approximately 1 2 months after the last  study vaccination). 
Resolution of an AE/SAE is defined as the return to pretreatment status or stabilization of the condition with the expectation that it will remain chronic.  
Follow-up procedures, evaluations and outcomes will be recorded on the appropri ate DCF  and 
entered into the eCRF . 
9.5 Halting Rules  
Additional enrollment and study interventions/administration of study products in this trial will be halted for DSMB review/recommendation if any of the following are reported: 
• Any subject e xperiences ulceration, abscess or necrosis at the injection site that is 
considered related to study product administration.  
• Any 2 or more subjects experience laryngospasm, bronchospasm or anaphylaxis within 1 day after administration of study product that is considered related to study product. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
80 • Three or more subjects experience generalized urticaria (defined as occurring at more 
than two body parts) within 3 days after administration of study product that is considered related to study product. 
• Any subject experiences an  SAE after administration of study product that is considered 
related to study product. 
• Any subject experiences acute weakness of limbs and/or cranial nerve innervated muscles 
(description of potential signal of GBS ) after administration of s tudy product. 
• Any subject develops a PIMMC  after administration of study product. 
This trial will also be halted for DSMB review/recommendation if, within 7 days after 
administration of either study vaccination, any of the following occurs:
 
• 7% or more of s ubjects (with a minimum of 3 subjects ) who received at least one dose of 
study vaccine to date, cumulative to all  study vaccine administration s, across all 
treatment arms , experience the same severe (Grade 3) study vaccine- related injection site 
reaction.  Ecchymosis, erythema and induration (hardness) /edema ( swelling ) will also be 
measured in mm but size will not be used as halting criteria.  
• 7% or more of subjects (with a minimum of 3 subjects ) who received at least one dose of 
study vaccine to date, cumulative to all  study vaccine administration s, across all 
treatment arms , experience the same severe (Grade 3) study vaccine- related subjective 
systemic reaction, for which the severity (grade) is corroborated by study personnel. 
• 7% or more of subjects (with a minimum of 3 subjects ) who received at least one dose of 
study vaccine to date, cumulative to all study vaccine administrations, across all 
treatment arms , experience the same severe (Grade 3) study vaccine- related quantitative 
systemic reaction.  
• 7% or more of subjects (with a minimum of 3 subjects)  who received at least one dose of 
study vaccine to date, cumulative to all study vaccine administrations, acro ss all 
treatment arms , experience the same severe (Grade 3) study vaccine- related clinical 
safety laboratory AE . 
Grading scales for solicited injection site and systemic (subjective and quantitative) reactions are 
included in Section 9.2.2. 
Grading scales for clinical safety laboratory AEs  are included in Section 9.2.3. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
81 If any of the halting rules are met following any subject receipt of any  study vaccination, then 
this trial will not continue with the remaining enrollments  or study vaccinations without a r eview 
by and recommendation from the DSMB  to proceed. 
DMID retains the authority to suspend additional enrollment and study 
interventions/administration of study products during this  trial, as applicable.  
The DMID Medical Monitor is empowered to stop enrol lment and study vaccinations if AEs that 
meet the halting criteria are reported . 
9.6 Safety Oversight  
9.6.1 Independent Safety Monitor (ISM)  
An ISM is a physician with relevant expertise whose primary responsibility is to provide to 
DMID an independent safety assessment  in a timely fashion.  This is a voluntary position that 
does not receive payment. The ISM must meet the requir ements of the NIAID  Conflict of 
Interest (COI) policy. 
For this clinical trial  an ISM is not required . However, at each participating VTEU site , upon 
DMID  Medical Monitor request , the site PI  will identify a physician with relevant expertise, to 
act as a Secondary Medical Assessor (SMA). The SMA will examine a subject and/or medical 
records and provide to DMID a medical assessment (or second medical opinion) of the safety 
event in question. The site  PI or appropriate sub- investigator will send to the DMID Medical 
Monitor, a summary of the event and include the site PI  or appropriate sub- investigator and SMA 
assessments. 
Note: In the case that DMID has requested this type of evaluation multiple times, DMID may 
request the participating VTEU site (s) identify an ISM t o assist DMID with safety oversight , and 
then the below requirements will apply. 
The ISM:  
• Is in close proximity to the study site and has the authority and ability to readily access 
subject  records in real time.  
• May be a member of the participating VTEU si te’s staff , but preferably be from a 
different organizational group within the institution.  
• Should not be in a direct supervisory relationship with the site  PI. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
82 • Should have no direct involvement in the conduct of the study. 
The ISM will: 
• Sign a COI certification at the time he/she is  asked to participate and provide updates to 
this information as needed. 
• Receive reports of SAEs from the site PI  or appropriate sub-investigator and will be 
notified by email when DMID is notified of the SAE.  
• Evaluate the SAE and report his/her clinical assessment to DMID in a timely manner . 
• Communicate with the site PI  or appropriate sub-investigator at the participating VTEU 
site as needed.  
• Review additional safety related events at the request of DMID.  
• Provide additional information to DMID and/or the DSMB by teleconference as 
requested.  
9.6.2 Data and Safety Monitoring Board (DSMB) 
Safety oversight will be co nducted by a DSMB  that is an independent group of experts that 
monitors subject safety and advises DMID. The DSMB members will be separate and independent of study personnel participating in this trial and should not have scientific, financial 
or other COI  related to this  trial. The DSMB  will consist of members with appropriate expertise 
to contribute to the interpretation of the data from this trial.  
The DSMB will operate under the rules of a DMID -approved charter that will be written at the 
organizational meeting of the D SMB. At this time, each data element that the DSMB needs to 
assess will be clearly defined. Procedures for DSMB reviews/meetings will be defined in the 
charter. The DSMB will review applicable data to include, but not limited to, study progress and subject, clinical, safety, reactogenicity , and immunogenicity data. Reports may include 
enrollment and demographic information, medical history, concomitant medications, physical assessments, clinical laboratory values, dosing compliance, solicited and unsolicite d AE/SAEs, 
and HAI and Neut antibody assay results. The DSMB will review SAEs on a regular basis and ad 
hoc during this trial. The DMID Medical Monitor and the ISM (as deemed necessary) will be 
responsible for reviewing SAEs in real time.  
The DSMB  will con duct the following reviews: 
• Data review for safety at trial- specific time frames; at least annually.  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
83 • Electronic review when 8 -day reactogenicity and clinical safety laboratory data following 
the first study vaccination is available for 25% of study subject s. 
• Data review when 8 -day reactogenicity and clinical safety laboratory data following the 
first study vaccination is available for 75% of study subjects . 
• Ad hoc when a halting rule is met, or DMID/DSMB chair may convene an ad hoc 
meeting if there are  immediate concerns regarding observations during the course of this 
trial. The DMID Medical Monitor is empowered to stop enrollment and study 
vaccinations if AEs that meet the halting criteria are reported.  
• Final review meeting  may be held  6 to 8 months after clinical databa se lock to review the 
cumulative unblinded safety and immunogenicity data for this trial. If a final review 
meeting is held, the data will be provided in a standard summary format. The DSMB may 
be asked to provide recommendations in response to questions posed by DMID. 
Additional data may be requested by the DSMB, and interim statistical reports may be generated 
as deemed necessary and appropriate by DMID. The DSMB may receive data in aggregate and 
presented by treatment arm. The DSMB may also be provided with expected and observed rates of the expected AEs in an unblinded fashion, and may request the treatment assignment be unblinded for an individual subject if required for safety assessment. The DSMB will review 
grouped and unblinded data in the closed se ssion only. As an outcome of each review/meeting, 
the DSMB will make a recommendation as to the advisability of proceeding with study 
vaccinations , as applicable, and to continue, modify or terminate this trial.  
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
84 10 CLINICAL MONITORING  
10.1 Site Monitoring Plan  
Site monitoring is conducted to ensure that the human subjects’  protections, study and laboratory 
procedures, study interventions/administration of study products, and data collection processes 
are of hig h quality and meet sponsor and ICH E 6 GCP guidelines and applicable federal 
regulations, and that this  trial is conducted in accordance with the protocol, protocol- specific 
MOP and applicable sponsor SOPs . DMID, the sponsoring agency, or its designee will conduct 
site-monitoring visits as detailed in the clinical monitoring plan.  DMID -designated clinical 
monitors will verify that this  trial is conducted and data are g enerated, documented (recorded) 
and reported in compliance with the protocol, ICH E6 GCP guidelines and applicable regulatory 
requirements. Clinical monitoring reports will be submitted to DMID.  
Site visits will be made at standard intervals as defined by DMID and may be made more frequently as directed by DMID.  Monitoring visits will include, but are not limited to, review of 
regulatory files, accountability records, eCRFs, ICFs , medical and laboratory reports, and 
protocol and GCP compliance. Site monitors will have access to each participating VTEU  site, 
study personnel and all study documentation according to the DMID-approved site monitoring plan. Study monitors will meet with site PI s to discuss any problems and actions to be taken and 
document visit findings and discussions. 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
85 11 STATISTICAL CONSIDERATIONS 
11.1 Introduction  
The goal of this clinical trial is to assess in healthy adults, 19 to 50 years of age, the safety, 
reactogenicity and immunogenicity of one or two doses 2013 and 2017 A/H7N9 IIVs, 
administered intramuscularly at different dosages (3.75 or 15 mcg of hemagglutinin (HA) per dose), given with or without AS03 adjuvant, using different heterologous and homologous 
prime -boost vaccination schedules. These treatment arms are included to all ow evaluation of the 
study vaccine dosage, study vaccination schedule and potential of the adjuvant to enhance the 
immune response to the 2013 and 2017 A/ H7N9 IIVs. Additional goals are to investigate novel 
methods for identifying and assessing alternative cellular correlates of protection against 
influenza infection. 
11.2 Study Hypo theses  
This Phase II study is not designed to test a formal null hypothesis. Rather, it is intended to obtain sufficient data to obtain meaningful estimates of the immune response induced by this 
vaccine and to uncover any safety issues that occur at a suf ficiently high rate that they might be 
observed in a study of this size. The sample size facilitates formal testing of selected hypotheses 
as discussed in Section 11.4.3, along with the probability of observing safety outcomes and the 
precision of immunogenicity outcomes. 
11.3 Study Outcome Measures  
Please refer to Study Outcome Measures outlined in Section 3.2. 
11.4 Sample Size Considerations  
Please refer to Study Design outlined in Section 4. 
11.4.1 Study Population  
The study population for this clinical trial includes males and non-pregnant females, 19 to 50 
years of age , who are in good health and meet all eligibility criteria . The su bjects will be 
recruited from the general population at each of the participating VTEU sites that have substantial experience conducting large influenza vaccine studies.  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
86 11.4.2 Subject Enrollment and Follow -up 
Based on the accrual rates observed in similar studies, it seems reasonable to expect that the 
participating VTEUs will be able to enroll this trial in a timely fashion. In previous DMID trials, 7 VTEUs recruited 388 healthy subjects, 19 to 64 years of age, in 14 weeks. Prior experience suggests up to 15% of subjects (approximately 10% of subjects assigned to the 4 -month interval 
and 5% of subjects assigned to the 21-day interval), 19 to 64 years of age, may be excluded from the per protocol (PP) analysis for the primary immunogenicity outcome either because they did not receive the second study vaccination, were lost- to-follow-up, or because they had a protocol 
deviation requiring their exclusion from the PP analysis. 
Follow-up will consist of 2 segments . The first encompasses the core data for this trial and will 
consist of results for all study visits through approximately 21 days after the last study 
vaccination. The second segment consists of a 6-month immunogenicity assessment and follow-
up safety as sessments through approximately 12 months after the last study vaccination. 
11.4.3 Sample Size  
This study is planned to enroll up to 180 subjects. The sample size for this study was selected to 
obtain preliminary estimates in a time critical manner. While this study is not designed to test 
any specific null hypothesis, the following illustrates the precision and power that are available 
for select estimates and comparisons of interest.  
Table 12 indicates the probability of observing one or more safety events, such as solicited 
injection site or systemic reactogenicity events or an unsolicited non -serious AE of a particular 
type for a single treatment arm (N=30), or in the trial as a whole (N=180).  
 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
87 Table 12: Power (%) to Detect Safety Events  
Event 
Frequency  N=30 N=180 
≥10% 
Very Common 95 >99 
≥1% 
Common 26 83 
≥0.1% 
Uncommon 2 16 
≥0.01% 
Rare  <1 1 
Binomial confidence intervals (CI) are widest (have the least precision) when the response rate is 
50%. Table 13 is presented to indicate the worst- case scenario for precision of observed exact 
(Clopper-Pearson) binomial confidence intervals. 
Table 13: Precision of Binomial Confi dence Intervals  
N 95% CI 
30 31-69 
180 42-58 
Table 14 illustrates the minimum detectable differences in the proportion of subjects responding 
(e.g. attaining seroconversion or a titer ≥ 1:40) between any two treatment arms (N=30) using a 
two-sided Likelihood Ratio Test and alpha = 0.05. It is assumed that up to 10 % of subjects (N=3) 
will be excluded from the per protocol analysis. Seroconversion rates of 10% to 50% are 
considered. 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
88 Table 14: Minimum Dete ctable Difference in Proportion Responders  
N per Group Proportion 
Responders in 
Comparator 
Group A 80% Power 
Minimal 
Detectable 
Difference  Proportion 
Responders in 
Comparator 
Group B 
N=27 0.10 0.32 0.42 
0.20 0.35 0.55 
0.30 0.38 0.68 
0.40 0.37 0.77 
0.50 0.34 0.84 
11.5 Planned Interim Analyses  
A DSMB will be convened by DMID to review study progress and subject, clinical, safety, 
reactogenicity, and immunogenicity data as described in Section 9.6.2. 
A set of “topline” immunogenicity and safety t ables produced on an expedited timeline wi ll be 
prepared as described in Section 11.6; though this report will be relea sed while subjects remain 
in this  trial for long- term safety follow -up, it will be considered the final analysis of these data. 
Emergent public health needs may dictate additional interim safety, reactogenicity and/or 
immunogenicity analyses be performed on available information at any time during this trial. If 
this occurs, immunogenicity data will be analyze d as results are available from Southern 
Research . 
Interim analyses will be used only to terminate this trial in the event that unanticipated safety events deemed to be of sufficient concern require such action by the sponsor. These assessments 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
89 will not be made on the basis of testing a formal statistical hypothesis; therefore, p -value 
adjustment will not be made to any analyses.  
11.5.1 Interim Safety Review  
An interim safety review  may inclu de enrollment and demographic information, medical history, 
concomitant medications, physical assessments , clinical laboratory values, dosing compliance, 
and solicited and unsolicited AE/SAEs.  Additional data may be requested by the DSMB, and 
interim statistical reports may be generated as deemed necessary and appropriate by DMID.  The 
DSMB may receive data in aggregate and presented by treatment arm . The DSMB may also be 
provided with expected and observed rates of the expected AEs in an unblinded fashion, and may 
request the treatment assignment  be unblinded for an individual subject if required for safety 
assessment . The DSMB will review grouped and unblinded data in the closed session only. The 
DSMB will meet and review this data at trial- specific time frames or ad hoc as needed during 
this trial as defined in the DSMB charter. As an outcome of each review/meeting, the DSMB will 
make a recommendation as to the advisability of proceeding with study vaccinations, as 
applicable, and to continue, modify or terminate this  trial. 
The interim safety reports generated for the DSMB are not intended to be published; they will be 
used only for informing emergency preparedness.  
Additionally, this  trial wi ll be monitored to determine if any of the halting rules described in 
Section 9.5 are met.  
11.5.2 Interim Immunogenicity Review  
Should emergent public health needs dictate interim immunogenicity review, immune responses 
will be summarized in terms of strain -specific 2013 and 2017 A/H7N9 HAI and Neut antibody 
titers  and the relationship to study vaccine dosage, adjuvant use and stud y vaccination schedule. 
It is anticipated that all analyses will be carried out in parallel for both assays, but reports may be prepared separately for HAI s and Neuts if results are available on different timelines. Interim 
analyses will focus on rates of titers ≥1:40, seroconversion (defined as either a pre -vaccination 
titer <1:10 and a post- vaccination titer ≥1:40 or a pre -vaccination titer ≥1:10 and a minimum 
four-fold rise in post-vaccination titer) and GMTs, along with corresponding 95% CIs. No formal hypothesis testing will be included in the interim analysis, and interim results will not have impact on conduct of this trial. 
Any immunogenicity reports would be provided by the SDCC to the DMID Scientific Lead, 
DMID Clinical Project Manager  and DSMB. Re ports will include data summarized by unblinded 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
90 treatment arm, but the presentation will be in a format that prevents inadvertent unblinding of 
any individual subject. 
There is no plan to halt this trial prior to full enrollment and completion of all follo w-up visits 
based on any interim immunogenicity results.  
11.6 Final Analysis Plan  
Clinical, safety  and reactogenicity data through approximately 180 days after the last study 
vaccination will represent the primary clinical database for this trial. Once the last subject 
completes the visit that occurs approximately 180 days after the second study vaccination and all HAI and Neut results are received, a “topline” subset of the immunogenicity and safety tables 
will be provided to DMID on an expedited timeline. These analyses may be made available to 
the sponsor for planning subsequent trials and to the lead PI  for publication. These analyses will 
not be used to make any decis ions concerning the conduct of this trial. As it is anticipated th at 
subjects will remain in long -term safety and immunogenicity follow- up at the time of these 
analyses, blinded site  investigators and DMID Medical M onitors not involved in the analysis, 
publication  or clinical study report (CSR) preparation will be responsible for assessing SAEs and 
MAAEs , including NOCMCs  and PIMMCs, until all subjects have completed the final follow -up 
visit. All analyses of data included in the topline tables  for early re lease will be considered the 
final analysis of these data, and also included in the final CSR. 
Analysis of exploratory immunogenicity endpoints, including cellular immun ology and 
additional serological assays , may be performed and released as the data are available from the 
research  laboratories . Any such analyses would be considered the final analysis for the endpoint, 
and included in the CSR. The final CSR will be completed after  the last subject’s last visit is completed, and the final 
clinical database, including all long- term safety follow -up data, is cleaned, monitored and 
locked . Additional exploratory immunogenicity endpoint data not available at the time of CSR 
preparation may be included in an addendum to the CSR. A formal statistical analysis plan (SAP) will be developed and finalized prior to unblinding for 
any analysis , which defines the analyses to be included in the topline tables  and final CSR. 
11.6.1 Analysis Populations 
The Safety Analysis population includes all subjects who received at least one dose of study 
vaccine.  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
91 The modified intent- to-treat ( mITT) population includes all subjects who received at least one 
dose of study vaccine and contributed both pre- and at least one post-study vaccination venous 
blood samples for HAI and  Neut antibody assays for which valid results were reported. For 
analyses using the mITT population, subjects will be grouped based on their randomized 
treatment arm.  
The PP population includes all subjects in the mITT subset with the following exclusions: 
• Data from all available visits for subjects found to be ineligible at baseline.  
• Data from all visits subsequent to major protocol deviations, such as: 
• Second study vaccination not received,  
• Second study vaccination received out of window, 
• Receipt of non- study licensed , live vaccine within 30 days before or after each 
study vaccination, 
• Receipt of non- study licensed , inactivated vaccine within 14 days before or after 
each study vacci nation, 
• Receipt of immunosuppressive therapy (e.g., corticosteroids) within 30 days before or after each study vaccination.  
• Data from any visit that occurs substantially out of window. 
For analyses using the PP population, subjects will be grouped based on study vaccinations 
received.  
11.6.2 Safety Data 
Summaries and analysis of safety data will be presented for the Safety Analysis Population. All summaries and analyses will be presented for all subjects.  
Solicited AEs will be summarized by severity for each day after each study vaccination (Days 1 -
8 post each study vaccination) and as the maximum severity over all 8 days. Additionally, 
solicited AEs will be analyzed by taking the most severe response over the follow-up period, 
dichotomizing into a binary variable (none versus mild, moderate or severe) and using standard 
techniques, such as exact CIs , to summarize the proportion of subjects reporting each symptom, 
any injection site symptom and any systemic symptom. Summaries of solicited AEs will be 
presented separately for each study vaccination as well as overall study vaccinations by 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
92 treatment arm. The proportion of subjects reporting symptoms may be compared between 
treatment arms using Chi-square or Fisher’s exact test. The proportion of subjects reporting 
solicited symptoms between the different study vaccinations (i.e., first and second) will be compared using McNemar’s test.  
Unsolicited AEs will be coded by Medical Dictionary for Regulatory Activities (MedDRA
) for 
preferred term and system organ class ( SOC). The numbers of SAEs and MAAEs, including 
NOCMCs  and PIMMCs, are likely to be small in this trial and will be reported by detailed 
listings showing the event description, MedDRA preferred term and SOC, relevant dates (study 
vaccinations and AEs), severity, relatedness, and outcome for each event. Non-serious unsolicited AEs will be summarized as number and percentage of subjects reporting at least one 
event in each MedDRA
 preferred term and SOC, cross -tabulated  by severity and relationship to 
study p roduct. Additionally, the proportion of subjects and exact 95% CIs  of AEs in aggregate 
and by MedDRA categories will be computed.  
Clinical laboratory data will be summarized by severity for each visit and as the maximum over 
all post-study vaccination visits. Graphical presentations may include box plots. 
11.6.3 Immunogenicity  Data  
Summaries and analysis of immunogenicity data will be presented for the m ITT and PP 
populations. 
Immune responses in terms of strain- specific 2013 and 2017 A/H7N9  HAI and Neut antibody 
titers will be summarized by treatment arm at each time point. Analyses will include number and 
percentage of subjects with a titer ≥1:40, number and percentage of subjects achieving seroconversion (defined as either a pre- vaccination titer < 1:10 and a post- vaccination titer ≥1:40 
or a pre -vaccination titer ≥1:10 and a minimum four -fold rise in post-vaccination antibody titer), 
and GMTs along with corresponding 95% CIs . Descriptive summary statistics will be provided 
for all assays and time poin ts. The correlation between HAI and Neut antibody titers will be 
evaluated. Plots such as reverse cumulative distributions or longitudinal presentations of GMTs will be presented.  
Additionally, the immune response, as described above, will be summarized by available 
covariates, such as age, sex, BMI , and prior receipt of seasonal or non-study pandemic influenza 
vaccine(s), and these covariates may be considered statistical modeling.  As an exploratory 
analysis, models may  be developed to evaluate the relatio nship between study vaccine d osage 
and adjuvant use as well as study vaccination schedule on the elicited immune response . For 
example, logistic regression may be used to examine the relationship of proportion of responders 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
93 with study vaccine dosage and adjuvant use as well as study vaccination schedule , and available 
covariates may be considered for inclusion in the model. 
At least a subset of samples  will also be tested for cross -reactive serum HAI and Neut antibody 
responses to antigenically drifted variants of influenza A/H7 viruses. Strain- specific results will 
be summarized using descriptive statistics as described above, correlations with 2013 and 2017 
A/H7N9 responses and association with study vaccine dos age and adjuvant use as well as study 
vaccination schedule. 
In addition, N9 NA-specific antibody assays are in development. N9 NA- specific serum antibody 
responses may  be assessed at baseline as well as immediately prior to and approximately 2 1 days 
after the second  study vaccination. For  each time point, summaries may  include number and 
percentage of subjects with detectable N9 NA response (to be defined in SAP following assay 
development and selection) and GMTs along with corresponding 95% CI s. Descriptive summary 
statistics will be provided for all assays and time points. The correlation of N9 NA- specific 
serum antibody responses with HAI and Neut antibody titers will be evaluated, and plots such as reverse cumulative distributions or longitudinal presentations of GMTs will be presented.  
Further more , a determination of the N9 NA content in  the 2013 and 2017 A/ H7N9 IIVs is 
planned, and may  be used to correlate the NA content of the 2013 and 2017 A/H7N9 IIVs with 
the elicited N9 NA -specific serum antibody responses . Detectable N9 NA -specific serum 
antibody responses and GMTs will be summarized stratified by NA content, and statistical 
modeling may be used to examine the relationship of NA response with NA content, HA antigen 
dosage, adjuvant, and study vaccination schedule. 
At least a subset  of samples  will also be tested for exploratory immunogenicity endpoints, 
including cellular  immunology and additional serological assays . Exploratory immunology 
analyses will be primarily descriptive and defined in the SAP . Results of any exploratory 
immunogenicity analysis will not be published prior to publication of the primary 
immunogenicity results for this trial.  
Further immunogenicity testing and/or analyses may be carried out in the future based upon subjects’ prior receipt of non- seasonal influenza vaccine, including type (inactivated or live 
attenuated), what subtype (e.g. A/H3, A/H5, A/H9) and approximate date of vaccination. 
11.6.4 Missing Values and Outliers  
All attempts will be made to collect all data per protocol. As missing data are expected to be 
minimal, no imputation will be performed for missing values. Any data point that appears to be erroneous or inexplicable based on clinical judgment will be investigated  as a possible outlier. If 
data points are identified as outliers, sensitivity analyses will be performed to examine the 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
94 impact of including or excluding the outliers. Any substantive differences in these analyses will 
be reported. 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
95 12 DATA COLLECTION FORM S AND ACCESS TO 
SOURCE DATA/DOCUMENT S 
Each participating VTEU site will maintain appropriate medical and research records for this 
clinical trial, in compliance with ICH E6  GCP  Section 4.9 and regulatory and institutional 
requirements for the protection of confidentiality of subjects. Each participating VTEU site will 
permit the study monitor or other authorized representatives of DMID  as well as  governmental  
regulatory agencies, such as the FDA,  to examine (and when required by applicable law,  to copy) 
clinical trial records for the purposes of quality assurance reviews, audits, monitoring and evaluation of the study safety and progress.  These representatives will be permitted access to all 
source data, which include, but are not limited to, hospital records, clinical and office charts, 
laboratory notes, memoranda, evaluation checklists, pharmacy dispensing records, recorded data 
from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x- rays, and 
subject files , and records kept at the pharmacy, at the laboratories and medico- technical 
departments involved in this  clinical trial.  Source data are all information, original reco rds of 
clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the clinical trial.  
Interview of subjects is sufficient for obtaining medical history. Solicitation of medical records from t he subject’s primary care provider is not required. 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
96 13 QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted site quality management plan, each  participating VTEU site  
(and its subcontractors) is responsible for conducting routine quality assurance (QA) and quality 
control (QC) activities to internally monitor study progress and protocol compliance. Each site  PI 
will provide direct access to all study- related sites, source data/ DCF s and reports for the purpose 
of monitoring and auditing by the sponsor, and inspection by local and regulatory authorities. 
Each  site PI will ensure all study personnel are appropriately trained and applicable 
documentation is current and maintained on sit e. 
The SDCC will implement QC procedures beginning with the data entry system and generate data QC  checks that will be run on the database. Any missing data or data anomalies will be 
communicated to the participating VTEU site (s) for clarification and reso lution. 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
97 14 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
14.1 Ethical Standard  
The site  PIs will ensure that this trial is conducted in full conformity with principles of the 
Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of 
Research  (National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research [April 18, 1979]) and codified in 45 CFR 46, 21 CFR 50 and 21 CFR 56, as 
applicable. The site  PIs will also ensure conformity with ICH E6 GCP and applicable fe deral 
regulations, guidance and guidelines for GCP and Clinical Trials with humans. 
14.2 Institutional Review Board  (IRB) 
Each institution engaged in this research will hold a current Federalwide Assurance (FWA) 
issued by the Office for Human Research Protection s (OHRP) for federally funded research.  The 
IRB must be registered with OHRP  [OHRP -only or OHRP/FDA] as applicable to the research.  
The IRB FWA number will be provided to DMID. 
Each site PI  will obtain IRB approval for this protocol to be conducted at his/her research site(s), 
and send supporting documentation to DMID before initiating recruitment of subjects. The site  
PI will submit applicable information to the IRB on which it relies for the review, to conduct the 
review in accordance with 45 CFR 46, ICH E6 GCP guidelines, and as applicable, 21 CFR 56 
(Institutional Review Boards), 21 CFR 50 (Protection of Human Subjects), and other federal, 
state and local re gulations and guidance . DMID must receive the documentation that verifies 
IRB approval for this protocol, associated informed consent documents, and upon request, any 
recruitment material and handouts or surveys intended for the subjects, prior to the recr uitment 
and enrollment of subjects. 
Any amendments to the protocol or consent materials will be approved by the IRB before they 
are implemented. IRB review and approval will occur at least annually throughout the enrollment 
and follow-up of subjects, and may cease if annual review is no longer requi red by applicable 
regulations. The site  PI will notify the IRB of protocol deviations and reportable SAEs  in 
accordance with  IRB requirements . 
14.3 Informed Consent Process  
Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
trial and continuing throughout the individual’s trial participation. Before any study procedures 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
98 are performed , informed consent will be obtained and documented. S ubjects will r eceive a 
concise and focused presentation of key information about the trial, verbally and with a written 
ICF. The explanation will be organized, and presented in lay terminology and language that 
facilitates understanding why one might or might not want t o participate.  The ICF must not 
include any exculpatory statements.  
The site  PIs or their designees will describe the protocol to potential subjects face -to-face. The 
key information about the purpose of the trial, the procedures and experimental aspects of the trial, risks and discomforts, any expected benefits to the subject, and alternative treatment will be presented first to the subject. 
Subjects will also receive an explanation that the trial involves research and a detailed summary 
of the proposed study procedures and study interventions/study products . This will include 
aspects of the trial that are experimental, the probability for random assignment to treatment 
arms, any expected benefits, all possible risks (including a statement that the particul ar treatment 
or procedure may involve risks to the subject or to the embryo or fetus, if the subject is or may 
become pregnant, that are currently unforeseeable), the expected duration of the subject’s participation in the trial, alternative treatment/proc edures that may be available, and the 
important potential benefits and risks of these available alternative treatment/procedures.  
Subjects will be informed that they will be notified in a timely manner if information becomes available that may be relevant to their willingness to continue participation in the trial. Subjects 
will receive an explanation as to whether any compensation and any medical treatments are 
available if injury occurs, and, if so, what they consist of or where further information may be obtained. Subjects will be informed of the anticipated financial expenses, if any, to the subject for participating in the trial, as well as any anticipated prorated payments, if any, to the subject 
for participating in the trial. They will be informed of  whom to contact (e.g., the site PI ) for 
answers to any questions relating to the research project.  
Information will also include the foreseeable circumstances and/or reasons under which the subject’s participation in the trial may be terminated. The subjects will be informed that 
participation is voluntary and that they are free to withdraw from the study for any reason at any time without penalty or loss of benefits to which the subject is otherwise entitled. 
The extent of the confidentiality of the subjects’ records will be defined, and subjects will be 
informed that applicable data protection legislation will be followed. Subjects will be informed 
that the monitors, auditors, IRB, NIAI D, and regulatory authorities  will be granted direct access 
to the subject’s original medical records for verification of trial procedures and/or data without violating the confidentiality of the subject, to the extent permitted by the applicable laws and 
regulations, and that, by signing a written ICF, the subject is author izing such access.  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
99 Subjects will be informed that records identifying the subject will be kept confidential and, to the 
extent permitted by the applicable laws and/or regulations, will not be made publicly available 
and, if the results of the trial are published, the subject’s identity will remain confidential. Subjects will be informed whether private information collected from this research and/or samples/specimens will be used for additional research, even if identifiers are removed.  
Subjects will be allowed sufficient time to consider participation in the trial, and have the opportunity to discuss the trial with their family, friends or legally authorized representative, or think about it prior to agreeing to participate.  
ICFs  will be IRB -approved and subjects will be asked to read and review the ICF. Subjects must 
sign the ICF prior to starting any study procedures being done specifically for the trial.  
Once signed, a copy of the ICF will be given to the subjects for their records. The subject(s) may 
withdraw consent at any time throu ghout the course of the trial. The rights and welfare of the 
subjects will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to participate in or withdraw from the trial. 
New information that significantly impacts the subject’s risk of receiving the study 
interventions/study products will be communicated by the site PI s or their design ees to the 
subjects who consent to participate in the trial in accordance with IRB requirements. The ICF will be updated and subjects will be re-consented in accordance with IRB requirements, if necessary. Subjects will be given a copy of all ICFs that the y sign.  
Study personnel may employ IRB-approved recruitment efforts prior to obtaining study consent if a patient -specific screening consent is on record or if the IRB has agreed that chart review is 
allowed without a ful ly executed  screening consent. In c ases where there is not a patient -specific 
screening consent on record, Clinical S taff may pre -screen via chart review and refer potential 
subjects to the Research staff . Research staff would obtain written consent per the standard 
informed consent process before conducting protocol- specific screening activities.  
After all subjects had enrolled, it was determined that B cell repertoire sequencin g is a form of 
genetic testing  that will be performed as part of this trial under this primary research protocol. 
Subjects will be informed and asked for their consent to use their samples/specimens and information for genetic testing , such as B cell repertoire sequencing . B cell repertoire sequencing  
results  (data) may  be shared broadly with other researchers  but will not be shared with subjects. 
Individual results will be stored indefinitely in an NIH restricted -access database, and a summary 
of results may  be placed in an unrestricted (open) database. 
The samples/specimens  will be en coded (labeled) only with a barcode and a unique tracking 
number to protect subject confidentiality. The genetic data in the NIH database will be coded in 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
100 such a way that information will be considered de-identified. Subjects will be informed of the 
risks,  including potential for re- identification and possible harm from the mis -use of data, 
however, NIH will require researchers to not re-identify the subjects. 
Subjects will have the right to withdraw consent for the use of their samples/specimens and/or 
data without penalty at any time. Samples/specimens and data that have already been used for 
primary research may not be able to be withdrawn.  
"Written", or "sign ed", refers to the use of  or writing on a paper or an electronic ICF. Re -consent 
(revised or separate consent form) for  primary  research  using samples/specimens and 
information for genetic testing , such as B cell repertoire sequencing , may use paper or electronic 
ICFs to obtain the subject’s written consent. The subject will have a discussion with study staff, 
who is able to answer the subject’s questions, including if re-consent is obtained off- site. A paper 
copy of the signed ICF will be given to the subject in person or mailed. 
14.4 Exclusion of Women, Minorities and Children (Special Populations)  
This trial will be inclusive of all s ubjects , 19 to 50 years of age, who meet the Subject I nclusion 
Criteria  (see Section 5.1.1) and do not meet the Subject Exclusion C riteria  (see Section 5.1.2), 
regardless of religio n, sex or ethnic background. Adults aged 18 are excluded because the CDC -
recommended adult immunization schedule considers adults as age 19 and above, and therefore 
this is the subject population chosen for this study [74]. Should the outcome of this trial be deemed acceptable, additional trials may be initiated including those in other populations. 
It is unknown if the 2013 and 2017 A/H7N9  IIVs with or without AS03 adjuvant pose any risks 
to an unborn child. As of November 22, 2015 ( per the GSK AS03 Adjuvant Investigator’s 
Brochure  dated February 2016),  the available data for women who become pregnant during 
clinical trials of AS03 -adjuvanted (pre) pandemic influenza vaccines do not suggest any causal 
relationship between adverse pregnancy outcomes and receipt of an AS03-adjuvanted vaccine. 
Women of childbearing potential who are not steril ized via tubal ligation, bilateral 
oophorectomy, salpingectomy, hysterectomy, or successful Essure
® placement (permanent, non-
surgical, non- hormonal sterilization) with documented radiological confirmation test at least 90 
days after the procedure, and still menstruating or <1 year has passed since the last menses if 
menopausal must agree to practice highly effective contraception that may include non- male 
sexual relationships, abstinence from  sexual  intercourse with a ma le partner, monogamous 
relationship with a vasectomized partner who has been vasectomized for 180 days or more prior to the subject receiving the first study vaccination , barrier methods such as condoms or 
diaphragms /cervical cap  with  spermicide , effective intrauterine devices, NuvaRing
®, and 
licensed hormonal methods such as implants, injectables or oral contraceptives (“the pill”) , with 
use of a highly effective method of contraception for a minimum of 30 days prior to study 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
101 vaccine exposure and agree to practice highly effective contraception for the duration of study 
vaccine exposure, including 60 days after their last study vaccination. A highly effective method 
of contraception is defined as one that  results in a low failure rate (i.e., less than 1% per year) 
when used consistently and correctly. In addition to contraceptive use, all women of childbearing potential will be required to have a negative urine or serum pregnancy test within 24 hours prior 
to each study vaccination.  If a female subject becomes pregnant while participating in this trial, 
we will ask her permission to follow -up with her about her health and the health of her baby 
through pregnancy outcome. 
Children will not be included in this trial as  presently there are no safety or efficacy data in 
adults. 
14.5 Subject Confidentiality  
Subject confidentiality is strictly held in trust by the site PI s, other study personnel, the sponsor, 
and their agents. This confidentiality incl udes documentation, investigation data, subject’s 
clinical information , and all other information generated during participation in this trial. No 
information concerning this trial or the data generated from this trial will be released to any 
unauthorized third party without prior written approval of the subject and DMID . 
Subject confidentiality will be maintained when trial results are published or discussed in 
conferences , and is extended to cover testing of samples/specimens.  The study monitor or other 
authorized representatives  of DMID as well as governmental regulatory agencies , such as the 
FDA, may inspect all documents and records required to be maintained by the site PI s. This 
includes, but is not limited to, medical records (office, clinic  or hospital) and pharmacy records 
for the subjects in this trial. The participating VTEU sites will permit access to such records.  
All records will be kept locked and all computer entry and networking programs will be carried 
out with coded numbers only and with password- protected systems. All non -clinical 
samples/ specimens, evaluation forms, reports, and other records that leave the site will be 
identified only by a coded number and will not be identified by the subject’s name. 
To protect privacy, we have received a C ertificate of Confidentiality. With this Certificate, the 
researchers cannot be forced to release information that may identify the subject, even by a court 
subpoena, in any federal, state or local civil, criminal, administrative, leg islative, or other 
proceedings.  The researchers will use the Certificate to resist any demands for information that 
would identify the subject, except as explained below. 
The Certificate cannot be used to resist a demand for information from personnel of the US  
Government that is used for auditing or evaluation of federally funded projects, like this trial, or 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
102 for information that must be released in order to meet the requirements of the FDA . 
A Certificate of Confidentiality does not prevent the subject from vol untarily releasing 
information about themselves or their involvement in this research. If any person or agency 
obtains a written consent to receive research information, then the researchers may not use the Certificate  to withhold that information. 
The Cer tificate of Confidentiality does not prevent the researchers from reporting without the 
subject’s consent, information that would identify the subject as a participant in the research project regarding matters that must be legally reported including: child  and elder abuse, sexual 
abuse or wanting to harm themselves or others. 
14.6 Study Discontinuation  
If this  trial is prematurely terminated by the sp onsor, any regulatory authority, the site  PI, or 
appropriate sub-investigator for any reason, the site PI  or appr opriate sub -investigator will 
promptly inform the subjects and assure appropriate therapy or follow-up for the subjects, as 
necessary. The site  PI or appropriate sub-investigator will provide a detailed written explanation 
of the termination to the IRB . If any subject’s private information will continue to be colle cted 
for this trial, the IRB must approve a n ICF with the study procedures, any risks and discomforts 
as well as  applicable elements, and the site PI  or designee will re -consent the subjects as 
approved by the IRB. 
If this trial is discontinued, subjects, who have signed the ICF, and are randomized and 
vaccinated, will continue to be followed for safety for the duration of the prescribed safety 
follow-up period. No further study vaccinations will be administered.  
14.7 Costs, Subject Compensation  and Research Related Injuries  
There is no cost to subjects for the research tests, study procedures/evaluations or study vaccine 
while taking part in this trial. 
Subjects may be compensated for their participat ion in this trial. Compensation will be in 
accordance with  local IRB requirements , and subject to local IRB approval. 
If it is determined by the participating VTEU site and the site  PI that an injury occurred to a 
subject as a direct result of the tests or  treatments that are done for this trial , then referrals to 
appropriate health care facilities will be provided to the subject.  Study personnel will try to 
reduce, control  and treat any complications from this trial. Immediate medical treatment may be 
provided by the participating VTEU site, such as giving emergency medications to stop 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
103 immediate allergic reactions to the study vaccin e. No financial compensation will be provided to 
the subject by NIAID, NIH or the parti cipating VTEU site for any injury suffered due to 
participation in this trial. 
For this protocol, the study products (2013 and 2017 A/H7N9 IIVs manufactured by Sanofi 
Pasteur and AS03 adjuvant manufactured by GSK) are covered under the PREP A ct, as 
describ ed in Section 2.1.1. 
14.8 Future Use of Stored Specimens  
Subjects who agree to participate  in this trial will have venous blood collected for ESR and  
clinical safety laboratory evaluations, serological and cellular immunology assays  as well as 
future research.  
Residual samples/specimens are those that are left over after protocol- specified testing for 
serological and cellular immunology assays and this trial have been completed . Any remaining 
(residual) specimens  (serum , plasma and  PBMCs ) derived from venous blood samples collected 
for serological and cellular immunology assays  will be kept for possible use in future research 
studies, such as examining additional immunological assessments or testing for antibodies against other viruses or bacteria.  Residual specimens  for future research use will be stored 
indefinitely at a central clinical storage facility  and may be shared for purposes other than PP 
analysis with investigators at the participating VTEU site and with other investigators at other institutions  once the CSR  has been finalized . An IRB will review future research prior  to the use 
of identifiable specimens or data.  
Additional venous blood samples for serum , plasma and PBMC specimens will be collected 
during this  trial specifically for the purpose of future research , including, but not limited to , 
detailed systems biology analyses , antibody epitope mapping, B and T cell repertoire 
determination, non- traditional immune assay development, assessing innate immune factors , and 
the ability of A/H7 study vaccine -induced antibodies to cross-react with other influenza virus es. 
These samples/specimens  might be used in new or different immunological laboratory tests, to 
provide information for the development of new vaccines, or for the studies of influenza or other 
infections. S amples/specimens collected during this trial spe cifically for the purpose of future 
research will be stored indefinitely at a central clinical storage facility  and may be shared with 
investigators at the participating VTEU site and with other investigators at other institutions . An 
IRB will review futur e research prior to the use of identifiable specimens or data.  
Residual specimens will be available upon the completion of this trial; however, 
samples/specimens collected during this  trial specifically for the purpose of future research may 
be requested from DMID and shipped from the DMID CMS  at any time.  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
104 There are no benefits to subjects in the collection, storage and future research use of their 
samples/specimens . Future research tests may benefit others by leading to new approaches in the 
development of vaccines or treatments for influenza. Future research use samples/specimens 
(residual specimens and  samples/specimens collected during this  trial specifically for the purpose 
of future research ) will not be sold or used directly for production of any commercial product. 
Each sample/specimen will be encoded (labeled) only with a barcode and a unique tracking 
number to protect subject confidentiality. Reports from  future research studies performed using 
subjects’ samples/specimens  will NOT be k ept in their health records and results will not be 
shared with subjects. 
Subjects will not  be given the option to decide if they want their residual  specimens  to be used 
for future research or have these specimens  destroyed at the end of this trial. S ubjects will be 
asked to consent to the future research use of residual  specimens  as a condition of their study 
participation.  
Subjects will not  be given the option to decide if they want their samples/specimens collected 
during this  trial specifically for  the purpose of future research  to be used for future research or 
have these samples/specimens  destroyed at the end of this trial. T hese samples/specimens  are 
protocol- required ; thus, subjects will be asked to consent to the future research use of these 
samples/specimens as a condition of their study participation. 
By signing a written ICF  for this trial, subjects agree to the collection, storage and future 
research use of their samples/specimens  (residual specimens and samples/specimens collected 
during this trial specifically for the purpose of future research ). 
After all subjects had enrolled, it was determined that g enetic test ing may  be performed on 
residual specimens and samples/specimens collected during this  trial specifically for the purpose 
of future use, under a secondary research protocol. Secondary research is research that is not part 
of this trial and will be performed in the future. Subjects will be informed and asked for  their 
consent to use their residual specimens and samples/specimens collected during this trial 
specifically for the purpose of future research  and information for genetic testing for  “secondary 
research ”. Genetic testing could include transcriptomics, whole genome or exome sequencing, or 
other types of genetic testing. Th is could contribute to identifying genetic factors involved in 
vaccine responses.  Genetic testing results (data) may be shared broadly with other researchers 
but will not be shared with subjects. Individual results will be stored indefinitely in an NIH 
restricted -access database, and a summary of results may  be placed in an unrestricted (open) 
database.  
The samples/specimens will be labeled as above for storage. The genetic data in the NIH database will be coded in such a way that information will be considered de -identified. Subjects 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
105 will be informed of the risks, including potential for re-identification and possible harm from the 
mis-use of data, however, NIH will require researchers to not re- identify the subjects.  
Subjects will have the right to withdraw consent for the use of their samples/specimens and/or 
data without penalty at any time. Samples/specimens and data that have already been used for secondary research may not be able to be withdrawn. 
"Written", or "sign ed", refers to the use of  or writing on a paper or an electronic ICF. Re -consent 
(revised or separate consent form) for secondary research  using samples/specimens and 
information, such as for genetic testing, may use paper or electronic ICF s to obtain the subject’s 
written consent. Th e subject will have a discussion with study staff, who is able to answer the 
subject’s questions, including if re-consent is obtained off- site. A paper copy of the signed ICF 
will be given to the subject in person or mailed. 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
106 15 DATA HANDLING AND RECORD KEEPI NG 
The site PI s are responsible to ensure the accuracy, completeness, legibility, and timeliness of the 
data reported.  
DCF s will be derived from the eCRF and provided by the SDCC to record and maintain data for 
each subject enrolled in this  trial. All DCF s should be completed in a neat, legible manner to 
ensure accurate interpretation of data.  Black or blue ink is required to ensure clarity of 
reproduced copies. When making a change or correction, cross out the original entry with a 
single line and initial and date the change.  Do not erase, overwrite or use correction fluid or tape 
on the original. 
Data reported in the eCRF derived from the DCF s should be consistent with the DCF s or the 
discrepancies should be explained. 
The sponsor and/or its designee will provide guidance to the site PI s and other study personnel 
on making corrections to the DCF s and eCRF.  
15.1 Data Management Responsibilities  
All DCF s and laboratory reports must be reviewed by the clinical team and data entry personnel, 
who will ensure that they are accurate and complete.  AEs  must be recorded on the appropriate 
DCF , assessed for severity and relationship, and reviewed by the site PI  or appropriate sub-
investigator.  
Data collection is the responsibility of the study personnel at each  participa ting VTEU site under 
the supervision of the respective site PI . During this  trial, the site PIs  must maintain complete 
and accurate documentation for this  trial. 
The SDCC for this trial will be responsible for data management, quality review, analysis, and 
reporting of the study data. 
15.2 Data Capture Methods 
Clinical ( including , but not limited to,  AE/SAEs, concomitant me dications, medical history, 
physical assessments , and clinical laboratory values ), reactogenicity and immunogenicity data 
will be entered  into a 21 CFR  11-compliant Internet Data Entry System provided by the SDCC.  
The data system includes password protection and internal quality checks, such as automatic 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
107 range checks, to identify data that appear inconsistent, incomplete  or inaccurate.  Clinical and 
reactogenicity data will be entered directly from the DCF s completed by the study personnel. 
15.3 Types of Data  
Data for this trial will include clinical, safety and outcome measures (e.g ., clinical  laboratory 
values , and reactogenicity  and immunogenicity data). 
15.4 Timing/Reports  
Clinical, safety  and reactogenicity data through approximately 180 days after the last study 
vaccination will represent the primary clinical database for this trial. Once the last subject 
completes the visit that occurs approximately 180 days after the second study vaccination and all 
HAI and Neut results are received, a “topline” subset of the immunogenicity and safety tables 
will be provided to DMID on an expedited timeline. These analyses may be made available to the sponsor for planning subsequent trials and to the lead PI  for publication. These analyses will 
not be used to make any decis ions concerning the conduct of this trial. As it is anticipated th at 
subjects will remain in long -term safety and immunogenicity follow- up at the time of these 
analyses, blinded site investigators and DMID Medical M onitors not involved in the analysis, 
publication  or clinical study report (CSR) preparation will be responsible for assessing SAEs and 
MAAEs , including NOCMCs  and PIMMCs, until all subjects have completed the final follow -up 
visit. All analyses of data included in the topline tables  for early re lease will be considered the 
final analysis of these data, and also included in the final CSR. 
Analysis of exploratory immunogenicity endpoints , including cellular immun ology and 
additional serological assays,  may be performed and released as the data are available from the 
research  laboratories . Any such analyses would be considered the final analysis for the endpoint, 
and included in the CSR. The final CSR will be completed after the last subject’s last visit is completed, and the final 
clinical database, including all long -term safety follow -up data, is cleaned, monitored and 
locked. Additional exploratory immunogenicity endpoint data not available at the time of CSR 
preparation may be included in an addendum to the CSR. 
Additional statistical reports may  be generated as deemed necessary and appropriate by DMID.  
Safety and immunogenicity summary reports may be generated for the DSMB . 
After the final CSR  is complete, and upon request and DMID approval, the SDCC will provide 
the participat ing VTEU sites with a s ummary of results by treatment arm  and/ or subject 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
108 treatment assignment . In this regard, the participating VTEU sites requesting such information to 
share with subjects must do so in accordance with IRB requirements . 
15.5 Study Records Retention  
Study records and reports, including, but not limited to , eCRFs, source documents, ICFs , and 
study drug disposition records shall be maintained for 2 years after a  marketing application is 
approved for the drug for the indication for which it is being investigated; or, if no application is 
to be filed or if the application is not approved for the drug, until 2 years after the investigation is discontinued and the FDA has been  notified. These documents will be retained for a longer 
period, however, if required by local regulations. ICF s for future research use will be maintained 
as long as the sample/specimen exists.  
No records will be destroyed without the written consent of the sponsor. It is the responsibility of the sponsor to inform the site PI  when these documents no longer need to be retained. The 
participating VTEU sites must contact DMID for authorization prior to the destruction of any 
study records. 
15.6 Protoc ol Deviations 
A protocol deviation is any noncompliance with the study protocol, GCP or protocol- specific 
MOP requirements. The noncompliance may be either on the part of the subject, the site PI  or 
other study personnel. As a result of protocol deviations , corrective actions are to be developed 
by the site and implemented promptly.  
These practices are consistent with ICH E6 GCP  guidelines: 
4.5 Compliance with Protocol, Sections 4.5.1, 4.5.2 and 4.5.3 
5.1 Quality Assurance and Quality Control, Section 5.1.1 
5.20 Noncompliance, Sections 5.20.1 and 5.20.2 
It is the responsibility of the site PI  and other study personnel to use continuous vigilance to 
identify and report protocol deviations within five working days of identification of the protocol 
deviation, or within five working days of the scheduled protocol-required activity. Protocol deviations must be promptly reported to DMID, via the SDCC’s AdvantageEDC
SM. 
Protocol deviations, as defined above, must be addressed on the appropriate DCF . A completed 
copy of the Protocol Deviation DCF  must be maintained in the regulatory file as well as in the 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
109 subject ’s chart. Protocol deviations must be sent to the IRB in accor dance with IRB 
requirements. The site PI  and other study personnel are responsible for knowing and adhering to 
IRB requirements.  
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
110 16 PUBLICATION POLICY  
All investigators funded by the NIH must submit or have submitted for them to the National 
Library of Medic ine’s PubMed Central ( http://www.ncbi.nlm.nih.gov/pmc/ ) an electronic 
version of their final, peer-reviewed manuscripts upon acceptance for publication, to be made 
publicly available no later than 12 months after the official date of publication. The NIH P ublic 
Access Policy ensures the public has access to the published results of NIH funded research. It 
requires all investigators to submit final peer -reviewed journal manuscripts that arise from NIH 
funds to the digital archive PubMed Central upon acceptan ce for publication. Further, the policy 
stipulates that these papers must be accessible to the public on PubMed Central no later than 12 
months after publication. 
Refer to:  
• NIH Public Access Policy, http://publicaccess.nih.gov/ 
• NIH Office of Extramural Res earch (OER) Grants and Funding, 
http://grants.nih.gov/grants/oer.htm 
As of January 2018, all clinical trials supported by the NIH must be registered on 
ClinicalTrials.gov, no later than 21 days after the enrollment of the first subject. Results of all clinical trials supported by the NIH, generally, need to be submitted no later than 12 months 
following the primary completion date. A delay of up to 2 years is available for trials that meet certain criteria and have applied for certification of delayed posti ng. 
As part of the result posting a copy of this protocol (and its amendments) and a copy of the 
Statistical Analysis Plan will be posted on ClincialTrials.gov.  
For this clinical trial, the responsible party is DMID which will register this  trial and post results.  
The responsible party does not plan to request certification of delayed posting. 
Refer to:  
• Public Law 110-85, Section 801, Clinical Trial Databases 
• 42CFR11 
• NIH NOT -OD-16-149 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
111 17 LITERATURE REFERENCES 
1. Centers for Disease, C. and Prevention, Emergence of avian influenza A(H7N9) virus 
causing severe human illness - China, February-April 2013. MMWR Morb Mortal Wkly 
Rep, 2013. 62(18): p. 366-71. 
2. Fouchier, R.A., et al., Avian influenza A virus (H7N7) associated with human 
conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A, 2004. 101(5): p. 1356-61. 
3. Lindstrom, S., et al., Human infections with novel reassortant influenza A(H3N2)v 
viruses, United States, 2011. Emerg Infect Dis, 2012. 18(5): p. 834-7. 
4. He, J. and J. Duan, First human case of avian influenza A (H5N6) in Yunnan province, 
China. SAGE Open Med Case Rep, 2015. 3: p. 2050313X15596484. 
5. Zhang, Y., et al., Human infections with novel reassortant H5N6 avian influenza viruses 
in China. Emerg Microbes Infect, 2017. 6(6): p. e50. 
6. Peiris, M., et al., Human infection with influenza H9N2. Lancet, 1999. 354 (9182): p. 916-
7. 
7. Perez -Padilla, R., et al., Pneumonia and respiratory failure from swine-origin influenza A 
(H1N1) in Mexico.  N Engl J Med, 2009. 361(7): p. 680-9. 
8. Subbarao, K., et al., Characterization of an avian influenza A (H5N1) virus isolated from 
a child with a fatal respiratory illness.  Science, 1998. 279(5349): p. 393-6. 
9. Resende, P.C., et al., Whole -Genome Characterization of a Novel Human Influenza 
A(H1N2) Virus Variant, Brazil. Emerg Infect Dis, 2017. 23(1): p. 152-154. 
10. Oxford, J.S., Influenza A pandemics of the 20th century with special reference to 1918: 
virology, pathology and epidemiology. Rev Med Virol, 2000. 10(2): p. 119-33. 
11. Patriarca, P.A. and N.J. Cox, Influenza pandemic preparedness plan for the United 
States. J Infect Dis, 1997. 176 Suppl 1: p. S4-7. 
12. Galasso, G.J., F.J. Tyeryar, Jr., and J.R. La Montagne, Overview of clinical trials of 
influenza vaccines, 1976.  J Infect Dis, 1977. 136 Suppl : p. S425-8. 
13. La Montagne, J.R., et al., Summary of clinical trials of inactivated influenza vaccine - 
1978. Rev Infect Dis, 1983. 5(4): p. 723-36. 
14. Couch, R.B. and J.A. K asel, Immunity to influenza in man. Annu Rev Microbiol, 1983. 
37: p. 529-49. 
15. Couch, R.B., et al., Antibody correlates and predictors of immunity to naturally 
occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Di s, 2013. 207(6): p. 974-81. 
16. Memoli, M.J., et al., Evaluation of Antihemagglutinin and Antineuraminidase Antibodies 
as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model. MBio, 2016. 7(2): p. e00417-16. 
17. Ennis, F.A., et al., Correlation of laboratory studies with clinical responses to A/New 
Jersey influenza vaccines.  J Infect Dis, 1977. 136 Suppl : p. S397-406. 
18. Gross, P.A., et al., Immunization of elderly people with high doses of influenza vaccine. J 
Am Geriatr Soc , 1988. 36 (3): p. 209-12. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
112 19. Keitel, W.A., et al., High doses of purified influenza A virus hemagglutinin significantly 
augment serum and nasal secretion antibody responses in healthy young adults. J Clin 
Microbiol, 1994. 32(10): p. 2468-73. 
20. Matzkin, H. and E. Nili, Accidental tenfold overdose of influenza vaccine: a clinical and 
serological study. Isr J Med Sci, 1984. 20(5): p. 411-5. 
21. Mostow, S.R., et al., Inactivated vaccines. 1. Volunteer studies with very high doses of 
influenza vaccine purified by zonal ultracentrifugation. Postgrad Med J, 1973. 49(569): 
p. 152-8. 
22. Palache, A.M., et al., Antibody response after influenza immunization with various 
vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine, 1993. 11(1): p. 3-9. 
23. Remarque, E.J., et al., Improvement of the immunoglobulin subclass response to 
influenza vaccine in elderly nursing-home residents by the use of high- dose vaccines.  
Vaccine, 1993. 11(6): p. 649-54. 
24. Ruben, F.L. and G.G. Jackson, A new subunit influenza vaccine: acceptability compared 
with standard vaccines and effect of dose on antigenicity. J Infect Dis, 1972. 125(6): p. 656-64. 
25. Ruben, F.L., C.W. Potter, and C.H. Stuart- Harris, Humoral and secretory antibody 
responses to immunization with low and high dosage split influenza virus vaccine. Arch Virol, 1975. 47(2): p. 157-66. 
26. Keitel, W.A., et al., Increasing doses of purified influenza virus hemagglutinin and 
subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol, 1996. 3(5): p. 507-10. 
27. Couch, R.B., et al., A randomized clinical trial of an inactivated avian influenza A 
(H7N7) vaccine.  PLoS One, 2012. 7(12): p. e49704. 
28. Treanor, J.J., et al., Safety and immunogenicity of an inactivated subvirion influenza A 
(H5N1) vaccine.  N Engl J Med, 2006. 354(13): p. 1343-51. 
29. Atmar, R.L. and W.A. Keitel, Adjuvants for pandemic influenza vaccines. Curr Top 
Microbiol Immunol, 2009. 333: p. 323-44. 
30. Bresson, J.L., et al., Safety and immunogenicity of an inactivated split-virion influenza 
A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet, 2006. 367(9523): p. 1657-64. 
31. Keitel, W.A., et al., Safety and immunogenicity of an inactivated influenza A/H5N1 
vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis, 2008. 198(9): p. 1309-16. 
32. Carmona, A., et al., Immunogenicity and safety of AS03-adjuvanted 2009 influenza A 
H1N1 vaccine in children 6-35 months. Vaccine, 2010. 28(36): p. 5837-44. 
33. Diez -Domingo, J., et al., Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 
(Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J, 2010. 29(6): p. e35-46. 
34. Leroux- Roels, I., et al., Antigen sparing and cross-reactive immunity with an adjuvanted 
rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet, 
2007. 370(9587): p. 580-9. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
113 35. McElhaney, J.E., et al., AS03-adjuvanted versus non-adjuvanted inactivated trivalent 
influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised 
trial.  Lancet Infect Dis, 2013. 13(6): p. 485-96. 
36. Vogel, F.R., et al., Emulsion-based adjuvants for influenza vaccines. Expert Rev 
Vaccines, 2009. 8(4): p. 483-92. 
37. Choe, Y.J., G.R. Bae, and D.H. Lee, No association between influenza A(H1N1)pdm09 
vaccination and narcolepsy in South Korea: an ecological study. Vaccine, 2012. 30(52): 
p. 7439-42. 
38. Dauvilliers, Y., et al., Increased risk of narcolepsy in children and adults after pandemic 
H1N1 vaccination in France. Brain, 2013. 136(Pt 8): p. 2486-96. 
39. Eurosurve illance editorial, t., Swedish Medical Products Agency publishes report from a 
case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexy.  Euro Surveill, 2011. 16(26).  
40. Force, N.N.T., Increased risk of narcolepsy observed  also among adults vaccinated with 
Pandemrix in Finland. N.I.f.H.a.W.T. Finland, Editor. 2013. 
41. Miller, E., et al., Risk of narcolepsy in children and young people receiving AS03 
adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ, 2013. 346: p. f794. 
42. Montplaisir, J., et al., Risk of narcolepsy associated with inactivated adjuvanted (AS03) 
A/H1N1 (2009) pandemic influenza vaccine in Quebec. PLoS One, 2014. 9 (9): p. 
e108489. 
43. Nohynek, H., et al., AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase 
in the incidence of childhood narcolepsy in Finland. PLoS One, 2012. 7(3): p. e33536. 
44. O'Flanagan, D., et al., Investigation of an association between onset of narcolepsy and 
vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010. Euro Surveill, 2014. 19(17): p. 15-25. 
45. Wijnans, L., et al., The incidence of narcolepsy in Europe: before, during, and after the 
influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine, 2013. 31(8): p. 
1246-54. 
46. Chen, W.H., et al., Safety, Reactogenicity, and Immunogenicity of Inactivated 
Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant. Open Forum Infect Dis, 2014. 1(3): p. ofu091. 
47. El Sahly, H.M. and D .N. NIH,  A Phase II Randomized, Partially-Blinded, Controlled, 
Trial in Healthy Adults Aged 65 Years and Older to Assess the Safety, Reactogenicity, and Immunogenicity of an MF59-Adjuvanted, Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered Intramuscularly at Different Intervals and Dosages. 
48. Jackson, L.A., et al., Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine 
With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.  JAMA, 2015. 314(3): p.  237-46. 
49. Jackson, L.A., et al., Immunogenicity and safety of varying dosages of a monovalent 2009 
H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis, 2012. 206(6): p. 811-20. 
50. Mulliga n, M.J., et al., Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 
Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open Forum Infect Dis, 2014. 1(3): p. ofu102. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
114 51. Mulligan, M.J., et al., Serological responses to an avian influenza A/H7N9 vaccine mixed 
at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA, 2014. 
312(14): p. 1409-19. 
52. Lee, Y.J., et al., Novel reassortant influenza A(H5N8) viruses, South Korea, 2014. Emerg 
Infect Dis, 2014. 20(6): p. 1087-9. 
53. Wu, H., et al., Novel reassortant influenza A(H5N8) viruses in domestic ducks, eastern 
China. Emerg Infect Dis, 2014. 20(8): p. 1315-8. 
54. Gao, R., et al., Human infection with a novel avian-origin influenza A (H7N9) virus. N 
Engl J Med, 2013. 368(20): p. 1888-97. 
55. Influenza at the human-animal interface. Summary and Assessment, 26 January to 2 March 2018. WHO Monthly Influenza Risk Assessment Summary, 2 March, 2018. 
56. Analysis of recent scientific information on avian influenza A(H7N9) virus. WHO  
Influenza Update, 2017. 
57. Zhou, J., et al., Biological features of novel avian influenza A (H7N9) virus.  Nature, 
2013. 499(7459): p. 500-3. 
58. Zhu, H., et al., Infectivity, transmission, and pathology of human-isolated H7N9 influenza 
virus in ferrets and pigs. Science, 2013. 341(6142): p. 183-6. 
59. Li, Y., et al., Evolving HA and PB2 genes of influenza A (H7N9) viruses in the fifth wave 
- Increasing threat to both birds and humans? J Infe ct, 2017. 
60. Belshe, R.B., et al., Safety and immunogenicity of influenza A H5 subunit vaccines: effect 
of vaccine schedule and antigenic variant. J Infect Dis, 2011. 203(5): p. 666-73. 
61. Goji, N.A., et al., Immune responses of healthy subjects to a single dose of intramuscular 
inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis, 2008. 198(5): p. 635-41. 
62. Gillard, P., et al., Long-term booster schedules with AS03A-adjuvanted heterologous 
H5N1 vaccines induces rapid and broad immune responses in Asian adults. BMC Infect Dis, 2014. 14: p. 142. 
63. Langley, J.M., et al., Immunogenicity of heterologous H5N1 influenza booster 
vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.  Vaccine, 2015. 33(4): p. 559-67. 
64. Madan, A., et al., Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic 
Influenza Vaccine in a Randomized Trial in Healthy Adults. J Infect Dis, 2016. 214(11): p. 1717-1727. 
65. Lasky, T., et al., The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 
influenza vaccines. N Engl J Med, 1998. 339(25): p. 1797-802. 
66. Haber, P., et al., Guillain -Barre syndrome following influenza vaccination. JAMA, 2004. 
292(20): p. 2478-81. 
67. De Wals, P., et al., Risk of Guillain -Barre syndrome following H1N1 influenza 
vaccination in Quebec. JAMA, 2012. 308(2): p. 175-81. 
68. Juurlink, D.N., et al., Guillain -Barre syndrome after influenza vaccination in adults: a 
population-based study. Arch Intern Med, 2006. 166(20): p. 2217-21. 
69. Salmon, D.A., et al., Association between Guillain-Barre syndrome and influenza A 
(H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.  Lancet, 
2013. 381(9876): p. 1461-8. 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
115 70. Wise, M.E., et al., Guillain -Barre syndrome during the 2009-2010 H1N1 influenza 
vaccination campaign: population-based surveillance among 45 million Americans. Am 
J Epidemiol, 2012. 175(11): p. 1110-9. 
71. Polakowski, L.L., et al., Chart-confirmed guillain-barre syndrome after 2009 H1N1 
influenza vaccination among the Medicare population, 2009-2010. Am J Epidemiol, 2013. 178(6): p. 962-73. 
72. Dodd, C.N., et al., International collaboration to assess the risk of Guillain Barre 
Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine, 2013. 31(40): p. 4448-58. 
73. Sullivan, S.S., Narcolepsy in adolescents. Adolesc Med State Art Rev, 2010. 21(3): p. 
542-55, x-xi. 
74. CDC, Recommended Immunizations for Adults: By Age. 2017. 
 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
116 Appendices 
Appendix A: Schedule of Study Procedures and Evaluations  
Appendix B: Schedule of Special Assays  
Appendix C : List of Potentially Immune-Mediated Medical Conditions  
 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
119 {}Targeted physical examination if indicated based on review of interim medical history.  
^ Performed locally by the site at the screening visit (optional) or within 24 hours prior to each study vaccination for all women of childbearing potential. Results 
must be negative and known prior to randomization on Day 1 and administration of each study vaccination.  
≠ Performed locally by the site at the screening visit (optional) or on Day 1 prior to the first study vaccination. The ESR val ue must be confirmed as less than 30 
mm per hour prior to randomization on Day 1 and administration of the first study vaccination.  
~ Includes WBC, Hgb, PLT, ALT, T. Bili, Cr.  
# Clinical safety laboratory evaluations assessed on Day 1 prior to the first study vaccination will be considered as baseline.  
Ψ Subje cts who receive only one dose of study vaccine will be encouraged to remain in this trial for follow -up safety assessments (may be conducted by phone 
call rather than in person) continuing through approximately 12 months after their last study vaccination.  These subjects will also be encouraged to provide a 
venous blood sample for serological assays approximately 21 and 180 days after their last study vaccination.  
& Inclusive of reactogenicity assessments performed on the day of each study vaccination throu gh 7 days after each study vaccination.  
4 AEs limited to SAEs and MAAEs, including NOCMCs and PIMMCs, for subjects who are discontinued from receipt of the second stud y vaccination and 
being followed for safety.  
 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
120 Table 16: Follow- Up Period for Treatment Arms 1 and 4 (Including Early Termination and Unscheduled Visits)  
Study Visit Number  
V12** 
V13 
V14** 
V15 
V16** 
Early Termination  
(if needed)  Unscheduled  
(if needed)  Study Day post first study vaccination  
D82 
D112  
D142  
D202  
D387  
Study Day post second study vaccination  
D61±7d  
D91±14d 
D121±14d  
D181±14d  
D366±14d  
Study Procedure/Evaluation  
Medical History@  X  X  X X (if indicated)  
Concomitant Medicationsς X X X X  X (if prior to 21 days 
after last study 
vaccination and receipt 
of any non-study 
influenza vaccines if 
within 180 days after 
last study vaccination)  X (if prior to 21 days 
after last study 
vaccination and receipt 
of any non-study 
influenza vaccines if 
within 180 days after last 
study vaccination)  
Vital Signs (Oral Temperature%, Pulse and BP)       X (may be obtained if 
indicated)  X (may be obtained if 
indicated)  
Physical Examination   {X}  {X}  {X} {X} 
Venous Blood Collection for Clinical Safety Laboratory Evaluations~       X (if within 7 days after 
last study vaccination)  X (if indicated)  
Venous Blood Collection for Serological Assays     XΨ  X (if within 21 days 
after last study 
vaccination)  X (if within  21 days after 
last study vaccination)  
Venous Blood Collection for Cellular Immun ology  Assays   X  X  X (if within 21 days 
after last study 
vaccination)  X (if within  21 days after 
last study vaccination)  
Venous Blood Collection for Future Research  X  X  X (if within 21 days 
after last study 
vaccination)  X (if within  21 days after 
last study vaccination)  
Examine Study Vaccination Site       X (if within 7 days after 
last study vaccination)  X (if within 7 days after 
last study vaccination)  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
121 Study Visit Number  
V12** 
V13 
V14** 
V15 
V16** 
Early Termination  
(if needed)  Unscheduled  
(if needed)  Study Day post first study vaccination  
D82 
D112  
D142  
D202  
D387  
Study Day post second study vaccination  
D61±7d  
D91±14d 
D121±14d  
D181±14d  
D366±14d  
Study Procedure/Evaluation  
Post-Administration Reactogenicity Assessments       X (if within 7 days after 
last study vaccination)  X (if within 7 days after 
last study vaccination)  
Review Memory Aid       X (if within 7 days after 
last study vaccination)  X (if within 7 days after 
last study vaccination)  
AE/SAE Assessment! X X X X X X (if after 21 days after 
last study vaccination)  X (if after 21 days after 
last study vaccination)  
**Phone call assessment.  
@ Complete medical history will be obtained by interview of subjects at the screening visit (optional) or on Day 1 prior to the  first study vaccination, and interim 
medical history will be obtained by interview of subjects at follow -up visits after the first  study vaccination.  
ς Receipt of any non -study influenza vaccines will be solicited through approximately 180 days after the last study vaccination, and reported in the eCRF. 
% Subjects must not eat or drink anything hot or cold, or smoke within 10 minutes  prior to taking oral temperature.  
{}Targeted physical examination if indicated based on review of interim medical history.  
~ Includes WBC, Hgb, PLT, ALT, T. Bili, Cr.  
Ψ Subjects who receive only one dose of study vaccine will be encouraged to remain in this trial for follow -up safety assessments (may be conducted by phone 
call rather than in person) continuing through approximately 12 months after their last study vaccination. These subjects wil l also be encouraged to provide a 
venous blood sample for se rological assays approximately 21 and 180 days after their last study vaccination.  
! AEs limited to SAEs and MAAEs, including NOCMCs and PIMMCs, that have occurred since the previous clinic visit or phone call . 
 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
124 3 At the screening visit (optional) or on Day 1 prior to the first study vaccination, a physical examination will be performed on all subjects to include the 
following organs and organ systems: skin, head and neck, lungs, heart, liver, spleen, extremities, lymph nodes, and nervous system, and  as an assessment for 
signs suggestive of PIMMCs.  
{}Targeted physical examination if indicated based on review of interim medical h istory.  
^ Performed locally by the site at the screening visit (optional) or within 24 hours prior to each study vaccination for all women of childbearing potential. Results 
must be negative and known prior to randomization on Day 1 and administration of e ach study vaccination.  
≠ Performed locally by the site at the screening visit (optional) or on Day 1 prior to the first study vaccination. The ESR val ue must be confirmed as less than 30 
mm per hour prior to randomization on Day 1 and administration of the  first study vaccination.  
~ Includes WBC, Hgb, PLT, ALT, T. Bili, Cr.  
# Clinical safety laboratory evaluations assessed on Day 1 prior to the first study vaccination will be considered as baseline.  
Ψ Subjects who receive only one dose of study vaccine will  be encouraged to remain in this trial for follow -up safety assessments (may be conducted by phone 
call rather than in person) continuing through approximately 12 months after their last study vaccination. These subjects wil l also be encouraged to provide a 
venous blood sample for serological assays approximately 21 and 180 days after their last study vaccination.  
& Inclusive of reactogenicity assessments performed on the day of each study vaccination through 7 days after each study vaccin ation.  
! AEs limited to SAEs and MAAEs, including NOCMCs and PIMMCs, that have occurred since the previous clinic visit or phone call . 
4 AEs limited to SAEs and MAAEs, including NOCMCs and PIMMCs, for subjects who are discontinued from receipt of the second stud y vaccinatio n and 
being followed for safety.  
 
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
125 Table 18: Follow-Up Period for Treatment Arms 2, 3, 5, and 6 (Including Early Termination and Unscheduled Visits) 
Study Visit Number  
V14** 
V15 
V16** 
V17 
V18** 
Early Termination  
(if needed)  Unscheduled  
(if needed)  Study Day post first study vaccination  
D181  
D211 
D241  
D301 
D486 
Study Day post second study vaccination  
D61±7d  
D91±14d 
D121±14d  
D181±14d  
D366±14d  
Study Procedure/Evaluation  
Medical History@  X  X  X X (if indicated)  
Concomitant Medicationsς X X X X  X (if prior to 21 days 
after last study 
vaccination and receipt 
of any non-study 
influenza vaccines if 
within 180 days after 
last study vaccination)  X (if prior to 21 days 
after last study 
vaccination and receipt 
of any non-study 
influenza vaccines if 
within 180 days after last 
study vaccination)  
Vital Signs (Oral Temperature%, Pulse and BP)       X (may be obtained if 
indicated)  X (may be obtained if 
indicated)  
Physical Examination   {X}  {X}  {X} {X} 
Venous Blood Collection for Clinical Safety Laboratory Evaluations~       X (if within 7 days after 
last study vaccination)  X (if indicated)  
Venous Blood Collection for Serological Assays     XΨ  X (if within 21 days 
after last study 
vaccination)  X (if within  21 days after 
last study vaccination)  
Venous Blood Collection for Cellular Immun ology  Assays   X  X  X (if within 21 days 
after last study 
vaccination)  X (if within  21 days after 
last study vaccination)  
Venous Blood Collection for Future Research  X  X  X (if within 21 days 
after last study 
vaccination)  X (if within  21 days after 
last study vaccination)  
Examine Study Vaccination Site       X (if within 7 days after 
last study vaccination)  X (if within 7 days after 
last study vaccination)  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
126 Study Visit Number  
V14** 
V15 
V16** 
V17 
V18** 
Early Termination  
(if needed)  Unscheduled  
(if needed)  Study Day post first study vaccination  
D181  
D211 
D241  
D301 
D486 
Study Day post second study vaccination  
D61±7d  
D91±14d 
D121±14d  
D181±14d  
D366±14d  
Study Procedure/Evaluation  
Post-Administration Reactogenicity Assessments       X (if within 7 days after 
last study vaccination)  X (if within 7 days after 
last study vaccination)  
Review Memory Aid       X (if within 7 days after 
last study vaccination)  X (if within 7 days after 
last study vaccination)  
AE/SAE Assessment! X X X X X X (if after 21 days after 
last study vaccination)  X (if after 21 days after 
last study vaccination)  
**Phone call assessment.  
@ Complete medical history will be obtained by interview of subjects at the screening visit (optional) or on Day 1 prior to the  first study vaccination, and interim 
medical history will be obtained by interview of subjects at follow -up visits a fter the first study vaccination.  
ς Receipt of any non -study influenza vaccines will be solicited through approximately 180 days after the last study vaccination, and reported in the eCRF. 
% Subjects must not eat or drink anything hot or cold, or smoke wit hin 10 minutes prior to taking oral temperature.  
{}Targeted physical examination if indicated based on review of interim medical history.  
~ Includes WBC, Hgb, PLT, ALT, T. Bili, Cr.  
Ψ Subjects who receive only one dose of study vaccine will be encouraged to remain in this trial for follow -up safety assessments (may be conducted by phone 
call rather than in person) continuing through approximately 12 months after their last study vaccination. These subjects wil l also be encouraged to provide a 
venous blood sample for serological assays approximately 21 and 180 days after their last study vaccination.  
! AEs limited to SAEs and MAAEs, including NOCMCs and PIMMCs, that have occurred since the previous clinic visit or phone call . 
 
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
129 ^ Drawn up to 28 days prior to the first study vaccination. The ESR value must be confirmed as less than 30 mm per hour prior to randomization and first study 
vaccination.  
* Not required if done at the optional screening visit.  
~ Includes WBC, Hgb, PLT, ALT, T. Bili, Cr.  
# Clinical safety laboratory evaluations assessed on Day 1 prior to the first study vaccination will be considered as baseline.  
† Blood must be drawn immediately prior to study vaccination.  
@ All sites will collect venous blood for this assay. Specified sites will utilize freshly isolated PBMCs. All other sites will process for frozen PBMCs.  
1 Specified sites  only.  
2 Sites processing only for Plasma/PBMC s. 
3 All sites.  
 
  Breakdown of Future Research Samples  
‘Omics (Plasma/PBMCs)  – 
specified sites  only  12 12 12 12  12 12 12 12     96 
Serum  – all sites      5     5     10 
Plasma/ PBMCs   41 or 
162 41 or 
162 41 or 
162 41 or 
162 163 41 or 
162 41 or 
162 41 or 
162 41 or 
162 163 163 163 163 1121 
or 
2082 
Per Visit Blood Volume  (BV) Totals  
Per Visit  CIA/FR Blood 
Volume Total  (mL)   80 20 24 65 24 48 20 24 65 24 16 56 48 514 
Per Visit Blood Volume 
Total  (mL)  4 105 20 24 75 24 73 20 24 75 24 31 56 63 618 
Running Blood Volume Totals  
Running Blood Volume 
Total  (mL)  4 109 129 1 53 228 2 47 320 340 3 64 444 458 489 545 618  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
131 ^ Drawn up to 28 days prior to the first study vaccination. The ESR value must be confirmed as less than 30 mm per hour prior t o randomization and first study 
vaccination.  
* Not required if done at the optional screening visit.  
~ Includes WBC, Hgb, PLT, ALT, T. Bili, Cr.  
# Clinical safety laboratory evaluations assessed on Day 1 prior to the first study vaccination will be considere d as baseline.  
† Blood must be drawn immediately prior to study vaccination.  
@ All sites will collect venous blood for this assay. Specified sites will utilize freshly isolated PBMCs. All other sites will process for frozen PBMCs.  
1 Specified sites  only.  
2 Sites processing only for Plasma/PBMC s. 
3 All sites.  
 
 B Cell Receptor 
Somatic 
Hypermutation and 
Repertoire 
Assessments   16†             16 32 
Future Research (FR)  
Future Research   16† 16 16 21 16 16 16† 16 16 21 16 16 16 16 234 
Breakdown of Future Research Samples  
‘Omics 
(Plasma/PBMCs)  – 
specified sites  only  12 12 12 12   12 12 12 12     96 
Serum  – all sites      5      5     10 
Plasma/ PBMCs   41 
or 
162 41 
or 
162 41 
or 
162 41 or 
162 163 163 41 or 
162 41 or 
162 41 or 
162 41 or 
162 163 163 163 163 1281 
or 
2242 
Per Visit Blood Volume (BV) Totals  
Per Visit CIA/FR 
Blood Volume Total 
(mL)   80 20 24 65 24 16 48 20 24 65 24 16 56 48 530 
Per Visit Blood 
Volume Total (mL)  4 105 20 24 75 24 31 73 20 24 75 24 31 56 63 649 
Running Blood Volume Totals  
Running Blood 
Volume Total (mL)  4 109 129 1 53 228 2 47 2 78 351 371 3 95 475 4 89 5 20 576 649  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
132 APPENDIX  C. LIST OF POTENTIALLY IMMUNE- MEDIATED 
MEDICAL CONDITIONS  
(also known as Adve rse Events of Special Interest [AESIs]) 
 
Gastrointestinal disorders  
• Celiac disease  
• Crohn’s disease 
• Ulcerative colitis  
• Ulcerative proctitis  
Liver disorders  
• Autoimmune cholangitis  
• Autoimmune hepatitis  
• Primary biliary cirrhosis  
• Primary sclerosing cholangitis  
Metabolic diseases  
• Addison’s disease 
• Autoimmune thyroiditis (including Hashimoto thyroiditis)  
• Diabetes mellitus type I  
• Grave ’s or Basedow’s disease  
Musculoskeletal disorders  
• Antisynthetase syndrome 
• Dermatomyositis  
• Juvenile chronic arthritis (including Still’s disease)  
• Mixed connective tissue disorder 
• Polymyalgia rheumatic  
• Polymyositis  
• Psoriatic arthropathy  
• Relapsing polychondritis 
• Rheumatoid arthritis  
• Scleroderma, including diffuse systemic form and CREST syndrome 
• Spondyloarthritis, including ankylosing spondylitis, reactive arthritis (Reiter ’s Syndrome) 
and undifferentiate d spondyloarthritis  
• Systemic lupus erythematosus  
• Systemic sclerosis  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
133 Neuroinflammatory disorders  
• Acute disseminated encephalomyelitis, including site -specific variants (e.g., non-
infectious encephalitis, encephalomyelitis,  myelitis, myeloradiculomyelitis)  
• Cranial nerve disorders, including paralyses/paresis (e.g., Bell’s palsy) 
• Guillain -Barré syndrome, including Miller Fisher syndrome and other variants 
• Immune-mediated peripheral neuropathies and plexopathies, including chronic 
inflammatory demyelinating pol yneuropathy, multifocal motor neuropathy and 
polyneuropathies associated with monoclonal gammopathy 
• Multiple sclerosis  
• Narcolepsy  
• Optic neuritis  
• Transverse myelitis  
• Myasthenia gravis, including Eaton-Lambert syndrome 
Skin disorders  
• Alopecia areata  
• Autoimmu ne bullous skin diseases, including pemphigus, pemphigoid and dermatitis 
herpetiformis  
• Cutaneous lupus erythematosus 
• Erythema nodosum 
• Morphoea 
• Lichen planus 
• Psoriasis 
• Sweet’s syndrome 
• Vitiligo  
Vasculitides  
• Large vessels vasculitis including: giant cell arteritis such as Takayasu ’s arteritis and 
temporal arteritis  
• Medium sized and/or small vessels vasculitis including: polyarteritis nodosa, Kawasaki’ s 
disease, microscopic polyangiitis,  Wegener ’s granulomatosis, Churg-Strauss syndrome 
(allergic granulomato us angiitis), Buerger’s disease thromboangiitis obliterans, 
necrotizing vasculitis and anti-neutrophil cytoplasmic antibody (ANCA) positive vasculitis (type unspecified), Henoch - Schonlein purpura, Behcet’s syndrome, 
leukocytoclastic vasculitis  
  
DMID Protocol 17- 0078  Version 4.0 
2013/2017 H7N9 Prime -Boost Interval  December 18, 2019  
 
134 Others  
• Antiphospholipid syndrome 
• Autoimmune hemolytic anemia  
• Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis rapidly 
progressive, membranous glomerulonephritis, membranoproliferative glomerulonephritis, 
and mesangioproliferative glomeru lonephritis) 
• Autoimmune myocarditis/cardiomyopathy  
• Autoimmune thrombocytopenia 
• Good pasture syndrome 
• Idiopathic pulmonary fibrosis 
• Pernicious anemia  
• Raynaud’s phenomenon 
• Sarcoidosis 
• Sjögren’s syndrome 
• Stevens -Johnson syndrome 
• Uveitis  
 